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ABSTRACT
WHEN TO INITIATE, WHEN TO SWITCH, AND HOW TO SEQUENCE
HIV THERAPIES: A MARKOV DECISION PROCESS APPROACH
Steven M. Shechter, PhD
University of Pittsburgh, 2006
HIV and AIDS are major health care problems throughout the world, with 40 million people
living with HIV by the end of 2005. In that year alone, 5 million people acquired HIV, and
3 million people died of AIDS. For many patients, advances in therapies over the past ten
years have changed HIV from a fatal disease to a chronic, yet manageable condition. The
purpose of this dissertation is to address the challenge of effectively managing HIV therapies,
with a goal of maximizing a patient’s total expected lifetime or quality-adjusted lifetime.
Perhaps the most important issue in HIV care is when a patient should initiate ther-
apy. Benefits of delaying therapy include avoiding the negative side effects and toxicities
associated with the drugs, delaying selective pressures that induce the development of re-
sistant strains of the virus, and preserving a limited number of treatment options. On the
other hand, the risks of delayed therapy include the possibility of irreversible damage to
the immune system, development of AIDS-related complications, and death. We develop a
Markov decision process (MDP) model that examines this question, and we solve it using
clinical data. Because of the development of resistance to administered therapies over time,
an extension to the initiation question arises: when should a patient switch therapies? Also,
inherent in both the initiation and switching questions is the question of which therapy to use
each time. We develop MDP models that consider the switching and sequencing problems,
and we discuss the challenges involved in solving these models.
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1.0 INTRODUCTION
Acquired Immune Deficiency Syndrome (AIDS) and its cause, the Human Immunodeficiency
Virus (HIV), are among the most pressing health care problems in the world, with approxi-
mately 40 million people living with HIV by the end of 2005. In that year alone, 5 million
people became infected with HIV while 3 million people died of AIDS [176]. Unfortunately,
the number of people living with HIV continues to grow [176].
HIV’s fatal effects arise from its attack of a person’s CD4 white blood cells. As these cells
become depleted, HIV patients become more vulnerable to certain infections, resulting in
AIDS and eventually death [169]. Antiretroviral therapy involves the administration of drugs
that are designed to inhibit HIV replication so as to preserve the vital CD4 cells. The first
drug for fighting HIV, AZT, was approved for use in 1986 [162]. Although promising at first,
the success of using a single therapy was not long lasting due to the rapid development of
resistant strains of the virus [162]. Therefore, new classes of drugs were developed in the early
1990s, leading to the widespread use of highly active antiretroviral therapy (HAART) in the
mid-to-late 1990s. HAART, the standard of care today, is also called combination therapy
or cocktail therapy because it involves patients taking three or more drugs simultaneously
from the various drug classes (we will also just refer to it as “therapy”). The increased use
of HAART in the past ten years has led to significant reductions in HIV-related morbidity,
mortality, and health care utilization [127, 170]. As such, many patients have seen HIV
transform from a fatal disease to a chronic, yet manageable condition [153].
This dissertation focuses on the effective management of HAART. Despite great advances
in HIV therapies, there is still considerable debate about the best way to use them. For
example, the best time for a patient to initiate HAART is an open question [2, 42, 75, 78,
79, 81, 87, 106, 113, 124, 131, 150, 171]. According to Dr. Anthony Fauci, the director of the
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National Institute of Allergy and Infectious Diseases, the question of when to initiate therapy
is “the most important question in HIV therapy” [79]. Benefits of delaying therapy include
avoiding the negative side effects and toxicities associated with the drugs, delaying selective
pressures that induce the development of resistance strains of the virus, and preserving a
limited number of treatment options [123]. On the other hand, the risks of delayed therapy
include the possibility of irreversible damage to the immune system, development of AIDS-
related complications, and death [123]. Of course, with the various therapies available, there
is also a question of which therapy to use first.
Along with the question of when to initiate therapy comes the question of when to
switch therapies. Upon initiating an effective therapy, viral load (the number of HIV RNA
copies/mL of blood) typically drops and CD4 count (the number of CD4 cells/mm3 of blood)
rises for some period of time. However, in the face of selective pressures, therapies typically
lose effectiveness due to the build-up of resistant mutations, resulting in a rise of viral load
(or virologic failure), a loss of CD4 cells (or immunologic failure), or the development of
AIDS-related complications (or clinical progression) [123]. These failures of therapies may
also happen because patients experience intolerable side effects from their therapies, do
not adhere well to their therapies, or have problems with drug absorption [123]. For these
reasons, deciding when to switch therapies and which therapy to use next are also major
considerations in HIV care.
Decisions involving the management of HAART are currently based on clinical judgment
and national guidelines for HIV care, which in turn are based on the outcomes of clinical
studies and expert opinion [123]. In Section 2.1 we review some of the studies that may have
influenced the current U.S. Department of Health and Human Services (DHHS) guidelines,
which are described in Section 2.2. Although clinical studies should be undertaken prior to
making any significant changes to treatment policy, such studies are not practical for narrow-
ing the field of potentially beneficial treatment plans. For example, cost, time, and ethical
considerations render randomized controlled trials unrealistic as the number of treatment
strategies increases. In such situations, mathematical models may prove quite useful to test
2
many possible treatment options with relatively little cost, in a relatively short amount of
time, and with no risk to patients. Therefore, the ultimate goal of our research is to provide
analyses and methods that can inform clinical studies.
1.1 PURPOSE AND CONTRIBUTIONS OF PRESENT RESEARCH
The purpose of this dissertation is to address the challenge of effectively manag-
ing HIV therapies, with a goal of maximizing a patient’s total expected lifetime
or quality-adjusted lifetime. We shall do this by developing Markov decision process
(MDP) models that capture essential aspects of HIV progression and treatment. Generally,
an MDP model is applicable whenever a decision maker observes the state of a system at
multiple points in time, and at each time, chooses an action to meet a goal (for example,
maximize the expected reward over the entire time horizon of the problem). Based on the
current state and action taken, a reward is received between time periods. Furthermore, due
to uncertainty in the way the system reacts to the chosen action, the decision maker has
only a probabilistic sense of how the system will evolve until the next period [140].
HIV therapy planning fits this framework. A physician sees an HIV patient periodically,
observing the patient’s state of HIV through laboratory measurements of key prognostic
variables such as CD4 count or viral load. Based on these measurements, the physician
decides (with the patient) whether to initiate therapy (and which one), switch to a different
therapy (and to which one), or continue as is until the next patient visit. Typically, decisions
are made with an overall goal of maximizing the patient’s expected lifetime or quality-
adjusted lifetime. For the former goal, the reward may equal the time between visits, and
for the latter, it may equal a quality-adjusted time between visits. Also, at the time of
the decision, it is not known how the prognostic variables will change over the next period
or whether the patient will even survive until the next visit. However, probabilities of the
different outcomes can be estimated based on clinical data.
To our knowledge, we are the first to utilize MDPs to consider optimal HIV therapy
planning. For a number of reasons, we believe this provides a natural and clinically valid ap-
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proach to the treatment problem. First, MDPs are designed to solve discrete-time stochastic
dynamic problems, and although patients may be seen at any time for specific problems,
most HIV care occurs at fixed intervals of time. Our MDP will consider actions taken at
these discrete time intervals (e.g., every month). Second, CD4 counts are known to vary con-
siderably day to day [169], so it is important to use a framework that considers the stochastic
progression of the disease. Third, MDPs include summable rewards and can consider the
possibility of patient death between time periods, both of which fit well with our objective
of maximizing expected lifetime or quality-adjusted lifetime. Finally, in addition to their
natural fit for HIV therapy planning and a variety of other decision problems, MDPs can be
used to gain deeper insight into a problem by investigating structural properties; that is, an
understanding of how certain structure on the input may guarantee certain structure on the
optimal solution. We refer the reader to [140] for extensive coverage of MDPs and references
to other literature on the topic. For a review of MDPs applied to health care, see [152].
The specific goals of this research are to:
1. Develop MDP models of the optimal time to initiate HIV therapy,
2. Use clinical data to solve for the optimal time to initiate therapy as a function
of a patient’s CD4 count,
3. Develop MDP models of the optimal sequencing and switching of HIV ther-
apies, and
4. Explore structural properties of each model.
The overall contribution of this research is to:
• Develop and solve the first HIV optimization models that aim to maximize
a patient’s lifetime or quality-adjusted lifetime.
4
The remainder of this dissertation is organized as follows. In Chapter 2, we describe
relevant literature, including clinical studies, mathematical studies, and the current national
guidelines for HIV therapy planning. Chapter 3 develops clinically based models of the
probabilistic progression of CD4 counts prior to initiating therapy, along with estimates of
remaining survival upon initiating therapy. These are used in Chapter 4, where we develop
an MDP of the optimal time to initiate therapy as a function of a single prognostic variable
(CD4 count). We explore structural properties and solve the model with the data-based
components of Chapter 3. Chapter 5 extends the framework to consider a two-dimensional
state space of CD4 count and viral load. Chapters 6 and 7 then consider the questions
of the optimal switching and sequencing of therapies. Chapter 6 considers these questions
assuming knowledge only about the lifetime distributions induced by the therapies, while
Chapter 7 takes the perspective of informative, periodic observations of a patient’s health.
We discuss conclusions, limitations, and future extensions of the dissertation in Chapter 8.
5
2.0 LITERATURE REVIEW
The literature on HIV and AIDS is extremely broad and deep. Here, we focus on research
related to the effective management of HAART. We divide our review into clinical studies
and mathematic models, and we give an overview of the U.S. Department of Health and
Human Services (DHHS) guidelines for HIV therapy management.
2.1 CLINICAL STUDIES
We review two major types of clinical studies that inform therapeutic decision making for
HIV: observational cohort studies and randomized controlled trials.
2.1.1 Observational Cohort Studies
In an observational cohort study, the outcomes of a patient’s chosen therapeutic course are
analyzed retrospectively, and then artificial treatment categories are created for comparison.
For example, outcomes of patients who initiated therapy when their CD4 counts were be-
tween 200 and 350 cells/mm3 of blood may be compared to similar outcomes for patients
who initiated therapy with a CD4 count greater than 350. Note that in this type of study,
there is no attempt to actually place patients into different treatment groups (which is the
case for randomized controlled trials). Relevant studies include [2, 8, 35, 61, 80, 106, 124,
126, 132, 168]. We review just some of them here.
Lepri et al. [106] analyzed a cohort of patients who initiated HAART for the first time
between 1997 and 1998. They grouped patients according to three categories of CD4 count
6
around the time of therapy initiation (referred to as the baseline CD4 count): ≤200, 201-
350, and >350. The authors found no significant difference in the risks of virological failure
between patients initiating therapy from the two higher CD4 categories. However, they did
find a notable difference in the risk between those initiating from the lower two categories.
Phillips et al. [132] aggregated patients from three cohort studies, and considered the
CD4 categories <200, 200-349, and ≥350, along with three categories of baseline viral load
(<10,000, 10,000-99,999, and ≥100,000 copies/mL of blood). They did not find a significant
correlation between lower baseline CD4 count and poorer virological outcomes. However,
they did find that patients initiating therapy with a viral load greater than 100,000 had
slower rates of obtaining viral suppression.
Egger et al. [61] analyzed 13 cohort studies and found that baseline CD4 category (<50,
50-99, 100-199, 200-349, ≥350) was highly associated with progression to AIDS or death.
Baseline viral loads above 100,000 were also associated with clinical progression.
Many cohort studies compare survival rates of patients from the time they initiate therapy
from, say, CD4 category 200-350 with the survival rates of patients from the time they initiate
therapy from CD4 category <200. Palella et al. [126], however, compared survival rates of
patients from the time they initiated therapy from the higher CD4 category with the survival
rates of patients from the time they delayed therapy from those same CD4 categories and
initiated therapy from lower categories. In other words, the authors compared patients
from the same starting point to estimate the effect of earlier versus delayed therapy. This
consideration of the survival of patients prior to initiating therapy (also referred to as lead
time) in conjunction with their survival after initiating therapy is essential for informing the
question of when to initiate therapy. The authors compared mortality rates for patients who
initiated versus delayed therapy from CD4 categories <200, 201-350, 351-500, and >500.
They found a clear survival benefit for patients who initiated as opposed to delayed therapy
in the CD4 category 201-350, and found that initiating versus delaying therapy when the
CD4 count is between 351 and 500 may also confer a benefit (results for the latter were not
statistically significant, with a p-value of .17). With respect to achieving an undetectable
viral load during three to four years of follow-up, the authors did find strong support for
patients initiating versus delaying therapy in the 351-500 range.
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Sterling et al. [168] also considered lead-time effects in comparing patients who initiated
therapy when their CD4 counts were between 350 and 499 with those who delayed therapy.
Kaplan-Meier curves of the time until a new AIDS-defining illness or death for patients in
the former group appeared better, though there was not a statistically significant difference
(p = .21). Based on these results, the authors support the guidelines policy of waiting until
the CD4 count falls below 350 before considering initiating HAART. For other studies that
consider lead-time effects, see [2, 8].
2.1.2 Randomized Controlled Trials
In a randomized controlled trial (RCT), patients are randomly assigned to different treat-
ment groups, which reduces the selection bias inherent in observational cohort studies. The
National Institute of Allergies and Infectious Diseases recently conducted an RCT, called
Strategies for Management of Antiretroviral Therapy (SMART), to compare two approaches
to HAART management: taking therapy immediately or waiting until the CD4 count falls
below 250 [44]. Patients in the latter group who initiate therapy also discontinue therapy
if their CD4 rises above 350. This trial was stopped in January 2006 because investigators
found that patients delaying and interrupting therapy experienced twice the risk of devel-
oping AIDS or dying compared to patients taking therapy immediately and continuously
[62, 120].
Robbins et al. [144] conducted an RCT that considered which three-drug regimen to
use as initial therapy. Within the same trial, Shafer et al. [155] examined the effectiveness
of initiating therapy with a four-drug regimen as compared to two sequential three-drug
regimens. Results supported the use of a particular three-drug regimen over others and did
not find support for initiating therapy with a four-drug regimen.
Martinez et al. [112] led an RCT to test the effect of a proactive switching policy
that switches between two drug regimens every three months, even if the viral load is still
suppressed at these times. They found that the switching policy yielded better virologic
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outcomes than the standard of care policy that switches therapy only when virologic failure
is detected. This trial was inspired by the mathematical modeling work of D’Amato et al.
[51], described more in Section 2.3.1.
An RCT conducted by Stebbing et al. [165] found that the recycling of certain drugs in
heavily pre-treated patients led to significant drops in viral load over a twelve week study
period.
Relationship to Present Research
In the introductory chapter, we noted that clinical studies should be carried out before
making any significant change to a treatment strategy. Therefore, we do not suggest that
the results of mathematical models, such as those developed in the following chapters, be
used directly to effect immediate change in treatment policy. Rather, we believe that well
constructed models provide efficient means for determining a feasible set of treatment options
to examine in a clinical study. Therefore, it is our hope to present our models, receive
comments on them, and refine them to the point that they are trusted tools to motivate
clinical studies, which in turn may justify changes to treatment policy.
2.2 NATIONAL GUIDELINES POLICIES
The following summarizes the most recent DHHS guidelines on initiating, switching, and
sequencing HIV therapies [123]. These guidelines are often revised as the results of new
studies, such as those discussed above, become available. Before proceeding, it will be
helpful to describe a little more about HIV therapies. There are three major classes of drugs
commonly used to combat the virus: Nucleoside Reverse Transcriptase Inhibitors (NRTIs),
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTIs), and Protease Inhibitors (PIs).
Currently, there are approximately 13 individual drugs within the NRTI class, 3 in the
NNRTI class, and 9 in the PI class. For more information on the different drug classes, refer
to [121].
9
2.2.1 Initiating Therapy
If a patient has had an AIDS-defining illness or experiences severe HIV symptoms, then
the guidelines indicate a patient should initiate therapy. Otherwise, the recommendations
are primarily driven by the patient’s CD4 count. When it is below 200, therapy should
be initiated, and when it is greater than 350, therapy should be delayed (although if the
viral load is greater than 100,000 copies/mL of blood, some clinicians recommend initiating
therapy). For CD4 counts between 201 and 350, the situation highly depends on the physician
and patient. For example, a physician may recommend a delay in therapy if the patient may
have trouble adhering to it.
Based on results of clinical studies, the DHHS recommends specific regimens to start
with and regimens that should be avoided. Recommended combination therapies contain
a “nucleoside backbone,” which consists of two drugs within the NRTI class. For initial
therapy, the third drug should come from either the PI or NNRTI class (refer to the DHHS
guidelines for names of specific drugs recommended).
2.2.2 Switching Therapy
The DHHS guidelines for when to switch antiretroviral therapy are much more complex than
their guidelines on when to initiate. For example, there are different ways in which therapy
may be thought of as failing: virological, immunological, and clinical. With treatment-naive
patients (patients never before on treatment), virologic failure occurs when there are repeated
viral load measurements of greater than 400 after 24 weeks or greater than 50 after 48 weeks.
Virologic failure also occurs if the viral load is repeatedly detected after being suppressed
below detectable limits. Immunologic failure is defined as the failure of the CD4 count to
increase by 25-50 cells/mm3 of blood above the baseline count over the first year of therapy
or a decrease of the CD4 count below the baseline at any time. Finally, clinical progression
is the occurrence of an AIDS-related illness or death at least three months after being on a
regimen. The three types of failure have distinct time courses and may occur independently
of one another. Typically, though, virologic failure is followed by immunologic failure and
then clinical progression.
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If some type of treatment failure is observed, the guidelines recommend that physicians
investigate the likely reason for the failure. If the problem seems to be with the patient’s
adherence to therapy, the physician may consider simplifying the regimen by decreasing
the quantity of pills or the frequency of taking them. For problems with side effects, the
physician may consider treating the symptom directly, changing from one drug to another
within the same class, or changing drug classes. For drug absorption problems, the physician
should check that the patient is taking the drugs in accordance with meal restrictions and
that there are no interactions between the patient’s HIV therapies and other medications
or dietary supplements. If the above do not present difficulties, then the likely reason for
failure is the development of drug resistance, and physicians should obtain resistance test
results while the patient is taking the failing regimen.
The guidelines state, “there is no consensus on the optimal time to change therapy for
virologic failure.” An aggressive approach would be to change therapy immediately for any
repeated detectable viral load levels, while some approaches allow detectable viral load up to
some level (e.g., between 1,000 and 5,000 copies/mL of blood). If drug resistance is present,
then the guidelines suggest switching therapies earlier rather than later, though this is vague.
For patients who have been on many therapies, the guidelines indicate that keeping them on
the same regimen may be reasonable if few treatment options remain. However, if the CD4
count is less than 100, it is recommended to switch therapies if any effective ones remain.
Even with no treatment options remaining, it may benefit patients to remain on a failing
therapy, as some evidence suggests that HIV is less fit as a mutated strain compared to
the original “wild-type” strain [117, 137, 141]. If the viral load is suppressed but there is
apparent immunologic failure, perhaps just one drug may need to be changed. In the case
of viral load suppression with clinical progression, an immune reconstitution syndrome may
be present (an inflammatory response sometimes triggered when a patient’s immune system
improves [36]), which may respond to anti-inflammatory treatment instead of a change of
therapy.
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Because drug resistance tends to be cumulative for a patient, upon deciding to switch
therapy, all prior treatment history and resistance test results should be considered to ensure
proper selection of effective drugs [123]. The guidelines recommend trying to find at least
two drugs that should be active against the current strain of virus. If that does not work,
then adding a PI with the drug ritonavir may be considered.
The DHHS guidelines emphasize careful consideration before switching to a new therapy,
as there are a limited number of effective regimens available to a patient. Therefore, although
maximal suppression of viral load is one stated goal, one needs to balance an inclination to
switch out a failing therapy against the preservation of a limited supply.
2.3 MATHEMATICAL MODELS
We next describe relevant literature in mathematical modeling. We begin by covering models
directly related to HIV therapy planning. Then we discuss well-studied areas of operations
research that, to our knowledge, have never been considered in the context of drug therapy
management despite having some natural connections. These areas are machine maintenance
and inventory depletion management. We also describe a class of problems that do not have
natural connections to therapy planning but which includes our models for the optimal time
to initiate HIV therapy. These are known as optimal stopping problems.
2.3.1 HIV Models
Several continuous-time control-theoretic models address optimal HIV therapy planning [7,
20, 21, 29, 33, 66, 87, 89, 97, 98, 181, 182]. Each of these models attempts to reduce viral
load to low levels or maintain CD4 counts within desired ranges. For example, Jeffrey et
al. [87] took a control-theoretic approach for evaluating the effect of initiating HIV therapy
during the acute infection stage, the asymptomatic stage, or the later stages of the disease.
They found that it is easiest to control viral load when it is at high levels during the acute
infection stage.
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Wein et al. [182] took a control-theoretic approach for deciding when to switch com-
bination therapy and which therapy to use next. Using ordinary differential equations to
model the progression of uninfected CD4 cells, viral strains that may emerge, and CD4 cells
infected by each viral strain, their objective was to minimize the total viral load over some
time horizon, T , where at each time point, t, one of a finite set of therapies may be used.
Two key assumptions were 1) that therapy can be changed at any instant of time, and 2)
that a clinician can perfectly observe a patient’s levels of CD4 cells and viral strains. Due
to the difficulty of finding a closed-form solution to their control-theoretic formulation, the
authors used approximation methods and dynamic programming to derive switching poli-
cies. Their proposed strategy was a dynamic index policy that at each point in time finds
the drug regimen that yields the largest index, where the index value for a certain regimen
represents that therapy’s effectiveness in preventing viral load increases. Using a simple
example of two viral strains and two drug therapies, they used a Monte Carlo simulation to
evaluate various policies including a static policy (of using just one therapy for the entire
time horizon), a simplified dynamic index policy, and the original dynamic index policy. The
two dynamic index policies yielded similar results and performed significantly better than
the static policy.
Brandt and Chen [29] modeled HIV, CD4 cell, and CD8 cell (another type of white blood
cell) dynamics using nonlinear continuous differential equations, and they used time-delay
feedback control to suppress viral load below detectable levels. Noting that actual patient
measurements are typically taken one to three months apart, they compared a more realistic
discrete-time version of their control problem with the continuous version and found that
the former performed quite well. The authors mentioned that feedback control, which lowers
drug doses as viral load declines, has the benefit of reducing side-effects from the drugs and
possibly increasing adherence.
Berman and Dubin [21] considered both a continuous-time deterministic model and a
discrete-time stochastic model for choosing the CD4 count at which to initiate therapy so
as to maximize the duration of time the CD4 count remains above a certain level (such as
200). The deterministic model assumed that the CD4 count declines linearly with some
slope m1 until therapy is introduced, at which point it levels out for an amount of time
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that may depend on the CD4 count. This plateau is supposed to represent the duration of
the therapy’s effectiveness. When this time expires, they assumed the CD4 level continues
to decline linearly with another slope m2. They found relationships between m1, m2, and
the duration function that determine whether initiating therapy earlier or later is better.
Their stochastic model considered random errors around the CD4 measurements at equally
spaced point in time and produced similar results to their deterministic model. Berman [20]
expanded on this model by forming a continuous stochastic model that employs diffusion
processes to model the change in CD4 count. Because these models were developed in the
pre-HAART era, they considered only one therapy (AZT).
Kamina [91] considered a patient’s immune response to HIV in deriving growth models
of the virus. Recent studies demonstrate the importance of the immune system response in
fighting HIV (see [91] for a list of such studies). Most of Kamina’s research was devoted to
developing a set of differential equations that describes the dynamics of the uninfected CD4
cells, the various viral strains, the actively and latently infected CD4 cells, and the immune
cells that attack the various viral strains. Kamina did, however, use Monte Carlo simulation
to test three different treatment strategies: 1) using a single drug, 2) alternating two equally
effective drugs at predetermined switching times, and 3) using those two drugs and switching
only when the resistant mutations exceeded a certain level. The second and third strategy
outperformed the first one, while the resistance threshold affected which of the second and
third strategy was better.
D’Amato et al. [51] developed a Monte Carlo simulation to evaluate the risks associated
with switching therapy too early or too late, based on various switching policies. They
assumed that viral load dynamics followed deterministic equations and that the viral load
measurements were subject to random error. Then they compared the different policies by
evaluating two measures of performance: the probability of switching therapy prior to the
viral load nadir, and the mean time until changing therapy for those patients who switch
after the nadir. Since the desire to minimize both these measures presents a conflict (making
one of these small tends to make the other one larger), they searched the parameter space in
discrete jumps to find the parameters that minimize the mean time until post-nadir switching
subject to a maximum probability of pre-nadir switching.
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D’Amato et al. [52], working within the above framework, developed approximate,
closed-form expressions for the two performance measures discussed above. They then tried
to obtain the policy that minimizes the expected time between viral rebound and regimen
switch, subject to a maximum limit on the probability of pre-nadir switching. Their opti-
mization problem was too difficult to solve exactly, so they used the simulation to evaluate
the various policies.
Freedberg et al. [67], using data from major clinical trials, developed a Monte Carlo
simulation model of the progression of viral load and CD4 count before and after patients
initiate HAART. They performed various cost effectiveness analyses such as deciding whether
or not three-drug therapy is cost effective compared to no therapy at all and evaluating
the cost effectiveness of initiating three-drug therapy at various CD4 counts. Their model
predicted that three-drug therapy is cost effective and that initiating therapy at a CD4 count
of 500 was more cost effective than initiating at a CD4 count of 350 or 200.
Richter et al. [143] built a Monte Carlo simulation of HIV patients undergoing up to
three sequential drug regimens. Their model considered progression to AIDS and mortality as
functions of CD4 count. They incorporated quality-of-life and cost measures into their model
and used it to test a hypothetical example comparing patients who do not take therapy with
those who do. A drawback of their model is that they only considered an immediate one-time
gain of CD4 with successful therapy (as opposed to an upward stochastic progression over
multiple time periods).
Braithwaite et al. [26] also developed a Monte Carlo simulation of HIV progression, which
differs from other models by explicitly considering patient adherence to therapy and the
development of resistant mutations of the virus. These are important features, as adherence
and resistance are major factors in the success or failure of HIV therapy [11, 18, 34, 37, 38,
63, 71, 115, 122, 123, 129, 147, 163]. The model has been used to estimate the impact of
alcohol consumption on HIV patient survival [27], to estimate the proportion of HIV patients
who die of comorbid diseases [25], and to explore the relationship between adherence and
mutation accumulation [28].
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Relationship to Present Research
Although ours is not the first mathematical modeling approach to HIV therapy planning,
we explore optimization models that capture clinical realities not covered by other models.
For instance, the control-theoretic models did not consider the possibility of patient death
nor model quality of life. Yet one of the studies assumed an infinite time horizon [182]. Also,
with the exception of [20, 21], the control-theoretic models assumed a set of deterministic
differential equation models and did not consider stochastic progression of patient health.
Furthermore, the models implicitly assumed continuous patient monitoring and changes of
therapy, which is not realistic in the HIV patient setting (such a framework is more suitable,
for example, for surgery patients receiving anesthesia infusions [84]).
The papers by D’Amato et al. [51, 52] on when to switch therapy did not consider the
issue in the context of optimizing patient outcomes. Rather, based on a proposed switching
strategy, their models considered tradeoffs between two undesirable events: switching therapy
earlier than necessary vs. later than one should. However, their models did not consider
the possibility of patient death or factor in long-run outcomes associated with switching
therapies. Furthermore, they made strong assumptions of deterministic viral load decay and
rebound and did not consider fluctuations in these values for reasons other than measurement
error.
Here we describe in more detail the advantages and disadvantages of Monte Carlo simu-
lation modeling versus MDP modeling and how they may complement each other. An MDP
solves for an optimal decision policy with respect to a single outcome of interest and returns
the exact value associated with the optimal policy. Moreover, the solution of an MDP rarely
requires an exhaustive search over all the possible policies. On the other hand, a simula-
tion takes as input a single decision policy and approximates various outcomes of interest
by averaging the results of many simulation replications. Although simulation models are
excellent tools for testing a variety of “what if” scenarios, to seek an optimal decision policy
through simulation, one would have to exhaustively test all possible decisions across multi-
ple time periods and compare the results of multiple replications. Furthermore, because the
simulation results are estimates, choosing the policy that yields the best outcome is subject
to a probability of being the incorrect choice (see [103] for further discussion of this topic).
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A clear advantage to simulations, however, is that they can accommodate considerably more
detail than MDPs and can easily generate a multitude of outcomes. As a result of the ad-
vantages and limitations of both methodologies, Monte Carlo simulations and MDPs may
be used together to inform decision making for complex problems. For example, a highly
detailed simulation model may suggest what outcome is most important and sensitive to the
decision making process. Then we can solve a simpler MDP model for the optimal policy
with respect to that outcome. In turn, the resulting policy may be used in the more detailed
simulation for further evaluation of a variety of outcomes not optimized for by the MDP.
2.3.2 Machine Maintenance Models
There are well over 1,000 papers discussing optimal policies for maintaining a system subject
to stochastic deterioration over time. Most of these are discussed or listed in various surveys
and bibliographies of the literature [86, 114, 135, 161, 177, 180]. Surveys and discussions
of applying these techniques to real problems can be found in [55, 149]. Also, classic books
discussing this subject include [12, 88]. Unless otherwise noted, the descriptions below are
based upon aggregating concepts from these sources.
In nearly every machine maintenance optimization model, a system undergoes stochastic
deterioration, and actions are available to alter the state of the system to either avoid
system failure or attend to failures. The actions are chosen to meet an underlying objective
such as minimizing the long-run average cost of the system or the long-run fraction of
the time the system is inoperable. Beyond this basic commonality, there are various ways
one can dichotomize the research on machine maintenance optimization. For example, one
such classification is whether the model is a “preventative” or “preparedness” maintenance
problem. In preventative models, it is assumed that one always knows the state of the system
and therefore knows when a failure occurs. The decision problem arises because performing
a repair or replacement after a failure is costlier than doing so beforehand. The problem
then becomes one of choosing the best time to replace or repair a machine. Two types of
models often considered are the “age-replacement” and “block-replacement” models. In the
age-replacement model, a machine is replaced whenever it reaches an age of T or whenever it
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fails. A typical objective is to determine the replacement time, T , that minimizes the long-run
average cost of system. With the block-replacement model, replacements are scheduled at
calendar times (T, 2T, . . .) and upon failures. These types of policies are generally considered
for systems with multiple parts in which advantages from economies of scale can be obtained
by ordering more than one part at a time. In preparedness models, the state of the system
is unknown until an inspection or replacement action is performed. Upon inspection, if the
system is in a failed state, a replacement is made. Otherwise, the decision maker can choose
to perform maintenance on the machine or choose the next time to inspect the machine.
There is a tradeoff between frequent and cheaper inspections and infrequent inspections
with a costly penalty for undetected system failures.
Another dichotomy is between systems with a single stochastically failing part and sys-
tems with multiple stochastically failing parts. For single-part systems, it is assumed that
the system depends entirely on the functioning of one vital part; when that part fails, the
system fails. For multi-part systems, the system may fail when some number of parts fail,
and policies indicate inspection and/or maintenance actions to take for each of the parts.
The actions to take for some parts may depend on the state of others, and savings may be
realized by replacing several parts at once (as with the block replacement policy mentioned
above).
The literature can also be separated into models for which an endless supply of replace-
ments (and infinite time horizon) is assumed versus those with a finite supply (and a finite
or random time horizon). Most models consider the infinite replacement model and assume
that replacements behave stochastically identical and independent of one another (referred
to as a renewal process) which is fairly easily solved for an optimal stationary policy. How-
ever, McCall [114] discussed finite time models for which the renewal assumptions do not
hold and stationary policies are no longer optimal. Rather, upon each maintenance action, a
new optimal policy is obtained that depends on the remaining time left. Derman et al. [58]
considered a finite number of replacements available, and we discuss this paper in detail in
Chapter 6. We discuss other models that consider a finite stock of replacements in Section
2.3.3.
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Another important dichotomy in the machine maintenance literature is between models
with two states (functioning or failed) and models with multiple states. In the former
case, one knows only whether or not a machine is operating. In the latter case, models
typically contain a failed state, and various degrees of functioning, from a new machine
to increasing levels of system deterioration. The literature shows two distinct approaches
to modeling the two-state vs. multi-state models. The two-state models generally take
a lifetime distribution approach in which the cumulative distribution functions describing
machine lifetimes are assumed known and the decision maker then chooses the best time
along those distributions to perform a maintenance action or inspection. The framework for
these models generally implies that the decision maker sets a policy a priori that will not
change over time. Solution approaches for the two-state modeling approach may involve a
combination of dynamic programming and calculus-based techniques for finding minima or
maxima of functions. We discuss scheduling HIV therapies in this context in Chapter 6.
The two-state modeling approach just described is in contrast to the MDP modeling
approach generally taken in the multi-state models [56, 83]. These models assume that
any information required to predict future system outcomes is contained in the description
of the current state of the system and is independent of past states. Whereas optimal
policies for the two-state models described above indicate a definite action to take at some
predetermined time t, the optimal policies for the multi-state models typically are of the
form: “if you observe that the system in state si, take action ai.” In other words, the MDP
allows for using updates of the system state to make decisions adaptively instead of a priori.
Authors typically seek conditions that guarantee optimal structural policies, such as control-
limit policies that say a machine should be replaced if it is in some state or worse and to do
nothing until the next period otherwise. We discuss scheduling HIV therapies in this context
in Chapter 7.
Klein [100] gives two justifications of the Markovian assumption in these models. The
first considers the observation of approximate exponential lifetime distributions for various
electronic components. From the memoryless property of the exponential, the Markov
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property follows. The other justification relates to the general practice in classical dynamics
of describing a physical system sufficiently well in order to predict outcomes based on the
present state, regardless of the path taken to get there.
Machine maintenance models are also separated by whether model components are as-
sumed to be known completely or partially. For example, in the two-state models, the lifetime
distribution of the system may not be known with certainty. In such cases, minimax policies
may be sought, or Bayesian updating may be employed [88]. For the Markov models, there
may be uncertainty as to the true state of the system, in which case one can use solution
techniques derived from MDPs, known as partially observable Markov decision processes
(POMDPs) (for a survey of POMDPs, see [118])
Shock models represent one modeling approach that does not fall neatly into any of
the dichotomies mentioned above (for a review, see [177]). These models describe a system
subject to shocks occurring at random times, causing a random amount of damage to the
system. The time between shocks and the amount of damage may depend on the damage
accumulated until some time, t. System damage is modeled through failure probabilities
and costs. Again, replacements made before system failure cost less than replacements made
after system failure, and all replacements act like new with identical stochastic deterioration.
Most authors seek optimal control-limit policies in which a replacement is made when the
accumulated damage reaches some threshold level or worse (unless a failure occurs before
that time, which leads to system replacement).
Relationship to Present Research
Although there is significant potential to apply ideas from machine maintenance theory to
health care, there are few examples in the literature. In his 1965 survey, McCall [114] points
out that medical applications of the analyses presented in his paper are virtually nonexistent.
Little has changed since then. Christer and Scarf [40] considered maintenance optimization
theory in the context of deciding when to replace medical ventilator equipment. Although
the burden to patients was considered using a penalty cost for inaccessible equipment, the
problem was primarily a cost minimization problem rather than a patient health optimization
problem. Some authors have applied inspection policies to the problem of scheduling medical
exams. For example, Lincoln and Weiss [109] discussed the scheduling of cervical cancer
20
examinations and the mean time until detection of a tumor under a given scheduling policy.
They sought the maximum inter-examination times that satisfied various objectives regarding
the time until tumor detection (e.g., the policy needed to ensure that the mean time until
detection of a tumor be less than some time T ). Kirch and Klein [96], Zelen [189], and
Biswas and Dewanji [23] took a slightly different approach by framing the detection delay
optimization problems in the context of a constraint on the number of examinations.
In their 1976 survey, Pierskalla and Voelker [135] discuss how the theory of machine
maintenance can be applied to human maintenance, thereby cutting costs and prolonging
patient lifetimes. Just as a systems manager has options for improving the “health” of a
system, physicians generally have options which can “repair” the health of a patient in the
short term. To our knowledge, Alagoz et al. [5, 6] are the only ones to have made an
explicit connection between human health optimization and machine maintenance planning
(with regard to liver transplantation). In subsequent chapters, we draw connections between
machine maintenance problems and HIV therapy planning.
2.3.3 Inventory Depletion Management
Another area of research that has connections to HIV therapy planning is inventory depletion
management (IDM), also referred to as optimal issuing policies (see, for example, [30, 31,
57, 64, 108, 134, 133, 188]). The basic framework of these problems is that there are a finite
number of similar items, with various ages, waiting in a stockpile. Items are selected from
the stockpile one at a time to be used in the field, at which time they generate a field life
that depends on the item’s age at issuance. An item is issued immediately from the stockpile
upon the termination of the previous item’s lifetime in the field. The objective is then to
maximize the field life (or expected field life) obtained by the sequence of selected items from
the stockpile. Under varying assumptions about the field life as a function of the item’s age
at issuance, authors give conditions under which LIFO (last in, first out) or FIFO (first in,
first out) policies are optimal. By LIFO, they mean to always select the youngest item and
by FIFO, to always select the oldest.
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For example, a paper by Brown and Solomon [31] considered n independent items, with
possibly different lifetime distributions that are multiplied by a factor d(t) when the item is
issued at time t (with d(0) = 1). That is to say, at time t = 0, item i has a field lifetime
distributed as Xi and at time t it has a field lifetime distributed as Xid(t) (presumably d(t)
decreases over time, although that is not required). An optimal policy is one that yields a
total field lifetime distribution which is stochastically greater than that of any other policy.
They considered distributions at time t = 0 that can be ordered in a certain stochastic sense.
For example, if Xi and Xj are continuous random variables with common support [a, b], then
Xi ≺ Xj if for all a < r < s < b, fXj(s)/fXi(s) ≥ fXj(r)/fXi(r). Their main result is that if
d(t) is positive and strictly concave (convex) then LIFO (FIFO) is the unique optimal policy.
Relationship to Present Research
We may be inclined to adapt the IDM framework to HIV therapy planning by selecting
n different HIV therapies from a stockpile in a way that maximizes the expected patient
lifetime from the sequencing. Suppose the n therapies have different levels of effectiveness
and that we can order them in the sense given above for the patient lifetime distributions
they induce at time t = 0. Also, suppose we have a function d(t), with a range between
zero and one, to indicate a decreasing therapy effectiveness over time (resistance to certain
therapies taken can confer resistance to other therapies not yet taken (known as “cross-
resistance”), thus decreasing the unused therapies’ effectiveness). Then if d(t) is strictly
convex, we may say that the optimal policy is to always select the most effective therapy
currently available. However, there is a key difference between the traditional IDM problem
and a therapeutic optimization problem: the IDM problem assumes that an item can be
replaced after its lifetime ends, whereas if a patient’s lifetime ends, leftover therapies in the
stockpile become worthless. The essence of the therapeutic optimization problem is to delay
the end of a patient’s lifetime by strategically replacing therapies. If the IDM models had
the following two extensions, then they would be more applicable to therapy planning. One
is to consider that while item i is activated in the field, there is a probability that it causes
system-wide failure in which remaining items in the stockpile become useless. The other
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extension is then to consider optimal issuing and removal policies that decide which item to
issue at what time and when to remove the item so as to strategically avoid system failure
and maximize the expected field life of the issuing and removal policy.
2.3.4 Optimal Stopping Problems
Optimal stopping problems describe situations in which a decision maker observes a system
periodically, accrues rewards and/or costs between periods, and at any period, can stop the
process and receive a terminal reward or cost. The decision maker’s goal is to decide when to
stop the process so as to maximize the total expected reward or minimize the total expected
cost [39, 65]. MDPs are often used to solve these problems because of their natural fit.
Examples of optimal stopping problems include the secretary problem [140] (when should
someone stop interviewing candidates for a job and hire the current candidate?) and the
parking problem [138] (when should someone stop searching for a better parking spot and
take the next open space?). A recent application to therapy planning is the optimal time
for a patient to accept a living-donor [5] or a cadaveric liver transplantation [6].
Relationship to Present Research
Our models for the optimal time to initiate HIV therapy, presented in Chapters 4 and 5,
fall into the class of optimal stopping problems. The reward a patient receives when waiting
from one month to the next can be defined as that one month of time or one quality-adjusted
month. Upon initiating therapy, patients in our model receive a terminal reward equal to
the expected remaining lifetime or quality-adjusted lifetime, based on their health state at
the time of initiation. When waiting, patients may die and lose the opportunity to receive
the larger terminal reward; however, initiating therapy when in a relatively healthy state
may be wasteful. The goal, therefore, is to decide the best time to stop the waiting process
and initiate therapy.
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3.0 STATISTICAL MODELING OF THE NATURAL HISTORY OF CD4
COUNT AND SURVIVAL UPON INITIATING THERAPY
3.1 INTRODUCTION
This chapter discusses the use of clinical data to build a discrete-time Markov model of
the natural history of CD4 progression (that is, progression without treatment) as well as
a survival model to estimate expected remaining lifetime upon initiating HIV therapy from
different CD4 strata [159, 160]. Both components will be used to solve the MDP model of
when to initiate therapy discussed in Chapter 4.
Our data are provided by the Veterans Aging Cohort Study (VACS), a prospective,
observational cohort study of HIV positive and HIV negative patients from Veterans Health
Administration (VA) hospitals across the U.S. [179]. The VA is the largest provider of HIV
care in the nation. Our cohort contains 25,550 HIV+ patients with a history of laboratory
measurements and 66,840 HIV- patients to draw from for controls (used in the survival
model). Because 98% of the HIV+ patients in this cohort are men, we focus our analyses
solely on male patients (25,041 HIV+ patients). We discuss the implications of this in
Sections 3.4 and 4.6.
Unless otherwise noted, all statistical work is done in the open-source statistical package
R, available at http://www.r-project.org/ (for references on using R, see [50, 178]).
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3.2 A DISCRETE-TIME MARKOV MODEL OF THE NATURAL
HISTORY OF CD4 COUNT
In addressing the question of the optimal time to initiate therapy in Chapter 4, we shall
consider antiretroviral-naive patients; the answer to the question may differ significantly for
patients who have prior antiretroviral experience and thus may have developed resistant
strains of the virus. We track the progression of patients’ CD4 counts because this is the
primary variable used to guide when patients should initiate therapy [123, 166]. We focus our
analysis on male patients between 40 and 50 years old upon their first CD4 measurement, as
this ten year age bracket has the largest number of patients in our cohort. Also, we categorize
the CD4 count into four distinct categories: 0−49, 50−199, 200−349, and ≥350 cells/mm3
of blood. Similar groupings can be found in other clinical studies, and these strata allow for
results to be interpreted in the context of the guidelines categories of <200, 200-350, and
>350 [123] (recall the recommendation that patients initiate therapy when CD4 falls below
200, wait when it is above 350, with debate on what to do between 200 and 350).
Our optimization model considers patients who visit their physician every month to
determine whether or not to initiate therapy based on their CD4 count. Although CD4
counts prior to the initiation of therapy generally decline, the actual measurements may vary
considerably from month to month. This is seen in the plots of actual CD4 measurements
taken over time for two VACS patients, labeled A and B (Figures 1 and 2). Therefore,
instead of considering just the mean decrease in CD4 counts over time [116], we want to build
a discrete-time Markov model that describes the monthly transition probabilities among the
various CD4 categories and death, prior to initiating HIV therapy. Discrete-time Markov
modeling is a common technique in medical decision making to predict and track patient
progression from one time period to the next, as a function of a patient’s current state [16,
145, 164]. The technique is also natural to use when clinical decisions may be considered at
discrete time periods. There may be several challenges in constructing transition probability
matrices, such as irregular observation times, incomplete data, and censored observations
[47, 48, 70, 85, 184]. Details of other discrete-time Markov models of CD4 progression can
be found in [1, 32, 68, 110, 111, 113, 154]. Freedberg et al. [68] also considered a Markov
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Figure 1: Actual CD4 measurements over time for Patient A
cycle length of one month to reflect the setting for HIV care. Because our MDP model
also requires estimates of expected remaining survival upon initiating therapy (discussed in
the next section), this chapter develops both parts of the model from a single data source
(VACS).
In addition to the variability in the CD4 counts, Figures 1 and 2 also demonstrate
irregularity in the time between consecutive CD4 measurements. In fact, many months may
elapse between measurements. Therefore, we use a method called smoothing splines to fit a
continuous curve to the data in a way that captures the variability of the data [73]. Then
we sample CD4 counts from this curve at monthly intervals, categorize them, and build
an empirical estimate of transition probabilities among CD4 categories and death from one
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Figure 2: Actual CD4 measurements over time for Patient B
month to the next. A similar approach was used by Alagoz et al. [4] to model the natural
history of end-stage liver disease.
A smoothing spline is a curve-fitting technique that allows one to make an explicit tradeoff
between how close the curve comes to the actual data (thus reducing the sum of squared
residuals) and how smooth the curve is. For example, a linear regression through a set of
data is the smoothest of all cubic splines, but with the greatest sum of squared residuals. On
the other hand, one can have a cubic spline go through each data point (i.e., interpolate the
data), which reduces the sum of squared residuals to zero, but it is considered the roughest of
all the splines. The tradeoff can also be made somewhere in between these two extremes. We
briefly describe the method more formally, based on [73]. Let g(·) be a twice-differentiable
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function and consider a set of n data points (ti, Yi), i = 1, . . . , n, along with the following
function, called the “penalized sum of squares”:
S(g) =
n∑
i=1
[Yi − g(ti)]2 + α
∫ tn
t1
[g′′(x)]2dx (3.1)
The first term of the sum gives the sum of squared residuals. The component
∫ t2
t1
[g′′(x)]2dx
measures the roughness of the function g and when multiplied by α, the term is referred
to as the “roughness penalty.” The parameter α, called the “smoothing parameter”, is a
user-defined input that represents the tradeoff between how smooth or variable one wants
the curve. Under a choice of α, the goal is to find a twice-differentiable function, gˆ, that
minimizes S(g). As α→∞, gˆ approaches the linear regression fit (hereon referred to as the
“smoothest spline”), and as α→ 0, gˆ approaches the interpolating curve (hereon referred to
as the “roughest spline”). It can be proven that the function gˆ is a natural cubic spline over
the interval [t1, tn], that is, a piecewise cubic polynomial connected at the points (t2, . . . , tn−1)
(also referred to as “knots”), such that the first and second derivatives of f are continuous
at each ti, and the second derivative equals 0 at t1 and tn.
Figure 3 shows the actual CD4 measurements along with three splines for Patient A.
Rather than adjust α, one may also adjust a parameter called the “degrees of freedom” (df),
which has a direct mathematical relationship with the smoothing parameter α. When df
equals 2, we obtain the smoothest spline and when df equals the number of data points,
we obtain the roughest spline (labeled as the “0 sum of squared residuals” in the figures).
The spline labeled “average”, is obtained by setting df to be (2 + #datapoints)/2 (df can
take on fractional values). Figure 4 shows the same for Patient B. Because of the significant
variability in a patient’s CD4 measurements over time, we use the roughest splines. In
Section 4.5, we examine the sensitivity of results to the choice of df .
To capture the period of time for which patients are antiretroviral-naive, we proceed as
follows. Our data include the date on which the patient first started therapy in VACS, so
we consider patients and their lab values prior to this date; if no such date is recorded, then
we include those patients and all of their lab values as well. From this set of patients, we
exclude anyone whose viral load at any time was below 5,000 copies/mL of blood, as it is
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Figure 3: Actual CD4 measurements with splines for Patient A
unlikely that an antiretroviral-naive patient would attain such a low level of viral load [90].
This reduces our patient set from 25,041 to 20,586.
We then build our discrete-time Markov model of the natural history of CD4 progression
as follows. Because patients may receive viral load tests at some times and CD4 measure-
ments at others, we keep only those patients for whom CD4 measurements exist prior to
the first therapy start date. Over 4,500 patients had viral load measurements but no CD4
measurements prior to initiating therapy, and thus our set reduces to 15,924 patients after
this step. Finally, we select patients between 40 and 50 years old upon their first CD4 mea-
surement (recall that this ten year age bracket has the largest number of patients in our
cohort), leaving us with 6,749 patients from which to build our natural history model. The
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Figure 4: Actual CD4 measurements with splines for Patient B
earliest CD4 measurement among these patients was taken on October 1, 1991 and the most
recent measurement was taken February 13, 2003.
For patients with four or more CD4 measurements (n = 1, 351), we fit a cubic spline (four
is the minimum number of data points required to construct a cubic spline); for patients with
two or three measurements (n = 1, 999), we fit a linear regression; and we eliminate patients
with only one CD4 measurement (n = 3, 399). Also, if the time between the patient’s final
antiretroviral-naive CD4 measurement and the first measurement is less than 25 days, we
eliminate the patient from our estimation of monthly transition probabilities. This happens
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for only one patient with four or more observations, and happens for 311 of the patients with
two or three observations. Therefore, we build our transition probability matrix using 1,350
cubic splines and 1,688 linear regressions.
CD4 counts are non-negative, and CD4 counts greater than 2,000 cells/mm3 of blood
are clinically unrealistic [24, 102]. When building our cubic splines that maximally capture
the CD4 fluctuations, the curves may very well extend beyond these limits (this happens
for 163 of the splines). When this occurs, we decrease df by one to construct a smoother
spline and determine if the curve lies within the limits. If not, we repeat this process until
we obtain a spline that stays completely within the CD4 range of 0 to 2000. If we reach
df = 2 (the linear regression) and still find that the the limits are crossed, then we simply
cap the estimates at these limits.
After obtaining our curves, we begin tabulating the transitions from the CD4 category at
the beginning of one month to the CD4 category at beginning of the next month (or death)
that occur as we proceed from the start of one patient’s curve to the end of that curve. Our
first step in recording the transitions to death is as follows. If the next event beyond the last
CD4 measurement is the patient’s death, and if this is within about a month of the last CD4
measurement (we chose six weeks, or about 1.5 months, as our cutoff), then we tabulate
a transition from that patient’s last curve-estimated CD4 category to death (n = 46). If
the death date is beyond this time (n = 111), then we take the average monthly change in
CD4 count from the patient’s first CD4 measurement until the last, ensure that this is no
more than zero (i.e., we do not allow for a positive slope in CD4 counts prior to initiating
therapy), and extend the monthly CD4 estimates beyond the final curve-derived estimate
by this amount, until arriving within 30 days of the patient’s death date. Then we tabulate
a transition from the final estimated CD4 category to death.
Figure 5 demonstrates the procedure of tabulating transitions for a hypothetical patient
who dies without ever taking therapy. The generated spline for the patient is shown, along
with vertical lines representing 30 day intervals along the spline. The table within the figure
shows the aggregate monthly transitions from day 0 until the patient dies after day 570. The
categories in the first column represent possible ranges of the patient’s CD4 count at the
beginning of a month, and the categories in the first row show the same categories along with
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Figure 5: Example of building a transition matrix for a hypothetical patient
the possibility of death by the beginning of the next month. The final transition is from a
CD4 count between 50 and 199 to death, and therefore we mark a 1 in the appropriate table
cell showing a transition to death. We proceed in this fashion for each patient, aggregate
the tables across all patients, and divide each cell count by the row sums to estimate the
natural history transition probabilities.
3.2.1 The Problem of Censored Observations
Note that we have only recorded 157 deaths from the 3,038 patients we are examining
(5%). The reason for this is the censoring of patients from the natural history progression.
Censoring, a concept from survival analysis, describes the situation in which the end-point
32
Table 1: Percent of monthly transitions from each category that are censored due to the
initiation of therapy
CD4 Categories
0-49 50-199 200-349 ≥ 350
Censors from Initiating Therapy 7.6% 4.9% 4.4% 2.1%
of interest is not observed for a patient [43]. For example, when tracking the survival of
patients prior to initiating therapy, there are three ways their pre-therapy survival may be
censored. One is that they have not started therapy and are still alive at the time the data
is collected. Another is that for some reason, they leave the study (e.g. moved away). This
is known as “loss to follow-up”. The third reason is that they initiate therapy, which is a
common type of censoring in HIV care because as patients’ CD4 counts decline, guidelines
suggest they initiate therapy at some point. In other words, few HIV patients go entirely
untreated; our data yield 2,690 patients (89%) whose natural history CD4 measurements are
censored by the initiation of therapy, and just 191 (6%) who are censored for other reasons
(the other 5% are the recorded patient deaths). To tabulate transitions from the various CD4
categories to censors attributable to the initiation of therapy, we consider whether or not the
patient initiates therapy within six weeks of the final CD4 measurement and follow a similar
procedure as described above (in the case of patient death) for extending the CD4 progression
up until the last month before the initiation of therapy. Table 1 shows the percentage of
transitions, from each CD4 category, that result in a censored observation attributable to
the patient initiating therapy by the beginning of the next month. This percentage is as
high as 7.6% for patients with CD4 counts < 50 and decreases monotonically in the CD4
categories to 2.1% for patients with CD4 counts ≥ 350.
Unfortunately, when censors are caused for reasons such as the initiation of therapy at
lower levels of CD4 count (referred to as “informative censors”), they invalidate standard
methods of survival analysis [43]. Moreover, survival analysis is concerned with estimating
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times until events, which is not our primary interest for this part of the model (this will
be our main interest in the next section when we want to derive estimates of expected re-
maining lifetime after initiating therapy). Instead, our objective here is to estimate monthly
transition probabilities among the CD4 categories and death. Our challenge, therefore, lies
in deciding how to handle these censored observations. It does not appear that other Markov
models of HIV have considered this problem (though some of them used cohorts of patients
from a time when few or no therapeutic options were available; hence, informative censoring
may have been negligible). Alagoz et al. [5] constructed natural history transition probabil-
ity matrices for patients with end-stage liver disease; however, they did not consider censored
observations. Unlike with HIV, in which it is rare for a patient to die before ever receiving
therapy, many end-stage liver disease patients do die before ever receiving a transplant, their
only viable therapy [5]. Therefore, in that context as well, informative censoring of the natu-
ral history progression may not present a significant issue. One study on diabetic retinopathy
did address the issue of censors attributable to therapeutic intervention by considering how
these censored observations may have been distributed had therapy not been initiated [53].
Also, Craig et al. [47] considered a Bayesian approach for handling informative censors.
First, we demonstrate that it is important to address censored observations. If we ignore
the censored observations and estimate remaining lifetimes associated with a policy of never
initiating therapy, then for patients whose CD4 counts are in categories 0 − 49, 50 − 199,
200− 349, and ≥350 we estimate expected remaining lifetimes of 14.4, 19.1, 21.7, and 23.6
years, respectively. These estimates are too high for HIV patients who never take therapy. It
is difficult to find other estimates of expected lifetime without ever taking therapy; however,
one paper reports median survival estimates in the pre-HAART era for CD4 categories ≤50,
≤200, and >200 of .99, 3.2, and 9.1 years, respectively [95].
Our method for handling the informative censors is similar to that just described in
[53]. For each CD4 category, we hypothesize how the censored observations may have been
distributed among the various CD4 categories and death, had therapy not been initiated
at that time period. We then derive empirical estimates of the natural history transition
probabilities. Table 2 presents four different scenarios for redistributing the informative
censors. For example, under Scenario 1, which we refer to as our baseline scenario, we
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assume that 90% of the transitions from CD4 category 0-49 at the beginning of one month
to the initiation of therapy by the beginning of the next month would have resulted in the
patient dying had therapy not been initiated, and 10% would have remained in the 0-49
CD4 range. The percentages for the other rows are interpreted similarly. Essentially, the
baseline model hypothesizes that for the two lower CD4 categories, a large percentage of
the patients would have died that month had they not initiated therapy (though less for the
50-199 category than for the 0-49 category), and for the two higher CD4 categories, a small
percentage of censored observations would have resulted in a patient death. For the two
higher categories, we hypothesize a higher weighting towards the transitions remaining in
the same CD4 category or moving down one (for example, we hypothesize that 40% of the
informative censors from CD4 category 200-349 would have remained in that CD4 category,
while 60% of the informative censors from the highest CD4 category would have remained in
that category). Scenario 2 presents a heavier weighting towards death, Scenario 3 presents
a lighter weighting towards death (relative to the baseline), and Scenario 4 presents an even
lighter weighting towards death. Note that in each scenario, we assume that a censored
observation would not have resulted in the patient’s CD4 count improving had therapy not
been initiated (shown by the upper triangle of 0s). Table 3 shows the monthly probability
of dying from each CD4 category under each censoring redistribution scenario (including
the case of ignoring censors discussed above), and Table 4 presents the expected remaining
lifetime implied by each scenario for patients never taking therapy, as a function of their
CD4 category. We chose Scenario 1 as the baseline because the resulting natural history
lifetimes appear clinically plausible, based on the estimates given above, found in [95]. We
discuss the optimal initiation policy implications of these scenarios in Section 4.5.
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Table 2: Censoring redistributions (Scenario 1: baseline; Scenario 2: heavier weighting to-
wards death; Scenario 3: lighter weighting towards death; Scenario 4: even lighter weighting
towards death)
Scenario 1 Death 0-49 50-199 200-349 ≥ 350
0-49 90% 10% 0% 0% 0%
50-199 40% 55% 5% 0% 0%
200-349 5% 5% 50% 40% 0%
> 349 2% 8% 10% 20% 60%
Scenario 2 Death 0-49 50-199 200-349 ≥ 350
0-49 90% 10% 0% 0% 0%
50-199 70% 20% 10% 0% 0%
200-349 50% 10% 30% 10% 0%
> 349 30% 10% 20% 30% 10%
Scenario 3 Death 0-49 50-199 200-349 ≥ 350
0-49 30% 70% 0% 0% 0%
50-199 10% 20% 70% 0% 0%
200-349 2.5% 7.5% 20% 70% 0%
> 349 .9% 1% 5% 13.1% 80%
Scenario 4 Death 0-49 50-199 200-349 ≥ 350
0-49 10% 90% 0% 0% 0%
50-199 2.5% 7.5% 90% 0% 0%
200-349 .9% 1% 8.1% 90% 0%
> 349 .1% 1.5% 3% 5.4% 90%
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Table 3: Probability of patient death within a month, according to censoring redistribution
scenario and CD4 category
Redistribution Scenario 0-49 50-199 200-349 ≥ 350
0 (ignoring censors) .0153 .0027 .0013 .0007
1 (baseline) .0829 .0221 .0035 .0012
2 (heavier towards death) .0829 .0366 .0233 .0070
3 (lighter towards death) .0371 .0075 .0024 .0009
4 (even lighter towards death) .0218 .0038 .0017 .0008
Table 4: Expected natural history remaining life years, according to censoring redistribution
scenario and CD4 category
Redistribution Scenario 0-49 50-199 200-349 ≥ 350
0 (ignoring censors) 14.43 19.11 21.67 23.57
1 (baseline) 1.51 2.96 4.68 6.30
2 (heavier towards death) 1.30 2.17 2.95 4.01
3 (lighter towards death) 4.35 7.19 9.21 11.07
4 (even lighter towards death) 8.89 12.93 15.34 17.21
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3.3 ESTIMATING SURVIVAL AFTER INITIATING HIV THERAPY
As mentioned, a key component of the MDP model of Chapter 4 is the expected remaining
lifetime for a patient initiating HAART from the various CD4 categories. Several authors
have compared survival rates across different CD4 categories after patients initiated HAART
[8, 61, 80, 126, 139, 167]. However, these studies focused on survival differences in the 3-5
years for which HAART was in use by the time the studies concluded. Because of the great
success of HAART, there is a large proportion of patients who are still alive on therapy since
starting it in the late 1990s. Figures 6 through 9 show Kaplan-Meier survival curves [93]
(along with 95% confidence bands) for 40-50 year old male VACS patients initiating therapy
from the various CD4 categories. Because we are interested in lifetime survival estimates, it
is necessary to extrapolate survival beyond the 6-7 year limits of our observations. However,
any parametric fit to the data will significantly overestimate the expected remaining survival
because the data do not reflect the increased age-related (non-HIV) mortality risks these 40-
50 year old patients will face as they turn 60, 70, 80, and so on.
Some authors have taken model-based approaches to estimate remaining lifetimes for
patients initiating therapy from the different CD4 categories [26, 67, 95, 113]. For example,
King et al. [95] report median survival times of 5.5, 8.5, and 15.4 years for patients initiating
HAART from CD4 categories ≤50, ≤200, and > 200, respectively. We describe a statistical
approach.
As we did with the natural history development, we start with our cohort of 25,041 male
HIV patients and exclude patients that appear to have been on some therapy prior to their
recorded date of first therapy (reducing the set to 20,586 patients). To be reasonably sure
that patients were initiating HAART (as opposed to monotherapy or double-drug therapy),
we select patients whose first therapy start date was on January 1, 1998 or later. Also,
because we estimate patient survival without therapy to be less than 10 years, we select
patients in the same 40-50 year old age bracket (upon initiating therapy) as with our natural
history model. These two steps reduce our set to 2,535. To associate therapy initiation with
a CD4 category, we keep only those patients who have a CD4 measurement within 24 days
of the first therapy start date, leaving us with 762 patients.
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Figure 6: Kaplan-Meier survival curve and its 95% confidence interval for patients initiating
therapy from CD4 category 0-49
For each of these patients with a date of death indicated, we record the survival time
since the start of therapy. When no date of death is indicated, we record the time between
the first therapy start date and the last observation date, and mark these observations as
censored. We group each survival or censor time according to the CD4 category near the
initiation of therapy to create the Kaplan-Meier survival curves shown in Figures 6 through
9. Table 5 gives a breakdown of the number of patients in each strata, the number of survival
times ending in death, and the number of censored times.
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Figure 7: Kaplan-Meier survival curve and its 95% confidence interval for patients initiating
therapy from CD4 category 50-199
To address the problem of the 6-7 year limits of our survival curves in deriving estimates
of expected lifetimes, we take the following steps. First, we use Cox proportional hazards
models [46] to calculate hazard ratios between male VACS HIV+ patients and HIV- controls
(further controlling for age and race) across the various CD4 categories (these calculations
were performed with the statistical package STATA). A hazard ratio compares the hazard
rate (in this case, the hazard rate of death) between two different groups, such as between a
“standard treatment” group and a “new treatment” group (in this case, between two different
types of VACS populations: HIV+ and HIV- males) [43]. We then apply these hazard ratios
40
Figure 8: Kaplan-Meier survival curve and its 95% confidence interval for patients initiating
therapy from CD4 category 200-349
to standard life table data and use a life table construction method [9] to estimate the
expected remaining lifetimes for 45-year-old HIV+ men from VACS who initiate therapy
from the various CD4 categories. Table 6 shows the results, with an expected remaining
survival time of 6.34 years for patients initiating therapy when their CD4 is below 50, to
24.79 years for those initiating when their CD4 count is at least 350.
By working with life table estimates of remaining lifetimes, we factor in the aging of the
cohort and fix the problem mentioned earlier about the survival curves of Figures 6 through
9 not extending long enough to consider an increasing age-based mortality. Note that we
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Figure 9: Kaplan-Meier survival curve and its 95% confidence interval for patients initiating
therapy from CD4 category ≥350
Table 5: Statistics on deaths versus censors when initiating therapy from each CD4 category
CD4 Categories
0-49 50-199 200-349 ≥ 350 Totals
Deaths 48 51 22 16 137
Censors 104 190 137 194 625
Patients 152 241 159 210 762
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Table 6: Expected remaining life years after initiating HAART from various CD4 categories
CD4 Categories
0-49 50-199 200-349 ≥ 350
Mean Remaining Lifetime 6.34 11.61 17.25 24.79
have directly applied the hazard rates for being HIV+ compared to HIV- in VACS to the
life table estimates of remaining survival because these estimates are mostly based on the
survival of an HIV- population. This makes the implicit assumption that HIV- patients in
VACS are similar to HIV- patients in general, which may not be the case. It may be feasible
to develop a hazard ratio of being HIV- in VACS compared to being HIV- in the rest of
the population, and apply this to the life table estimates before applying the hazard ratios
comparing HIV+ and HIV- VACS patients. We leave this for future work.
3.4 CONCLUSIONS
This chapter has focused on using clinical data to develop two key components of the MDP
model we present in Chapter 4: a discrete-time Markov model that estimates monthly tran-
sition probabilities among different CD4 categories and death, and estimates of expected
remaining lifetime after initiating HAART, as a function of those same CD4 categories upon
initiation. We have discussed some of the literature and challenges unique to each compo-
nent. One should keep in mind that these analyses were based on male patients only; it is
not clear how outputs would vary when generated from female patients. In Section 4.5, we
will solve the MDP model based on the results of this chapter, as well as explore the MDP’s
sensitivity to variations in our statistical outcomes.
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4.0 THE OPTIMAL TIME TO INITIATE HIV THERAPY:
ONE-DIMENSIONAL STATE SPACE (CD4 COUNT)
4.1 INTRODUCTION
As discussed in Chapters 1 and 2, the question of when to initiate HIV therapy is central
to effective HIV care, and is therefore subject to much research and debate. The treatment
strategy has changed over the years, from a paradigm of “hit hard, hit early” [78] in the
late 1990s, to a more cautious strategy of “hit hard, but only when necessary” [75]. The
latter approach is reflected in current DHHS guidelines that suggest delaying the initiation
of HAART until the CD4 count drops to 200-350 cells/mm3 of blood [123]. However, as
discussed below, there are reasons to reconsider the earlier paradigm of treating HIV earlier
in its course. Clearly, the best time to initiate HAART is unresolved and evolving.
Because CD4 count is arguably the most important factor in considering when to initiate
therapy [123, 166], this chapter develops an MDP of the optimal time to initiate therapy as a
function of this variable alone. However, the model is general enough to handle any important
prognostic variable. We consider objectives of maximizing a patient’s total expected lifetime
or quality-adjusted lifetime. In Chapter 5, we consider a two dimensional state space of CD4
count and viral load, as the latter is also an important prognostic indicator of HIV outcomes
[116]. The current chapter is the basis of a paper by Shechter et al. [158].
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4.2 MODELING FRAMEWORK
We consider a patient in a chronic stage of HIV (the period starting about three weeks after
being infected with the virus [10]) who must decide (with his or her physician) when to
initiate therapy. We assume the patient visits a physician periodically, and at each visit, the
patient’s CD4 count is measured. The frequency of these visits may depend on the physician
as well as the stage of HIV, but we shall assume they occur monthly (as discussed in Section
3.2, Freedberg et al. [68] also considered a model with monthly cycles to reflect the setting
for HIV care). Based on the measurement, a decision is made either to initiate therapy or
to wait and reevaluate the situation at the next visit (if the patient is alive at that time).
If the patient initiates therapy, a terminal reward is received and the process terminates.
We consider terminal rewards such as expected lifetime or expected quality-adjusted lifetime
from the time of initiating therapy from various categories of CD4 count. If the patient
waits, a reward is accrued between physician visits, and the patient transitions to another
CD4 category or death at the next visit with some known probability distribution. The
one-period reward may be the time or quality-adjusted time between visits, which may also
depend on the patient’s CD4 category. Our objective is to maximize the total expected
lifetime reward for the patient.
Formally, the components of the MDP are described as follows:
T = {1, 2, ...,∞}: the monthly decision epochs.
s: the health state of the patient, represented by a range of CD4 count. We let
s = 0 indicate an absorbing state for which no further rewards accrue (i.e., death) and let
s ∈ {1, . . . , N} represent different CD4 categories (with higher states representing higher
ranges of CD4 count). Let S represent the set of all states.
a(s): the decision taken when the patient is in CD4 category s prior to initiating ther-
apy. a ∈ {W, I} where W indicates to continue waiting and I indicates to initiate therapy.
r(s): the reward the patient receives when waiting in state s. We assign r(0) = 0.
R(s): the expected total remaining reward, received when the patient initiates therapy
from state s. We assign R(0) = 0. As discussed more next through the transition probabili-
ties, R(s) represents a terminal reward for the process.
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p(j|s): the probability that the patient’s CD4 category goes from s at time t to j at
time t + 1 when waiting another period. Patient death is represented by p(0|s), and we
assume the probability structure ensures that state 0 is reachable from every state. Also,
state 0 is absorbing, so that p(0|0) = 1. If a(s) = I, the patient receives reward R(s) and
moves with certainty to state 0, an absorbing state of 0 reward. Let P represent the matrix
of transitions probabilities when waiting.
v∗(s): the value vector that gives the optimal expected remaining reward when the
patient is in state s and has not yet initiated therapy. By our construction, v∗(0) = 0.
Our setup fits the framework of a stochastic longest path problem [22], for which it is
known that v∗(s) is the unique optimal solution to the following set of recursive optimality
equations, also known as Bellman’s equations [17, 140]:
v(s) = max
{
r(s) +
∑
j∈S
p(j|s)v(j), R(s)
}
for all s ∈ S. (4.1)
For example, if the objective is to maximize a patient’s total expected lifetime, then we
let r(s) = 1 month, we let R(s) ≡ L(s) = the expected remaining life months upon initiating
therapy from state s, and we obtain the optimal expected remaining lifetime from each CD4
category as the solution of:
v(s) = max
{
1 +
∑
j∈S
p(j|s)v(j), L(s)
}
for all s ∈ S. (4.2)
We note that the values of L(s) will depend on the patient’s age. In Section 3.3, we estimated
the expected remaining lifetimes upon initiating therapy for 45-year old male patients. In
Section 4.6, we discuss the assumption that L(s) does not decrease from period to period.
An issue that often arises in the medical decision making literature is that of discounting
future health outcomes [59, 72]. Although it is intuitive to include a discounting factor for
future monetary outcomes, it is less clear that one should do so for future health outcomes.
However, it is standard practice in cost-effectiveness analyses to discount both (and at the
same rate) [94, 183]. We note that incorporating a discount factor presents no conceptual
or computational challenges for our model. It is well known that if we include a discount
factor λ < 1, any solution to Bellman’s equations is the unique optimal solution [140].
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Furthermore, under our finite state and action sets, any decision rule that satisfies Bellman’s
equations (called a conserving decision rule) forms an optimal stationary policy [140]. With
no discounting (λ = 1), then in general one cannot say that a solution to Bellman’s equations
yields an optimal solution. Moreover, an optimal policy need not even exist [146]. However,
in the case that there is an absorbing state with a reward of 0 that is eventually reached with
probability 1, a solution to Bellman’s equations is in fact optimal and a conserving decision
rule forms an optimal stationary policy [140, 146]. This is the situation we present here; we
indicated above that the death state is absorbing, yields a reward of 0, and is eventually
reached from every other state. Also, for both discounting and no discounting, the value
and policy iteration algorithms converge to the optimal solution [140]. Therefore, for the
sake of clarity, we do not include a discount factor in our equations (i.e., we maximize total
expected undiscounted rewards).
4.3 STRUCTURAL PROPERTIES
Before solving the MDP using the clinically based components developed in Chapter 3, we
consider how certain structure on the model input may guarantee certain structure on the
model output (i.e. the optimal values and policies). In addition to providing deeper insight
into the overall problem, discovering such structural properties can make implementation
easier and accelerate solution time.
We first state the following definition [12]:
Definition 4.1. An N × N transition probability matrix P is said to be IFR (increasing
failure rate) if its rows are in increasing stochastic order. That is, P is IFR if
y(i) =
N∑
j=s
p(j|i),
is nondecreasing in i for all s ∈ {1, . . . , N}.
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The IFR property is often used in the machine maintenance literature. In the context
of our framework, the IFR property implies that patients in better health states have a
higher probability of moving to any particular health state or better. Conversely, patients
in worse health states have a higher probability of going to any particular health state or
worse (including death).
We will also make use of the following lemma, whose proof is similar to Lemma 4.7.2
in [140]. We show the proof because it will be instructive for the proof of Lemma 7.1 in
Chapter 7.
Lemma 4.1. Suppose {vi} (i=0,...,N) is a sequence of numbers, and {pi} and {qi} (i=0,...,N)
are two discrete probability distributions such that
N∑
i=k
qi ≥
N∑
i=k
pi for all k ∈ {0, . . . , N}. (4.3)
Then, if {vi} is nondecreasing (nonincreasing) in i,
N∑
i=0
qivi ≥ (≤)
N∑
i=0
pivi
.
Proof. We prove the lemma for the case that {vi} is nondecreasing in i. Define v−1 = 0.
Then:
N∑
i=0
qivi =
N∑
i=0
qi
i∑
j=0
(vj − vj−1) (4.4)
=
N∑
i=0
(vi − vi−1)
N∑
j=i
qj (4.5)
=
N∑
i=1
(vi − vi−1)
N∑
j=i
qj + v0
N∑
j=0
qj (4.6)
≥
N∑
i=1
(vi − vi−1)
N∑
j=i
pj + v0
N∑
j=0
pj (4.7)
=
N∑
i=0
pivi, (4.8)
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where (4.4), (4.5), and (4.6) follow by a rearrangement of terms, and (4.7) follows by the
assumption that {vi} is nondecreasing in i, the condition of (4.3), the fact that probabilities
are nonnegative, and the fact that
∑N
j=0 qj =
∑N
j=0 pj. Finally, (4.8) follows by similar steps
to go from (4.4) to (4.6).
Now consider the following assumptions:
(As4.1) r(s) and R(s) are both nonnegative and nondecreasing in s.
(As4.2) P is IFR.
As4.1 states that as the CD4 category increases, the reward over one period and the
terminal reward do not decrease, and As4.2 indicates that patients waiting in better health
states have better transitions probabilities than those waiting in worse health states.
In the following intuitively appealing theorem, we show that lower health states are
“worse,” and higher states are “better”. In the proof that follows and other places in the
dissertation, we refer to MDP solution algorithms such as value iteration and policy iteration.
We refer the reader to [140] for details on these algorithms.
Theorem 4.1. Under assumptions As4.1 and As4.2, v∗(s) is nonnegative and nondecreasing
in s.
Proof. We prove this by induction. Let i ∈ {0, 1, . . .} represent iteration i of the value
iteration algorithm, and let vi be the resulting value vector of that iteration. We suppose
that vi(s) is nonnegative and nondecreasing in s (note that v0(s) = 0 for all s satisfies this
property for i = 0). By this assumption and assumption As4.2 (i.e., P is IFR), we apply
Lemma 1 to obtain:∑
j∈S
p(j|s+ 1)vi(j) ≥
∑
j∈S
p(j|s)vi(j) ≥ 0 for all s ∈ S.
Combining this with assumption As4.1 (i.e., r(s) is nonnegative and nondecreasing in s
for all s), we have:
r(s+ 1) +
∑
j∈S
p(j|s+ 1)vi(j) ≥ r(s) +
∑
j∈S
p(j|s)vi(j) ≥ 0 for all s ∈ S. (4.9)
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We also know by assumption As4.1 that:
R(s+ 1) ≥ R(s) ≥ 0 for all s ∈ S. (4.10)
Combining (4.9) and (4.10) yields:
max
{
r(s+ 1) +
∑
j
p(j|s+ 1)vi(j), R(s+ 1)
}
(4.11)
≥ max
{
r(s) +
∑
j
p(j|s)vi(j), R(s)
}
≥ 0 for all s ∈ S. (4.12)
According to the value iteration algorithm,
vi+1(k) = max
{
r(k) +
∑
j
p(j|k)vi(j), R(k)
}
for all k ∈ S. (4.13)
Therefore, (4.12) and (4.13) imply:
vi+1(s+ 1) ≥ vi+1(s) ≥ 0 for all s ∈ S.
Thus, vi+1(s) is nonnegative and nondecreasing in s. Then, because limn→∞ vn(s) = v∗(s),
it follows that v∗(s) is nonnegative and nondecreasing in s.
In addition to establishing structure on the optimal value vector, it is common to find
conditions on the input parameters that lead to structured optimal policies. The following
establishes both a necessary and sufficient condition for initiating therapy in every state to
be an optimal policy. The condition in the theorem states that the value of initiating therapy
in each state is at least as great as the value of waiting one period in that state and initiating
therapy the next period. As discussed in Section 4.5, our data satisfy this condition.
Theorem 4.2. a∗(s) = I for all s if and only if:
R(s) ≥ r(s) +
∑
j
p(j|s)R(j) for all s ∈ S.
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Proof. If a∗(s) = I for all s, then v∗(s) = R(s) for all s. Furthermore, v∗ must satisfy
Bellman’s equations:
v(s) = max
{
r(s) +
∑
j
p(j|s)v(j), R(s)
}
for all s ∈ S,
which implies:
R(s) ≥ r(s) +
∑
j
p(j|s)R(j) for all s ∈ S.
Now suppose
R(s) ≥ r(s) +
∑
j
p(j|s)R(j) for all s ∈ S.
Letting v(s) = R(s), we see that v satisfies Bellman’s equations given in (4.1). Therefore,
v(s) = R(s) is an optimal value function which is achieved by the policy a∗(s) = I for all
s.
Similarly, the following gives a sufficient condition for waiting to be uniquely optimal for
a particular health state. In other words, it is not also optimal to initiate therapy from that
state.
Corollary 4.1. If R(s′) < r(s′)+
∑
j p(j|s′)R(j) for some s′ ∈ S, then a∗(s′) = W , uniquely.
Proof. Bellman’s equations indicate that v∗(s) ≥ R(s) for all s ∈ S. Therefore, if R(s′) <
r(s′) +
∑
j p(j|s′)R(j) it follows that R(s′) < r(s′) +
∑
j p(j|s′)v∗(j) which implies that
a∗(s′) = W , uniquely.
Another structured policy that may arise is that of an optimal control-limit policy, in
which states are given a meaningful ordering, there are two actions available, and for states
below a threshold state it is optimal to choose one action, whereas for states at or above the
threshold it is optimal to choose the other action. We call this threshold state the control
limit. In the case of HIV therapy, such a policy may imply that below a certain CD4 category,
a patient should initiate therapy; otherwise, it is best to wait. As discussed in Section 2.2,
the current DHHS guidelines appear to suggest a control-limit policy: patients with lower
CD4 counts should initiate therapy, whereas patients with higher CD4 counts should wait.
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Other authors have explored sufficient conditions for the existence of optimal monotone
policies (of which a control-limit policy is a special case) in general, infinite horizon MDPs
with possibly many actions [83, 140]. For example, some of the conditions involve both the
reward and transition probability structure having subadditivity properties or both having
superadditivity properties (see [140] for an explanation of these properties). However, by
the fact that R(s) represents a lifetime reward from initiating therapy and r(s) represents
a single period reward, it can be shown that the reward structure in our problem satisfies
the superadditivity property. On the other hand, one can also check that the transition
probability structure satisfies the subadditivity property. Alagoz et al. [5] presented a set
of sufficient conditions to guarantee an optimal control-limit policy for a model with similar
structure to ours; however, our data-driven model is far from satisfying those conditions.
Here we explore a different situation that guarantees an optimal control-limit policy.
Consider the clinically plausible case of a patient’s health never improving prior to ini-
tiating therapy, i.e. consider the following assumption:
(As4.3) p(j|s) = 0 whenever j > s.
Some authors have explicitly made this assumption in their models [32, 68, 111, 113]. Our
data indicate a low probability of upward movement (approximately .04).
Additionally, consider the following assumption stating that the difference in value, be-
tween successive states, of a policy that waits in the current state and initiates therapy in all
lower states is at least as great as the difference in value, between those states, of a policy
that initiates therapy immediately:
(As4.4)
r(s+1)+
P
j<s+1 p(j|s+1)R(j)
1−p(s+1|s+1) −
r(s)+
P
j<s p(j|s)R(j)
1−p(s|s) ≥ R(s+ 1)−R(s) for all s ∈ S.
As4.4 also has intuitive appeal as it essentially implies that with a better health state, delay-
ing therapy is relatively more appealing than initiating therapy (this is a type of subadditivity
condition).
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We can now prove the existence of an optimal control-limit policy.
Theorem 4.3. Suppose assumptions As4.3 and As4.4 hold. Then an optimal control-limit
policy exists.
Proof. Either a∗(s) = I for all s, or there exists a smallest CD4 category, s′, for which
a∗(s′) = W , uniquely. The former is vacuously a control-limit policy. Considering the latter,
if we prove that a∗(s′) = W implies a∗(s′+1) = W , then the result follows by induction. By
Bellman’s equations, we know that a∗(s′) = W and As4.3 imply:
r(s′) +
∑
j<s′ p(j|s′)R(j)
1− p(s′|s′) ≥ R(s
′). (4.14)
If we add
r(s′ + 1) +
∑
j<s′+1 p(j|s′ + 1)R(j)
1− p(s′ + 1|s′ + 1) −
r(s′) +
∑
j<s′ p(j|s′)R(j)
1− p(s′|s′)
to the left-hand side of (4.14) and add R(s′+1)−R(s′) to the right-hand side of (4.14), then
by assumption As4.4 and (4.14), we obtain:
r(s′ + 1) +
∑
j<s′+1 p(j|s′ + 1)R(j)
1− p(s′ + 1|s′ + 1) ≥ R(s
′ + 1).
By induction, we can see that for all s ≥ s′,
r(s) +
∑
j<s p(j|s)R(j)
1− p(s|s) ≥ R(s).
Because v∗(j) ≥ R(j) for all j, it follows that
r(s) +
∑
j<s p(j|s)v∗(j)
1− p(s|s) ≥ R(s) for all s ≥ s
′,
which implies that a∗(s) = W for all s ≥ s′.
In Theorem 4.8 of Section 4.4 below, we show how knowing the existence of a control-limit
policy accelerates solution time.
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4.3.1 Patient-Specific Considerations
While national guidelines policies are based on studies from entire cohorts of patients, there
is a push to make HIV therapy more patient-focused [77]. Therefore, we incorporate two
important patient factors for deciding when to initiate HIV therapy: quality of life and
adherence.
Quality of Life
One reason patients may want to delay initiating therapy is to avoid negative side effects
of the drugs such as nausea, fatigue, or lipodystrophy syndrome [37, 60, 105]. Of course,
even without therapy, advanced stages of any disease will reduce patients’ quality of life.
Patients with advanced stages of HIV, for example, may experience “opportunistic infections”
such as mycobacterium avium complex, tuberculosis, Kaposi’s sarcoma, pneumocystis carinii
pneumonia, or cytomegalovirus [3]. Tengs and Lin [172] provide a meta-analysis of studies
eliciting patient utilities for different stages of HIV. Estimates by CD4 strata can be found in
[68, 151]. However, none of the papers we reviewed [14, 15, 41, 45, 68, 69, 82, 105, 119, 125,
128, 142, 148, 151, 174, 175, 185, 186] presents patient-based utility estimates according to
both stage of HIV as well as whether or not the patient is on therapy. For example, a patient
with a high CD4 count taking HAART would presumably elicit a lower quality of life than
a patient with the same CD4 count who is not taking therapy. This is a key distinction to
make in evaluating the optimal time to initiate therapy. Lenert et al. [105], have come the
closest to uncovering this distinction by estimating a utility decrement of .20, beyond the
reduced utility for having HIV, for patients with lipodystrophy complications from therapy.
It is not clear, however, to what extent the baseline estimates included patients on HAART
and thus experiencing the burden of taking therapy or experiencing side effects other than
lipodystrophy syndrome. In Section 4.5, we solve our MDP by performing sensitivity analyses
around CD4-based and therapy-based utility estimates.
For now, we let 0 ≤ uw(s) ≤ 1 be the utility associated with waiting to initiate therapy
when in state s, and we let 0 ≤ ui(s) ≤ 1 be the average utility for the remainder of the
patient’s life, when initiating therapy from state s. We note that this average remaining
utility may depend on the patient’s age. Applying these utilities to Bellman’s equations that
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maximize expected remaining lifetime (4.2) yields Bellman’s equations for the problem of
maximizing quality-adjusted lifetime:
y(s) = max
{
uw(s) +
∑
j
p(j|s)y(j), ui(s)L(s)
}
for all s ∈ S,
where y(s) represents the expected remaining quality-adjusted lifetime from state s, and
L(s) is the expected remaining (unadjusted) lifetime after initiating therapy from state s.
We shall use these equations in Section 4.5 to obtain the solution of the MDP under a
quality-adjusted lifetime framework.
Adherence
Another important issue that may delay the initiation of therapy is the degree to which a
physician believes a patient may adhere to the prescribed therapy [123]. Various studies have
demonstrated associations between lower adherence and worse outcomes such as higher viral
load [76], lower CD4 count [129], higher incidence of AIDS [11], more days in the hospital
[129], and higher mortality rates [34]. Though by most conventions taking at least 80%
of prescribed medication implies compliance with the therapy, a study by Paterson et al.
[129] exposed significant differences in outcomes even for adherence levels that differ in the
80-100% range. However, adherence rates are often lower than this as various studies have
reported 40-50% of patients taking less than 80% of their medication [18, 63, 71].
Our model implicitly represents the effects of partial adherence to the extent this is
represented in the data-based estimates of the expected remaining lifetime upon initiating
therapy. In other words, the estimates reflect the partial adherence exhibited by VACS
patients. We now explicitly consider how a particular patient’s tendency to adhere may
affect optimal policies. Specifically, we consider a patient-dependent multiplier, m, that
applies to L(s) for each s. If the patient tends to adhere better than the average adherence
level of the cohort, then m > 1 and the estimates of L(s) are increased proportionally to
reflect better outcomes for this patient relative to the average patient. If the patient adheres
poorly, then m < 1 and the estimates of L(s) are reduced to reflect worse outcomes. We
explore structural properties of this model and consider building more complex models of
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patient adherence in future research. For example, the model explicitly considers adher-
ence under the framework of maximizing expected lifetime, and we discuss the inclusion of
adherence in a quality-adjusted lifetime framework in Section 4.6.
Note that by our model formulation, the adherence factor only affects the estimated
reward for initiating therapy, R(s); it has no affect on the pre-therapy components P and
r(s). Explicit consideration of patient adherence under the objective of maximizing expected
lifetime leads to the following Bellman’s equations:
z(s|m) = max
{
1 +
∑
j
p(j|s)z(j|m), mL(s)
}
for all s ∈ S
where z(s|m) represents the expected remaining lifetime from state s for a patient whose
adherence parameter is m.
Suppose the optimal policy for the problem of maximizing expected lifetime without ex-
plicit consideration of patient adherence is to initiate therapy for all states (i.e., the condition
of Theorem 4.2 is satisfied). Then the following result allows us to identify conditions on
m that will ensure such a policy is no longer optimal when explicitly considering adherence.
First we define the following:
∆s ≡ L(s)− [1 +
∑
j
p(j|s)L(j)] for all s ∈ S,
∆min ≡ min
s∈S
∆s, and
∆max ≡ max
s∈S
∆s.
In words, ∆s is the difference (for the expected lifetime problem without explicit consider-
ation of adherence) between the terminal reward of initiating therapy from state s and the
value associated with waiting one period in state s and initiating therapy the next period.
The following results should be interpreted in the context of the problem of maximizing
total expected lifetime under an explicit consideration of patient adherence.
Theorem 4.4. For every state s such that 1/m > 1 + ∆s, it is uniquely optimal to wait.
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Proof. As a consequence of Corollary 4.1, it is uniquely optimal to wait in state s if
mL(s) < 1 +
∑
j
p(j|s)mL(j).
This is equivalent to
L(s) < 1/m+
∑
j
p(j|s)L(j),
which is equivalent to
1/m > L(s)−
∑
j
p(j|s)L(j).
By the definition of ∆s, the above is equivalent to:
1/m > 1 + ∆s.
It follows that if 1/m > 1 + ∆max, it is optimal to wait in every state. The following
corollary provides the least restrictive condition to guarantee an optimal policy for which it
is optimal to wait in some state. We let smin be a state that minimizes ∆s.
Corollary 4.2. a∗(smin) = W , uniquely, if and only if 1/m > 1 + ∆min.
Proof. The sufficiency part of the proof follows directly from Theorem 4.4.
To prove necessity, suppose a∗(smin) = W , uniquely. Also, suppose (towards a contra-
diction) that 1/m ≤ 1+∆min. Then it follows that 1/m ≤ 1+∆s for all s. By the definition
of ∆s, we have:
1/m ≤ L(s)−
∑
j
p(j|s)L(j) for all s ∈ S.
Multiplying through by m and rearranging terms yields:
mL(s) ≥ 1 +
∑
j
p(j|s)mL(j) for all s ∈ S.
By Theorem 4.2, this implies that a∗(s) = I for all s, which contradicts our first assumption
that a∗(smin) = W , uniquely. Therefore, 1/m > 1 + ∆min.
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Note that by Theorem 4.2, if the optimal policy in the expected lifetime problem without
explicit consideration of patient adherence is to initiate therapy in every state, then ∆min > 0.
In that case, it follows from Corollary 4.2 that a necessary condition for waiting to be uniquely
optimal in state smin with explicit consideration of patient adherence is that m < 1. In other
words, the optimal policy of initiating therapy from each state will change only if the patient
adheres poorly.
We prove the following additional results. The first one says that patients with greater
levels of adherence have greater expected remaining lifetimes, as expected.
Theorem 4.5. z(s|m) is nondecreasing in m for each s.
Proof. Let m1 ≤ m2. We prove this by performing parallel iterations of the value iteration
algorithm to solve for z(s|m1) and z(s|m2) for all s. Suppose for some iteration, i, of the
algorithm zi(s|m1) ≤ zi(s|m2) for all s (note that starting each problem with zero vectors
satisfies this). Then for each s,
zi+1(s|m1) = max
{
1 +
∑
j
p(j|s)zi(j|m1), m1L(s)
}
, and (4.15)
zi+1(s|m2) = max
{
1 +
∑
j
p(j|s)zi(j|m2), m2L(s)
}
. (4.16)
By the inductive assumption, 1 +
∑
j p(j|s)zi(j|m1) ≤ 1 +
∑
j p(j|s)zi(j|m2) and by the
assumption that m1 ≤ m2, m1L(s) ≤ m2L(s). Therefore, zi+1(s|m1) ≤ zi+1(s|m2). Taking
the limit of the value iterates proves the result.
Our final result for explicit considerations of adherence concerns control limit policies.
It says that if optimal control-limit policies hold for two patients with adherence levels m1
and m2, respectively, then assuming patient health does not improve while waiting (As4.3),
the patient with the greater adherence level will initiate therapy whenever the other patient
does, and perhaps earlier.
Theorem 4.6. Suppose the optimal policies for patients with adherence levels m1 and m2
(m1 ≤ m2) have control limits given by c1 and c2, respectively. Then if As4.3 holds, c1 ≤ c2.
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Proof. First, let us assume that a∗(1|m1) = I (otherwise, the result holds vacuously). Then
by As4.3,
m1L(1) ≥ 1
1− p(1|1) , (4.17)
and by the assumption that m1 ≤ m2,
m2L(1) ≥ 1
1− p(1|1) . (4.18)
Therefore, a∗(1|m2) = I as well. Now let s′ > 1, arbitrarily, and assume that for s < s′,
a∗(s|m2) = I. We complete the proof by showing that if a∗(s′|m1) = I, then a∗(s′|m2) = I
as well. By As4.3, a∗(s′|m1) = I implies
m1L(s
′) ≥ 1 +
∑
j<s′ p(j|s′)m1L(j)
1− p(s′|s′) , (4.19)
which is equivalent to
L(s′) ≥ 1/m1 +
∑
j<s′ p(j|s′)L(j)
1− p(s′|s′) . (4.20)
Because m1 ≤ m2 by assumption, it follows that
L(s′) ≥ 1/m2 +
∑
j<s′ p(j|s′)L(j)
1− p(s′|s′) , (4.21)
which, is equivalent to
m2L(s
′) ≥ 1 +
∑
j<s′ p(j|s′)m2L(j)
1− p(s′|s′) . (4.22)
By the inductive assumption that a∗(s|m2) = I for s < s′, it follows that a∗(s′|m2) = I.
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4.4 COMPUTATIONAL CONSIDERATIONS
In this section, we make some observations about solving optimal stopping problems rep-
resented by Bellman’s equations in (4.1). The model we solve in the next section is small
enough that we do not encounter any computational difficulties in solving it. However, the
results of this section apply to optimal stopping time problems for which large state spaces
may impose computational burdens.
It is known that if vi is the value vector generated by the ith iteration of the policy
iteration algorithm, and if vi+1 is the value vector generated by the (i+ 1)st iteration, then
vi+1 ≥ vi, componentwise [140]. Because the optimal stopping problem contains 2N policies,
in theory it takes at most 2N iterations to guarantee an optimal policy. However, we can
show that it actually takes at most N iterations to obtain an optimal policy.
Theorem 4.7. The optimal stopping problem represented by (4.1) can be solved in at most
N iterations of the policy iteration algorithm.
Proof. Let d0 be the decision rule that accepts the terminal reward, R(s), for every state
s. Then the policy evaluation step gives v0(s) = R(s) for every s. Now consider the
policy improvement step. If there is no policy improvement, then the algorithm terminates.
Otherwise, there exists a state s′ such that r(s′) +
∑
j p(j|s′)R(j) > R(s′), and we set the
action for that state to W . Because we have the property that each successive iteration of
the algorithm yields a value vector no smaller than the previous one, it must be that the
optimal action in state s′ is to wait. In other words, once an iteration is reached in which the
action switches from I to W for some state, all subsequent iterations retain the W decision
for that state. Hence, there can be at most N switches from the initial decision rule. Because
the algorithm terminates when two successive iterations yield the same policy, the algorithm
takes at most N steps.
If the lower triangular property given in As4.3 holds, then the optimal solution is obtained
in just one iteration of the Gauss-Seidel variant of the value iteration algorithm (in which
the value vector is updated after each state evaluation and used in the evaluation of the next
state). The reason for this is that As4.3 implies that the value of a given state does not
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depend on the value of any states above it, so we can start with s = 1, solve for v∗(1), use
this to obtain v∗(2) and continue until solving the entire problem after reaching state N and
solving for v∗(N) using the values of v∗(s) obtained along the way. A similar result is found
in [22]. If As4.4 also holds, then finding an optimal policy requires even less work.
Theorem 4.8. If both As4.3 and As4.4 hold, then an optimal policy can be determined in
at most blog2(N) + 1c steps.
Proof. From Theorem 3, we know that an optimal control-limit policy exists. Then, by the
lower triangular property of As4.3 and the fact that v∗(k) ≥ R(k) for all k ∈ S, we know
that a∗(s) = I if and only if
1+
P
j<s p(j|s)R(j)
1−p(s|s) ≤ R(s). It takes a binary search to find the
smallest s′ such that this latter condition does not hold, implying that a∗(s) = W for s ≥ s′
and a∗(s) = I for s < s′. This search takes at most blog2(N) + 1c steps.
4.5 DATA-DRIVEN IMPLEMENTATION
In Chapter 3, we discussed the use of clinical data to build two key components of an MDP
of the optimal time to initiate HIV therapy: the CD4 natural history transition probability
matrix and the expected remaining lifetimes upon initiating therapy from the different CD4
categories. We constructed both components from 40-50 year old male patients in the co-
hort, and therefore, we present results of optimal policies and expected remaining rewards
for those patients.
Results
Recall from Chapter 3 that we examined various scenarios for handling the censored
observations in the natural history Markov model. In the present analysis, we shall use three
of those scenarios: the baseline weighting of redistributing censored observations towards
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death, a heavier weighting, and a lighter weighting (not the lightest weighting that we
presented). Table 6 of that chapter also presented what we refer to as the baseline results
for the survival model. Here we also consider estimates at 90% and 110% of those values.
Table 7 gives the optimal policy along with the optimal value function (in life years)
for each combination of the natural history and survival models, under an objective of
maximizing expected lifetime. For the optimal policy vector, “I” indicates to initiate therapy
from that CD4 category, while “W” indicates to continue waiting. The table does not
show the case of the heavier censoring redistribution towards death, because this yields
the same optimal policies and values as for the case of the baseline natural history model,
namely to initiate therapy immediately. Under our baseline natural history model and
by letting r(s) = 1 month for all s, assumptions As4.1 and As4.2 hold. Therefore, as
proven by Theorem 1, our solution produces an optimal value vector that is nonnegative and
nondecreasing in the CD4 category. Furthermore, our MDP components satisfy the sufficient
condition of Theorem 4.2, and hence, we obtain an optimal policy of initiating therapy from
each of the CD4 categories. In fact, it is not until reducing the survival estimates to .43 of
our baseline values that we first obtain an optimal policy other than initiating therapy from
ever state. Note that the lighter redistribution of censors to death along with the baseline
and 90% survival models yield counter-intuitive optimal policies that exhibit a control-limit
structure in the opposite direction than expected. However, neither of the value functions for
these cases differs substantially from the value function of the policy that initiates therapy
from each state. We comment on this more in the next section.
As indicated in Section 3.2, our natural history Markov model depends on the choice
of degrees of freedom (df) for the spline, and we chose the parameter yielding the roughest
curve: i.e., the one that maximally captures the data fluctuations. Here we consider us-
ing the average spline instead (the spline with df half way between the value yielding the
smoothest and roughest splines). Table 8 shows the expected remaining lifetime implied by
each censoring scenario for patients never taking therapy, as a function of their CD4 cate-
gory. The values in parentheses correspond to the values from Table 4 of Section 3.2, which
were based on the rougher spline. These values exceed the values from the smoother spline
in every case but one. Table 9 presents the optimal policy and value function using the
62
Table 7: Optimal policy and value vector under various combinations of the natural history
and survival models
NH model Survival Model Output 0-49 50-199 200-349 ≥ 350
baseline baseline Optimal Policy I I I I
Optimal Values 6.34 11.61 17.25 24.79
baseline 110% Optimal Policy I I I I
Optimal Values 6.97 12.77 18.98 27.27
baseline 90% Optimal Policy I I I I
Optimal Values 5.71 10.45 15.53 22.31
lighter baseline Optimal Policy W W I I
Optimal Values 6.38 11.70 17.25 24.79
lighter 110% Optimal Policy I I I I
Optimal Values 6.97 12.77 18.98 27.27
lighter 90% Optimal Policy W W W I
Optimal Values 5.97 10.76 15.56 22.31
smoother spline, and now every combination of natural history and survival model indicates
a patient should initiate therapy from every state.
Next we consider the objective of maximizing a patient’s expected quality-adjusted
lifetime by incorporating utility weights associated with the different CD4 categories and
whether or not the patient is on therapy. As discussed in Section 4.3.1, it is not clear from
the literature how utility estimates for various stages of HIV may be distinguished between
patients on versus off therapy. For the present analysis, we use patient-derived estimates
found in [151] and [68] to estimate off-HAART utilities according to our CD4 categories
(Table 10). We incorporate these into the MDP by multiplying the 1-month reward associ-
ated with waiting by the CD4-based utility weights presented. We then perform sensitivity
analyses around the on-therapy utilities by considering various weighings of the off-therapy
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Table 8: Expected natural history remaining life years, according to censoring redistribution
scenario and CD4 category, using a smoother spline (with the results of the rougher spline
in parentheses)
Redistribution Scenario 0-49 50-199 200-349 ≥ 350
0 (ignoring censors) 8.53 (14.43) 12.73 (19.11) 15.80 (21.67) 18.81 (23.57)
1 (baseline) 1.10 (1.51) 2.24 (2.96) 3.99 (4.68) 6.22 (6.30)
2 (heavier towards death) 1.05 (1.30) 1.83 (2.17) 2.63 (2.95) 4.03 (4.01)
3 (lighter towards death) 2.84 (4.35) 5.19 (7.19) 7.34 (9.21) 10.02 (11.07)
4 (even lighter towards death) 5.45 (8.89) 8.95 (12.93) 11.69 (15.34) 14.48 (17.21)
utilities. For example, in one analysis, we multiply each CD4-based off-therapy utility by
.9 to represent CD4-based on-therapy utilities. We then take these utilities and multiply
them by our estimates of expected remaining lifetime to generate terminal rewards in terms
of expected remaining quality-adjusted lifetime. Table 11 shows the on-HAART utilities
associated with three different multiplicative factors of the off-therapy utilities (.9, .7, and
.5).
Table 12 shows the results of the MDP solution for the different ratios of on-HAART
to off-HAART utility, under our baseline natural history and survival models. Note that
the value vector is now in terms of quality-adjusted life years instead of life years. We see
that even if we estimate on-HAART utility to be half as much as off-HAART utility, the
MDP still returns an optimal policy of initiating therapy from each CD4 category, using
both utility references. In fact, further testing reveals that it is not until reducing the ratio
to .34 (for the set of utilities in Schackman et al. [151]) or .29 (for the set of utilities in
Freedberg et al. [68]) that we obtain a solution for which it is optimal to wait in some CD4
category. Using the Schackman et al. [151] utilities for being off HAART and applying
the .34 multiplier leads to on-therapy utility estimates of .30, .31, .33, and .33 for the CD4
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Table 9: Optimal policy and value vector under our baseline run and various combinations
of the natural history and survival models, using a smoother spline
NH model Survival Model Output 0-49 50-199 200-349 ≥ 350
baseline baseline Optimal Policy I I I I
Optimal Values 6.34 11.61 17.25 24.79
baseline 110% Optimal Policy I I I I
Optimal Values 6.97 12.77 18.98 27.27
baseline 90% Optimal Policy I I I I
Optimal Values 5.71 10.45 15.53 22.31
lighter baseline Optimal Policy I I I I
Optimal Values 6.34 11.61 17.25 24.79
lighter 110% Optimal Policy I I I I
Optimal Values 6.97 12.77 18.98 27.27
lighter 90% Optimal Policy I I I I
Optimal Values 5.71 10.45 15.53 22.31
Table 10: Estimates of off-HAART utilities
CD4 Categories
Reference 0-49 50-199 200-349 ≥ 350
Schackman et al. [151] .88 .91 .97 .97
Freedberg et al. [68] .79 .84 .94 .94
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Table 11: Estimates of on-HAART utilities
CD4 Categories
Reference Utility Scenario 0-49 50-199 200-349 ≥ 350
Schackman et al. [151] Scenario 1 (.9) .79 .82 .87 .87
Scenario 2 (.7) .62 .64 .68 .68
Scenario 3 (.5) .44 .46 .49 .49
Freedberg et al. [68] Scenario 1 (.9) .71 .76 .85 .85
Scenario 2 (.7) .55 .59 .66 .66
Scenario 3 (.5) .40 .42 .47 .47
categories 0− 49, 50− 199, 200− 349, and ≥350, respectively. These appear too low based
on existing literature of utility estimates for a variety of health conditions. Of 82 quality-of-
life estimates for patients with HIV or AIDS, only three were at or below the .30-.33 range
of estimates [173]. To compare with another disease and its drug treatment, of 44 utility
estimates for breast cancer with chemotherapy, only five were at or below the .30-.33 range
[173]. Also, as discussed in Section 4.3.1, Lenert et al. [105] estimated that therapy-related
complications may reduce the utility for HIV patients by .20.
In another analysis, we incorporate utility estimates from VACS patients based on dif-
ferent CD4 categories along with whether or not the patients experienced side effects from
HAART (unpublished data not shown). We use the utilities of side effects versus no side
effects as proxies for utilities associated with being on therapy versus off therapy [24]. In
doing so, we still obtain an optimal policy of initiating therapy from each CD4 category,
and this policy does not change until the ratio of on-HAART to off-HAART utility falls to
approximately .43.
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Table 12: Optimal policy and value vector under different utilities
Reference On-HAART Utility Output 0-49 50-199 200-349 ≥ 350
Schackman et al. [151] Scenario 1 (.9) Optimal Policy I I I I
Optimal Values 5.01 9.52 15.01 21.57
Scenario 2 (.7) Optimal Policy I I I I
Optimal Values 3.93 7.43 11.73 16.86
Scenario 3 (.5) Optimal Policy I I I I
Optimal Values 2.79 5.34 8.45 12.15
Freedberg et al. [68] Scenario 1 (.9) Optimal Policy I I I I
Optimal Values 4.50 8.82 14.66 21.07
Scenario 2 (.7) Optimal Policy I I I I
Optimal Values 3.49 6.85 11.39 16.36
Scenario 3 (.5) Optimal Policy I I I I
Optimal Values 2.54 4.88 8.11 11.65
4.6 CONCLUSIONS
Because therapeutic options and the understanding of HIV have increased markedly over
the last twenty years, the prognosis for HIV patients has changed from a fatal disease to a
serious yet manageable, chronic condition [153]. As such, the proper administration of these
therapies has become extremely complex and open to debate. We have proposed the first
application of MDPs for examining the contentious issue of the optimal time to initiate HIV
therapy.
Several of our results support the former strategy of treating earlier in the course of
disease as opposed to the more recent approach of treating later. With an objective of
maximizing expected remaining lifetime, our baseline run of the natural history model yielded
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optimal policies of initiating therapy from all states, under each survival model (see Table
7). Under the lighter redistribution of censors to death and the baseline survival model, we
obtained a counter-intuitive optimal policy of waiting when the CD4 count is less than 200,
and initiating when it is at or above 200. However, the values associated with CD4 categories
<50 and 50 − 199, 6.38 and 11.70 life years, do not differ much from the value associated
with initiating therapy from those states (6.34 and 11.61 life years). In other words, although
technically the solution yields a counter-intuitive policy, it is not substantially different from
the policy of initiating therapy from all states. Therefore, because of the sensitivity of
results to particular data estimates, for the sake of clarity and ease of implementation, one
may argue that it is best to use the “suboptimal” policy of initiating therapy from all CD4
categories over the policy generated from the MDP solution. A similar argument applies
to the results of the lighter natural history model and the 90% survival model. On the
other hand, consider a policy of waiting when the CD4 count is > 350 and initiating therapy
whenever it is in a lower category (this is one interpretation of the DHHS guidelines [123]). In
that case, the value associated with CD4 category >350 (under the baseline natural history
and survival models) is 18.0 years, as opposed to the 24.8 years under the optimal policy.
This large difference strengthens the support for initiating therapy from the highest CD4
categories under the objective of maximizing expected lifetime.
Even under the quality-adjusted lifetime framework, our results strongly favor a policy of
initiating therapy immediately. As shown in Table 12 and the discussion that surrounded it,
under the baseline natural history and survival models, it takes an unrealistically low ratio of
on-HAART to off-HAART utility to obtain an optimal policy other than initiating therapy
from all CD4 categories. Interestingly, a simulation model by Schackman et al. [150] also
found that it took a 70% decrease in on-therapy quality-of-life before initiating treatment at
a CD4 count of 350 appeared worse than initiating treatment at a CD4 count of 200.
Yet further support for our “hit hard, hit early” results comes from the fact that our
model biased the results toward waiting in some states. We did not decrement the terminal
reward over time, which means that waiting in some states would be even less appealing if
we were to reduce the rewards associated with initiating therapy from other states at later
times.
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In addition to the study by Schackman et al. [150], other recent work suggests that earlier
treatment may be better than delayed treatment. Holmberg et al. [81] argued against recent
trends toward delayed treatment by citing various studies demonstrating survival benefits,
immunologic benefits, and reduced toxicities associated with earlier treatment. At a recent
conference, Lichtenstein et al. [107] reported that concerns about toxicities associated with
earlier treatment may be unfounded and suggested that earlier initiation of HAART may
be better. Also, as mentioned in Section 2.1.2, the SMART trial was recently terminated
because it was found that continuous use of HAART was better than a strategy of having
patients stay off therapy until their CD4 counts fell below 250 and having them go off therapy
again when their CD4 counts rose above 350. We wonder to what degree the worse outcomes
of this latter strategy had to do with the initial delay of therapy.
There are areas for refinement with our model. Our explicit consideration of patient ad-
herence assumed that a single multiplier applied equally to all state-based terminal rewards.
Future work may consider state-based adherence multipliers instead. Also, in the above anal-
yses, we considered utilities and adherence separately. Future research will consider a model
that simultaneously incorporates utilities and adherence under an objective of maximizing
expected quality-adjusted lifetime. Such a complex model will require understanding how
patient utilities affect adherence levels which in turn affect the length and quality of life.
Some of the limitations of our model also lie within the statistical modeling of the natural
history health progression and the survival estimates after initiating therapy. We addressed
these limitations in the previous chapter and note that testing suggests that our results
are sensitive to assumptions on the redistribution of censored observations in the natural
history model. We also note that the estimates of remaining survival in our present model
implicitly assume that after initiating therapy, patients progress according to the treatment
decisions presently made in practice with regard to choice of initial therapy, time to switch
to subsequent therapies, and choice of those therapies. In other words, we took a modeling
perspective of determining the optimal time to initiate therapy as it is administered today,
as opposed to the optimal time to initiate therapy under a completely optimized treatment
process. Chapters 6 and 7 consider the latter framework.
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Our model assumed that the transition probability matrix was Markovian with respect
to the CD4-based health state, though we did not verify this statistically. One study found
that the history of CD4 counts did not inform the short term probability of death differently
than using just the current level of CD4 count [54]; however, the history may influence the
transitions to other living health states [49]. Our state space is small enough that there
would be no computational difficulty to include some of the CD4 history, but we decided to
first explore structural properties and solve the problem as a function of a patient’s current
CD4 count before expanding the state space to include recent CD4 measurements as well.
We also note that current DHHS guidelines do not consider a patient’s recent CD4 count
progression in their recommendations; they just focus on the current CD4 count [123].
We made two time-homogeneity assumptions in our model. We assumed that P , our
transition probability matrix for the natural history of CD4, is time homogenous. Although
patients surely have an increased risk of death with time, we assumed that the time prior
to initiating therapy was not so long as to significantly increase a patient’s risk of death.
Indeed, the Markov chain induced by P (under our baseline model) yields expected remaining
lifetimes of 1.51, 2.96, 4.68, and 6.30 years for patients in CD4 categories 0 − 49, 50− 199,
200 − 349, and ≥350, respectively. We did capture the increased risk of death with age
through our estimates of survival after initiating therapy (the terminal rewards), as described
in the previous chapter. Our other time-homogeneity assumption was that patients receive
these terminal rewards regardless of when therapy is initiated. In order to consider a time-
based decrement to the terminal reward, the model would have to become significantly more
complex and require much more data. As noted above, however, our assumption biased the
model towards waiting in some states.
Recall that our MDP solutions were based on components generated from an all-male
cohort of patients. Because we do not know how the natural history of CD4 counts and
survival upon initiating HAART differ in the female VACS population, care should be used
in applying our results to such patients. Similarly, because VACS patients may tend to
have different health problems than other patient populations, one should also be careful
in applying our results to non-VACS populations. We note, however, that we can easily
generate the MDP components and solutions based on data from other cohorts.
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In summary, an MDP is both a natural and useful approach for modeling the optimal time
to initiate HIV therapy: upon HIV diagnosis, patients see their physicians periodically until
the decision is made to initiate therapy, and there is uncertainty in how the patient’s health
will progress until that time. Previous analytical approaches have not modeled this problem
as a sequential, dynamic and stochastic decision problem with an objective of maximizing
a patient’s expected lifetime or quality-adjusted lifetime. The MDP framework allows us
to gain deeper insight into how changes in model inputs affect the outputs. Of particular
interest to policy makers is the strength of our results in suggesting that we move away from
recent trends of initiating therapy later in the course of disease and to “hit early” instead.
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5.0 THE OPTIMAL TIME TO INITIATE HIV THERAPY:
TWO-DIMENSIONAL STATE SPACE (CD4 COUNT AND VIRAL LOAD)
5.1 INTRODUCTION
Although CD4 count is the single most important variable in the decision of when to initiate
therapy, another significant prognostic variable is the patient’s viral load [116]. As discussed
in Section 2.2.1, when the viral load exceeds 100,000 copies/mL of blood, some clinicians may
recommend their patients initiate therapy regardless of their CD4 count [123]. Therefore,
this chapter considers a state space that includes both the patient’s CD4 count as well as
the viral load.
With the two-dimensional aspect of the state space, a natural ordering does not exist.
For example, with the single dimension, it was intuitive that a higher CD4 count is better
than a lower CD4 count. However, now we have to consider comparing states such as higher
CD4 count and higher viral load with lower CD4 count and lower viral load. The order is
not clear and may depend on the differences between each dimension. We present a plausible
framework that leads to certain structural properties.
5.2 MODELING FRAMEWORK
As with the CD4-based model of the previous chapter, we consider a patient with chronic
HIV who must decide when to initiate therapy. Now we assume that upon each visit to the
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physician, measurements are taken of both the CD4 count and the viral load. We consider
rewards and probability transitions that are functions of both of these variables, and seek to
maximize the total expected lifetime of a patient.
The components of the MDP are described as follows.
• T = {1, 2, ...,∞}: the monthly decision epochs.
• (c, l): the state of the patient, where c indicates the CD4 category and l indicates the
viral load category. We let c ∈ {0, 1, . . . , C} (where 0 indicates an absorbing state of no
further reward, such as death), and we let l ∈ {1, . . . , L + 1} (where L + 1 is also an
absorbing state of no further reward). Higher CD4 categories are associated with better
health states and higher viral load categories are associated with worse health states.
Also by convention, we say that c = 0 if and only if l = L+ 1.
• a(c, l): the decision taken when patient is in state (c, l). a ∈ {W, I} where W indicates
to continue waiting, and I indicates to initiate therapy.
• r(c, l): the reward the patient receives when waiting in state (c, l). We assume r(0, L +
1) = 0.
• R(c, l): the expected total remaining reward, received when the patient initiates therapy
from state (c, l). We assume R(0, L+ 1) = 0.
• α[(c′, l′)|(c, l)]: the probability of transitioning to state (c′, l′) at time t+1 given that the
patient waits in state (c, l) at time t. Death is indicated by the absorbing state (0, L+1),
and we assume the probability structure ensures that the death state is reachable from
every state. Note that when a(c, l) = I, the patient receives R(c, l) and moves to the
absorbing state (0, L+ 1) with certainty.
• v∗(c, l): the value vector that gives the optimal expected remaining reward when the
patient is in state (c, l) and has not yet initiated therapy.
With this setup, v(0, L + 1) = 0, and for all (c, l) 6= (0, L + 1), Bellman’s equations are as
follows:
v(c, l) = max
 r(c, l) +
∑
c′
∑
l′ α[(c
′, l′)|(c, l)]v(c′, l′),
R(c, l).
(5.1)
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At times it will be convenient to think of the state transitions while waiting as a two-step
process: first there is a transition at the next time period to one of the two variables and
then there is a transition to the other variable conditional on the first movement. We explain
this more by creating the following components.
• ψ[c′|(c, l)]: the probability of transitioning to a state with CD4 category c′ at time t+ 1
given that at time t the patient is in state (c, l) and chooses to wait.
• Ψl: the transition probability matrix representing the above transitions over CD4 cate-
gories when the viral load category at time t is l.
• p[c′|l′, (c, l)]: the conditional probability of transitioning to a state with CD4 category c′
at time t+ 1 given that at time t+ 1 the patient’s viral load category is l′ and at time t
the patient is in state (c, l) and chooses to wait.
• Pl,l′ : the transition probability matrix representing the above transitions over CD4 cat-
egories when the viral load category at time t is l and the viral load category at time
t+ 1 is l′.
• q[l′|(c, l)]: the probability of transitioning to a state with viral load category l′ at time
t+ 1 given that at time t the patient is in state (c, l) and chooses to wait.
• Qc: the transition probability matrix representing the above transitions over viral load
categories when the CD4 category at time t is c.
• γ[l′|c′, (c, l)]: the conditional probability of transitioning to a state with viral load cate-
gory l′ at time t+1 given that at time t+1 the patient’s CD4 category is c′ and at time
t the patient is in state (c, l) and chooses to wait.
• Γc,c′ : the transition probability matrix representing the above transitions over viral load
categories when the CD4 category at time t is c and the CD4 category at time t+1 is c′.
Therefore, we can express α[(c′, l′)|(c, l)] as either q[l′|(c, l)]p[c′|l′, (c, l)] (by conditioning
the CD4 transition on the viral load category the patient moves to) or ψ[c′|(c, l)]γ[l′|c′, (c, l)]
(by conditioning the viral load transition on the CD4 category the patient moves to). Letting
v(0, L+ 1) = 0, then for all (c, l) 6= (0, L+ 1), we can rewrite Bellman’s equations as
v(c, l) = max
 r(c, l) +
∑
l′ q[l
′|(c, l)]∑c′ p[c′|l′, (c, l)]v(c′, l′),
R(c, l),
(5.2)
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or equivalently,
v(c, l) = max
 r(c, l) +
∑
c′ ψ[c
′|(c, l)]∑l′ γ[l′|c′, (c, l)]v(c′, l′),
R(c, l).
(5.3)
5.3 STRUCTURAL PROPERTIES
In this section, we develop conditions that lead to structured optimal policies. We first state
a definition used in what follows [101].
Definition 5.1. Let P and P ′ be two N x N transition probability matrices. We say P ′
dominates P , P ′ º P , if ∑Nj=k p′[j|i] ≥∑Nj=k p[j|i] for 1 ≤ i, k ≤ N.
In other words, if higher states are associated with better outcomes, then one would prefer
to transition according to the probabilities in P ′ than P .
We now consider the following assumptions:
(As5.1) r(c, l) is nondecreasing in c for each l and nonincreasing in l for each c.
(As5.2) R(c, l) is nondecreasing in c for each l and nonincreasing in l for each c.
As5.1 and As5.2 say that as CD4 categories improve (i.e., move to higher levels) or viral
load categories improve (i.e., move to lower levels), the one-period reward (As5.1) and the
terminal reward (As5.2) do not decrease.
(As5.3) Ψ1 º Ψ2 . . . º ΨL.
As5.3 says that a patient would prefer to be in a state with lower levels of viral load
than higher levels with respect to transitions on CD4 categories.
(As5.4) Pl,l′ is IFR.
As5.4 says that given the viral load category is l at time t and is l′ at time t + 1, a
patient has better transition probabilities over CD4 categories when coming from a higher
CD4 category at time t.
(As5.5) Pl,1 º Pl,2 . . . º Pl,L.
As5.5 says that a patient with a viral load category l at time t would prefer to transi-
tion to a lower viral load category at time t+1 with respect to transitions on CD4 categories.
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The next three assumptions are analogous to As5.3-As5.5, respectively. They differ in the
variable (CD4 category or viral load category) that is considered in the transition.
(As5.6) Q1 º Q2 . . . º QC .
(As5.7) Γc,c′ is IFR.
(As5.8) Γc,1 º Γc,2 . . . º Γc,C .
We can now prove the following:
Theorem 5.1. Suppose assumptions As5.1-As5.8 hold. Then:
(a) v∗(c, l) is nondecreasing in c for each l.
(b) v∗(c, l) is nonincreasing in l for each c.
Proof. We prove this by induction. Let i ∈ 0, 1, . . . and suppose vi(c, l) is nondecreasing in
c for each l and nonincreasing in l for each c. Note that v0(c, l) = 0 for all c, l satisfies this
property. Fix l′ ∈ {1, . . . , L}, and for all c, define:
vi+1(c, l′) = max
 r(c, l′) +
∑
l q[l|(c, l′)]
∑
c′ p[c
′|l, (c, l′)]vi(c′, l),
R(c, l′),
and
vi+1(c+ 1, l′) = max
 r(c+ 1, l′) +
∑
l q[l|(c+ 1, l′)]
∑
c′ p[c
′|l, (c+ 1, l′)]vi(c′, l),
R(c+ 1, l′).
Note the similarity between these equations and the Bellman equations of the type given in
(5.2).
By the assumption that vi(c, l) is nondecreasing in c for each l and assumption As5.4,
we apply Lemma 4.1 for each l to obtain:∑
c′
p[c′|l, (c+ 1, l′)]vi(c′, l) ≥
∑
c′
p[c′|l, (c, l′)]vi(c′, l). (5.4)
Now let l1 ≤ l2. Then we have:∑
c′
p[c′|l1, (c+ 1, l′)]vi(c′, l1) ≥
∑
c′
p[c′|l2, (c+ 1, l′)]vi(c′, l1) (5.5)
≥
∑
c′
p[c′|l2, (c+ 1, l′)]vi(c′, l2), (5.6)
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where (5.5) holds by the assumption that vi(c, l1) is nondecreasing in c, As5.5, and Lemma
4.1. Then (5.6) follows by the assumption that vi(h′, l) is nonincreasing in l. Therefore:∑
c′
p[c′|l, (c+ 1, l′)]vi(c′, l) is nonincreasing in l. (5.7)
Furthermore, ∑
l
q[l|(c+ 1, l′)]
∑
c′
p[c′|l, (c+ 1, l′)]vi(c′, l) (5.8)
≥
∑
l
q[l|(c, l′)]
∑
c′
p[c′|l, (c+ 1, l′)]vi(c′, l) (5.9)
≥
∑
l
q[l|(c, l′)]
∑
c′
p[c′|l, (c, l′)]vi(c′, l), (5.10)
where (5.9) follows from (5.8) by As5.6, (5.7) and Lemma 4.1, and (5.10) follows from (5.9)
by (5.4).
By assumption As5.1 and the relationships in (5.8)-(5.10), we have:
r(c+ 1, l′) +
∑
l
q[l|(c+ 1, l′)]
∑
c′
p[c′|l, (c+ 1, l′)]vi(c′, l)
≥ r(c, l′) +
∑
l
q[l|(c, l′)]
∑
c′
p[c′|l, (c, l′)]vi(c′, l). (5.11)
Next, by assumption As5.2,
R(c+ 1, l′) ≥ R(c, l′). (5.12)
Combining the relationships expressed in (5.11) and (5.12) we get:
max
{
r(c+ 1, l′) +
∑
l
q[l|(c+ 1, l′)]
∑
c′
p[c′|l, (c+ 1, l′)]vi(c′, l), R(c+ 1, l′)
}
≥ max
{
r(c, l′) +
∑
l
q[l|(c, l′)]
∑
c′
p[c′|l, (c, l′)]vi(c′, l), R(c, l′)
}
,
which in turn implies:
vi+1(c+ 1, l′) ≥ vi+1(c, l′).
Thus, vi+1(c, l) is nondecreasing in c for an arbitrary l. In almost identical fashion, we can
also show that vi+1(c, l) is nonincreasing in l for an arbitrary c by switching the concept of
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CD4 categories with viral load categories, using the form of Bellman’s equation expressed
in (5.3), and proceeding using assumptions As5.7, As5.8, and As5.3, in place of As5.4,
As5.5, and As5.6, respectively. Then, taking the limit of the iterates proves that v∗(c, l) is
nondecreasing in c for each l and nonincreasing in l for each c.
The following theorem and corollary are analogous to Theorem 4.2 and Corollary 4.1. The
theorem gives necessary and sufficient conditions for an optimal policy of initiating therapy
from all states, and the corollary gives sufficient conditions for waiting to be uniquely optimal
for a particular health state. They are stated without proof.
Theorem 5.2. a∗(c, l) = I for all (c, l) if and only if:
R(c, l) ≥ r(c, l) +
∑
c′
∑
l′
α[(c′, l′)|(c, l)]R(c′, l′) for all (c, l).
Corollary 5.1. If R(c′, l′) < r(c′, l′) +
∑
c
∑
l α[(c, l)|(c′, l′)]R(c, l) for some (c′, l′), then
a∗(c′, l′) = W , uniquely.
Next we explore conditions under which an optimal control-limit policy exists. Analogous
to Assumption As4.3, we consider the following two assumptions.
(As5.9) p[c′|(c, l)] = 0 for c′ > c.
(As5.10) q[l′|(c, l)] = 0 for l′ < l.
As5.9 and As5.10 imply that the CD4 category and viral load category, respectively,
cannot improve while waiting to initiate HIV therapy, which has intuitive appeal.
We define the following:
f(c, l) ≡ r(c, l) +
∑
c′<c
∑
l′≥l α[(c
′, l′)|(c, l)]R(c′, l′) +∑l′>l α[(c, l′)|(c, l)]R(c, l′)
1− α[(c, l)|(c, l)] .
In words, f(c, l) is the value associated with a patient being in state (c, l), under a policy that
waits whenever in that state, but initiates therapy when a transition is made to a worse state
(this is under the assumptions As5.9 and As5.10). We present two additional assumptions.
(As5.11) f(c+ 1, l)− f(c, l) ≥ R(c+ 1, l)−R(c, l) for all (c, l).
(As5.12) f(c, l − 1)− f(c, l) ≥ R(c, l − 1)−R(c, l) for all (c, l).
As5.11 can be thought of as saying that as the CD4 category improves, there is more
to be gained by waiting relative to initiating therapy. Conversely, it says that as the CD4
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category worsens, there is more to be gained by initiating compared to waiting. As5.12
makes the same statement with respect to changes in viral load.
We are now ready to prove sufficient conditions for the existence of a two-dimensional
optimal control-limit policy, along with structure on the control limits themselves.
Theorem 5.3. Under assumptions As5.9-As5.12
(a) an optimal CD4-based control-limit policy exists for each level of viral load. That is to
say, for each l there exists CLC(l), called the “CD4-based control limit,” such that whenever
c < CLC(l), a
∗(c, l) = I, and whenever c ≥ CLC(l), a∗(c, l) = W .
(b) an optimal viral-load-based control-limit policy exists for each level of CD4. That is
to say, for each c there exists CLL(c), called the “viral load-based control limit,” such that
whenever l ≤ CLL(c), a∗(c, l) = W , and whenever l > CLL(c), a∗(c, l) = I.
(c) CLL(c) is nondecreasing in c and CLC(l) is nondecreasing in l.
Proof. Consider l = L, and let c′ be the smallest c such that a∗(c, L) = W (if no such c′
exists, then a trivial CD4-based control-limit policy of a∗(c, L) = I for all c exists). By
assumptions As5.9 and As5.10, and Bellman’s optimality equations, this implies that
f(c′, L) ≥ R(c′, L).
By assumptions As5.11 and As5.12, it follows that
f(c, l) ≥ R(c, l) for all (c, l) such that c ≥ c′ and l ≤ L. (5.13)
Because f(c, l) ≥ R(c, l) for all (c, l) with c ≥ c′ and l ≤ L, and because f(c, l) represents
the value of waiting in state (c, l) and initiating therapy for all other states that may follow,
the value of waiting in state (c, l) and taking the optimal action for all other states that
may follow can be no worse. Therefore, v∗(c, l) ≥ R(c, l) and a∗(c, l) = W for all (c, l) with
c ≥ c′ and l ≤ L. By definition, CLC(L) = c′ and CLL(c) = L for all c ≥ c′. Next, consider
l = L−1. Let c′′ be the smallest value of c such that a∗(c, L−1) = W . By the previous step,
we know that c′′ ≤ CLC(L). If c′′ < CLC(L), then it follows that f(c′′, L− 1) ≥ R(c′′, L− 1),
and by the same reasoning as above, we can conclude that a∗(c, l) = W for all (c, l) with
c ≥ c′′ and l ≤ L − 1. Iterating in this fashion, from l = L down to l = 1, proves the
theorem.
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Figure 10: Partial optimal policy after first inductive step
Figure 10 shows how the optimal policy matrix may look after completing the first step
of the proof (where l = L), and Figure 11 shows how it may look after the final step of the
proof.
Comment on Control-Limit Policies in Two Dimensions
Although establishing control-limit policies arises in many problems, there is little in the
literature regarding existence of such policies in multidimensional state spaces. Benyamini
and Yechiali [19] considered a nonstationary machine maintenance problem with a system
variable indicating the state of the machine and another variable indicating the age. They
established sufficient conditions for an optimal control-limit policy (with respect to actions
of wait or replace) in the following sense: for a fixed age t, there is a control-limit policy
with respect to the machine states, and for a fixed machine state i, there is a control-limit
policy with respect to the machine’s age. There are also some references to two-dimensional
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Figure 11: Example of an optimal policy under Theorem 5.3
control-limit policies, or “switching curves”, in the queueing control literature. Hajek [74]
considered a two-station queueing network, which is controlled as follows: a new customer
has some probability of going to each queue, an extra worker spends some portion of time
servicing each queue, and customers needing rework are to be sent from one queue to the
other according to some station-dependent probability. Under assumptions on the cost and
probability transition structures of the network, Hajek proved the existence of a switching
curve policy that says: for a given level of customers at station 1, if the number of customers
at station 2 is below a certain value, send new arrivals to station 2; otherwise send them to
station 1. Furthermore, this limit increases with the number waiting at station 1. Wu et al.
[187] considered a two-stage tandem queueing system in which configurable resources can be
assigned to work on either queue. They also proved that the optimal policy has a switching
curve structure in terms of which queue the configurable resource should service. Unlike
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in [74], they were unable to prove monotonic structure of the curve; however, over 30,000
simulations supported this property. Finally, Alagoz et al. [6] developed a model of patient
acceptance of cadaveric liver donations with a two-dimensional state space of patient health
and liver quality. The authors established conditions guaranteeing an optimal control-limit
policy with respect to liver qualities for a given health level, and vice-versa.
5.4 CONCLUSIONS
This chapter expanded on the previous chapter by including an extra variable in the state
space. We presented clinically plausible assumptions that led to structural properties analo-
gous to those obtained in the one-dimensional case of the previous chapter. We have not yet
constructed the MDP model with actual data; however, we plan to do that in the near future.
Our contribution with this chapter was to prove structural properties for a problem with
a multidimensional state space. Despite many real problems requiring a multidimensional
state space, little theoretical work has been done in this area.
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6.0 LIFETIME DISTRIBUTION APPROACH TO THE OPTIMAL
SEQUENCING AND SWITCHING OF THERAPIES
6.1 INTRODUCTION
Whereas the previous two chapters focused on the optimal time to initiate therapy, this
chapter and the next explore methodological frameworks for considering the optimal switch-
ing and sequencing of HIV therapies. This problem is significantly more challenging than
the question of when to initiate therapy, both from a computational standpoint as well as
a data standpoint. Instead of considering an optimal time to go from being off of therapy
to initiating therapy, here we have the problem of timing the start of the first therapy, the
start of the second therapy, and so on. Moreover, we have all the permutations of therapy
sequences to contend with. Perhaps even more challenging is building a data-driven model.
For example, we are limited to available data for actual sequences of therapies that have
been offered in clinical settings; it is difficult or even infeasible to estimate the effects of
certain sequences of therapies that have never been tried before. The rest of this chapter
forms the basis of a paper by Shechter et al. [157].
In thinking of the body as a system to be maintained and therapies as components to be
replaced over time, we are able to glean insights from machine maintenance problems and
extend them to the context of therapeutic optimization. Despite some natural connections,
very little work has been done in this area. We begin by describing one paper in particular
from the machine maintenance literature and then extend it to the scheduling of therapies.
Most machine maintenance models assume an infinite supply of replacements and assume
that each one behaves stochastically identical and independent of the others. As a result,
optimal periodic policies can be obtained by modeling the system as a renewal process.
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Derman et al. [58], however, considered a system with one vital component and a finite
number of spares. Moreover, unlike most machine models that allow replacements after a
failure, they assumed that a failure ends the system’s lifetime. Under the usual assumption
that the lifetime of a spare is independent and identically distributed (iid) to the lifetimes
of the other spares, the authors sought a replacement schedule that maximizes the expected
lifetime of the system. In other words, they considered the following question: how much of
a current part’s lifetime should be used up before replacing it with a new part?
We can think of this problem in the context of maintaining a patient’s life: the patient
is the system, available therapies are the spare parts, and our objective is to maximize the
expected lifetime of the patient (system). Because therapies may have different levels of
effectiveness, we extend the work by Derman et al. by considering replacing components
whose lifetimes may not be identically distributed. Also, because the use of one therapy
can alter the effectiveness of another therapy not yet used (due to cross-resistance), ideally
one should consider these dependencies when evaluating a particular sequence. The problem
becomes not just one of timing replacements, as in Derman et al., but also one of determining
an optimal sequence for them. Clearly, if a patient dies while on a given therapy, there is
nothing more that can be done; therefore, the problem lies in trying to prolong the time
until this happens by strategically scheduling replacements over time. We begin by keeping
the assumption of independent lifetime distributions, while relaxing the assumption that
they are all identical. In Section 6.3.3, we consider relaxing the independence assumption as
well. We note that implicit in both frameworks is that there are no state observations other
than whether the patient (system) is alive (functioning) or dead (failed). All we know in
this framework are the lifetime distributions. Chapter 7 considers the possibility of periodic
informative state observations.
6.2 BACKGROUND
We describe in detail some of the work by Derman et al. [58], which considers a system
with one vital component and n identical spare components. The lifetime distributions of
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the components are iid with common cumulative distribution F (t), continuous density f(t),
support (0, T ) (0 < T ≤ ∞), and finite mean µ. Once a component is replaced with a
spare component, it cannot be used again, and if the component in service fails, the system
lifetime ends. The objective is then to determine when to replace functioning components so
as to maximize the expected total lifetime of the system. They let vi represent the maximum
expected system lifetime when there are i spare components available. Thus v0 represents
the expected system lifetime when no spare components are available and the system uses
only the initially installed component. Hence v0 = µ. For i ≥ 1, vi satisfies the optimality
equation given by
vi = max
0≤t≤T
φi(t),
where
φi(t) =
∫ t
0
τf(τ) dτ + F¯ (t)(t+ vi−1) (6.1)
=
∫ t
0
F¯ (τ) dτ + F¯ (t)vi−1, (6.2)
where F¯ (t) ≡ 1− F (t), and (6.2) is obtained from (6.1) by integration by parts. Let ti be a
switching time that yields vi.
In some instances it may never be optimal to install a new component. To address this,
the authors consider a distribution “new worse than used in expectation” (NWUE) [13],
which is when F has a finite mean and
µ ≤
∫ T
t
F¯ (τ) dτ
F¯ (t)
for all 0 ≤ t ≤ T . (6.3)
In other words, F is NWUE if at every point in time, the conditional expected remaining
mean (the right hand side of (6.3)) is at least as great as the mean of a new component (the
left hand side of (6.3)). The following is equivalent to (6.3),
µ ≥
∫ t
0
F¯ (τ) dτ + F¯ (t)µ for all 0 ≤ t ≤ T ,
which in the context of the above problem is equivalent to being optimal to never switch
components. Therefore, the authors assume that F is not NWUE and concentrate on policies
for which it is best to eventually replace a component. This implies that v1 > v0 and leads
to the following results:
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(i) vi is strictly increasing in i. That is, there is an increase in expected system lifetime
with an increase in spares.
(ii) vi − vi−1 < vi−1 − vi−2, n ≥ 2. That is, there are diminishing marginal returns with
more spares.
(iii) 0 < tn < tn−1... < t1 < T . That is, the optimal time to wait before replacing a working
component with one of the spares increases as the remaining spares decreases.
6.3 EXTENSION TO NON-IDENTICAL THERAPIES
We now extend the work by Derman et al. to consider the optimal scheduling of n possibly
different therapies, while maintaining the assumption of independence between them. We
assume a patient is currently not on any therapy and has n therapies available. We label each
therapy by i (i = 1, ..., n), assume the cumulative distribution function of patient survival
under therapy i is known and given by Fi(t), with continuous density given by fi(t), support
given by 0 ≤ T ≤ ∞, and finite mean µi. In other words, if the patient starts taking therapy
i and remains on it until death, the patient’s remaining lifetime distribution is characterized
by Fi, and the patient’s expected lifetime is µi. We allow the possibility that a patient does
not initiate therapy immediately and let F0 be the distribution function representing the
patient’s remaining lifetime when never taking therapy. By a schedule we mean a sequence
of the therapies {a1, a2, . . . , an} and an associated sequence of durations {t0, t1, t2, . . . , tn−1},
such that the patient starts taking therapy a1 after t0 units of time pass, remains on therapy
a1 for t1 units of time, switches to therapy a2 and remains on that for t2 units of time, and
so on, until the patient is on the final therapy, an, and remains on that therapy until death.
We assume that once patients initiate therapy, they remain on therapy for the remainder of
their lives. DHHS guidelines for therapy recommend against going off therapy later in the
course of treatment as rapid progression to AIDS and death has been observed in patients
who do so [123]. We also assume that once a therapy is used, it cannot be used again (we
discuss this more in Section 7.5).
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6.3.1 Special Case: Two Therapies Available
Before considering the optimal scheduling of many therapies, we first consider how to do this
for two available therapies. Moreover, we explore structural properties in this framework.
Starting with this simplified setting provides insight to our approach for the more complicated
situation of more than two therapies available, discussed in Section 6.3.2.
Consider two therapies, A and B, and suppose the patient initiates therapy immediately.
We want to know if it is better for the patient to start with therapy A and switch to B
at some time, or vice-versa. If the patient begins with therapy A followed by B, then the
optimal value associated with this sequence, vAB, is found via:
vAB = sup
0≤t≤T
φAB(t), (6.4)
where
φAB(t) =
∫ t
0
τfA(τ) dτ + F¯A(t)(t+ µB)
=
∫ t
0
F¯A(τ) dτ + F¯A(t)µB. (6.5)
In words, φAB(t) is the patient’s expected lifetime when starting with therapy A and
switching to therapy B after t units of time, and vAB finds the supremum of this function
over the possible values of t. We assume φAB(t) (and φBA(t)) is continuous and bounded;
therefore, if T (the upper limit of the distributions) is finite, we can find a value of t, say tA,
that attains the supremum in φAB(t). However, if T is infinite, then the supremum might
only be attainable in the limit. We provide an example of this in the next section.
As above, if we begin with therapy B, we have:
vBA = sup
0≤t≤T
φBA(t),
where
φBA(t) =
∫ t
0
F¯B(τ) dτ + F¯B(t)µA.
We then define
v∗ = max{vAB, vBA}.
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To gain insight into this framework, we consider three separate conditions for the lifetime
distributions of the therapies: 1) independent exponential lifetime distributions with possibly
different rates, 2) independent uniform distributions over possibly different ranges, and 3)
independent triangular distributions with possibly different modes and ranges.
Exponential Lifetime Distributions
Suppose therapies A andB have independent exponential lifetime distributions with rates
λA and λB, respectively. The memoryless property of the exponential distribution suggests
that there is no merit to the notion of “using up” some lifetime under one exponential
distribution and switching to another exponential distribution. Therefore, the optimal policy
should be to use only the therapy with the smallest exponential rate. Formally, we have
φAB(t) =
∫ t
0
e−λAτ dτ +
e−λAt
λB
.
Evaluating the integral, and referring to (6.4), results in
vAB = sup
0≤t≤∞
[
(λA − λB)e−λAt + λB
λAλB
]
.
Clearly, if λA > λB (and hence µA < µB), vAB is obtained by letting t = 0, which
means it is optimal to immediately replace therapy A with therapy B. If λA < λB, then it
is optimal (in a limiting sense) to let t be as large as possible, which in this case means to
never replace therapy A with B. As mentioned earlier, this is a case of vAB being attained
only in the limit as t → ∞. Note that if λA = λB, then it does not matter if or when
therapy A is replaced with B. Generalizing these results to n therapies with independent
and exponentially distributed lifetimes with different rates, it is optimal to use only the
therapy with the smallest rate.
Uniform Lifetime Distributions
Suppose therapies A andB have independent uniform lifetime distributions with supports
[0, a] and [0, b], with means µA = a/2 and µB = b/2, respectively. Then,
φAB(t) =
∫ t
0
(a− τ)/a dτ + µB(a− t)
a
.
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This results in
vAB = sup
0≤t≤a
[
t− µBt
a
− t
2
4µA
+ µB
]
,
which is maximized when t = a− µB. Therefore, if A must precede B, and if a < µB, then
it is optimal to discard A immediately and only use therapy B. Otherwise, it is optimal to
use A for a− b/2 time units and then switch to B. By symmetry, if B must precede A and
b < µA, then it is optimal to discard B immediately and use only A. Otherwise, it is optimal
to use B for b − a/2 time units and then switch to A. Interestingly, if the patient has to
use therapy A before therapy B and if a < µB, then the patient should not spend any time
on therapy A. However, if the patient must use B before A, then the patient should use
therapy A at some point (specifically, after b− µA time units).
In considering the optimal sequencing of A and B, we consider three cases: 1) b < a/2,
2) b > 2a, and 3) a/2 ≤ b ≤ 2a (or, equivalently, b/2 ≤ a ≤ 2b). By the above discussion, we
can see that if case 1 holds, then it is optimal to start with therapy A, wait a− µB units of
time, and then switch to therapy B. If case 2 holds, then it is optimal to start with therapy
B, wait b − µA units of time, and then switch to therapy A. For case 3, we show that it is
optimal to start with therapy A if a > b or to start with therapy B if b > a. We have the
following:
vAB = a− b/2− b(a− b/2)
2a
− (a− b/2)
2
2a
+ b/2, and
vBA = b− a/2− a(b− a/2)
2b
− (b− a/2)
2
2b
+ a/2.
After simplification, we find that vAB − vBA > 0 if a > b and (a+ b)2 < 5ab. Suppose a > b
and consider two functions, g1(t) ≡ (b + t)2, and g2(t) ≡ 5bt, where b < t ≤ 2b. Then we
see that g2 is the line connecting (b, 5b
2) with (2b, 10b2), and g1 is the parabola connecting
(b, 4b2) with (2b, 9b2). Because the line lies above the parabola for the range of t, we see
that if b < a ≤ 2b, then (a + b)2 < 5ab and thus vAB > vBA. By symmetry, if a < b ≤ 2a,
it is optimal to sequence B followed by A. Note that if a = b, then the sequencing of the
therapies does not matter. The optimal policy is achieved by starting with either one and
switching after µA = µB units of time.
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In summary, if a ≥ b, it is optimal to start with therapy A and switch to B after a− µB
units of time and if b ≥ a, it is optimal to start with therapy B and switch to A after
b− µA units of time. This also demonstrates that it is optimal to sequence the therapies in
decreasing order of the means. In some sense, it seems intuitive that if one therapy has a
lifetime distribution with a greater mean than another, then it is optimal to get as much life
out of that first therapy before switching to the other one at some later time. As we show
next, however, this does not always hold.
Triangular Lifetime Distributions
Suppose therapies A and B have independent triangular lifetime distributions LA and
LB described by [0, αA, βA] and [0, αB, βB], respectively, where αA represents the mode of
the lifetime distribution for therapy A, and 0 and βA represent the lower and upper limits of
the distribution (similarly defined for therapy B). The mean lifetime on therapy A is given
by µA = (0 + αA + βA)/3, and
F¯A(t) =

1− t2
αAβA
: 0 ≤ t ≤ αA,
(βA−t)2
βA(βA−αA) : αA < t ≤ βA.
In evaluating φAB(t), we have to consider whether t ≤ αA or t > αA. We have,
φAB(t) =

∫ t
0
(1− τ2
αAβA
) dτ + µB(1− t2αAβA ) : 0 ≤ t ≤ αA∫ αA
0
(1− τ2
αAβA
) dτ +
∫ t
αA
(βA−τ)2
βA(βA−αA) dτ + µB
(βA−t)2
βA(βA−αA) : αA < t ≤ βA.
(6.6)
Consider LA defined by [0, 50, 55] (µA = 35) and LB defined by [0, 10, 80] (µB = 30).
Figure 12 shows how φAB(t) and φBA(t) vary over the switching times, and we can see that
φAB(t) reaches a maximum of around 47, whereas φBA(t) reaches a maximum of around
40. Therefore, it is optimal to sequence A before B. Now consider LA defined by [0, 5, 100]
(µA = 35) and LB defined by [0, 30, 60] (µB = 30). In Figure 13, we see that φBA(t) reaches
a maximum value of around 46, whereas φAB(t) reaches a maximum of around 39. As a
result, it is optimal to sequence B before A. Therefore, we have found an example of where
it is optimal to use the therapy with the smaller mean before using the therapy with the
larger mean. Next, we consider stronger assumptions on the lifetime distributions of the
therapies and whether such assumptions allow us to make general statements about the
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Figure 12: Plots of φAB(t) and φBA(t) when A ∼ Triang(0, 50, 55) and B ∼ Triang(0, 10, 80)
optimal sequencing of two therapies. Surprisingly, we shall show that even these stronger
conditions do not provide sufficient conditions to know a priori the optimal sequencing.
Sequencing Two Therapies under General Stochastic Ordering Relationships
In this section, we consider more restrictive orderings based on information concerning
the entire distribution instead of a single parameter such as the mean. We might posit
that knowing a stochastic ordering of the therapies can allow us to say something about
the optimal sequencing of the therapies. Knowing the optimal sequencing a priori would
decrease the overall computational burden of the problem. The following definitions are
found in [156].
Definition 6.1. Y is larger than X under the usual stochastic order (Y ºst X) if for all t,
F¯Y (t) ≥ F¯X(t).
Definition 6.2. Y is larger than X under the hazard rate order (Y ºhr X) if F¯Y (t)/F¯X(t)
is nondecreasing in t.
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Triangular A(0,5,100); Triangular B(0,30,60)
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Figure 13: Plots of φAB(t) and φBA(t) when A ∼ Triang(0, 5, 100) and B ∼ Triang(0, 30, 60)
Definition 6.3. Y is larger than X under the likelihood ratio order (Y ºlr X) if fY (t)/fX(t)
is nondecreasing in t over the union of the supports of X and Y .
In Definitions 6.2 and 6.3, a/0 ≡ ∞ when a > 0. Now let mX(t) represent the expected
remaining lifetime of X, given it has survived until time t. That is, mX(t) ≡ E[X−t|X > t].
Similarly, let mY (t) ≡ E[Y − t|Y > t]. We then have the following definition [156].
Definition 6.4. Y is larger than X under the mean residual life order (Y ºmrl X) if
mY (t) ≥ mX(t) for all t.
With these definitions, the following relations hold [156]:
Y ºlr X ⇒ Y ºhr X ⇒ Y ºst X ⇒ µY ≥ µX ,
and
Y ºhr X ⇒ Y ºmrl X.
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Returning to the two therapies A and B, intuition may suggest that if LB ºst LA, then
it is optimal to use therapy B for some time before switching to therapy A. And if this
is true, then the strongest of ordering conditions, (LB ºlr LA), would also guarantee the
optimality of starting with therapy B. Unfortunately, as we show next, even the strongest
of these stochastic ordering conditions does not guarantee a priori knowledge of the optimal
sequencing of two therapies.
Example: Let LA ∼ Triang(0, 5, 10) and LB ∼ Triang(0, 6, 12). We begin by showing
that LB ºlr LA. To demonstrate this, we show that fB(t)/fA(t) is nondecreasing in t over
(0, 12). Based on these distributions, the probability density functions for LA and LB are
fA(t) =

t/25 : 0 ≤ t ≤ 5
(10− t)/25 : 5 < t ≤ 10
and
fB(t) =

t/36 : 0 ≤ t ≤ 6
(12− t)/36 : 6 < t ≤ 12.
In the following, we let r(t) ≡ fB(t)/fA(t).
Case I: t ≤ 5
r(t) = 25/36 which is clearly nondecreasing.
Case II: 5 < t ≤ 6
r(t) = 25t
36(10−t) . Note that limt→5+ r(t) = 25/36 = r(5). Furthermore, r
′(t) = 25
36(10−t) +
25t
36(10−t)2 , which is positive on (5, 6], and therefore, r(t) is increasing on that interval.
Case III: 6 < t < 10
r(t) = 25(12−t)
36(10−t) . Note that limt→6+ r(t) = 25/24 = r(6). Furthermore, r
′(t) = −25
36(10−t) +
25(12−t)
36(10−t)2 , which is positive on (6, 10), and therefore, r(t) is increasing on that interval as well.
Case IV: 10 ≤ t < 12
As discussed above, r(t) =∞.
Hence, fB(t)/fA(t) is nondecreasing in t over (0, 12), from which it follows that LB ºlr
LA. We now show the counterintuitive result that vBA < vAB. First let us derive the
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value of vAB. In doing so, we will make use of the expression for φAB(t) given in (6.6). In
seeking the maximum of φAB(t), we consider φ
′
AB(t) for t ≤ 5 and t > 5. For t ≤ 5 we
have φ′AB(t) = 1 − t2/50 − 6t/25, which has a local maximum at t = 12−
√
344
−2 ≈ 3.274. For
t > 5, φ′AB(t) = (10 − t)2/50 − 12(10 − t)/50, so that φAB(t) is decreasing on (12−
√
344
−2 , 10).
Therefore, if one is to sequence therapy A followed by B, it is optimal to switch from A to
B at tA =
12−√344
−2 . The value associated with doing so is given by:
φAB(tA) =
∫ tA
0
(1− τ 2/50) dτ + 6(1− t2A/50),
which evaluates to ≈ 7.754. A similar argument shows that φBA(tB) ≈ 7.688, and therefore
vBA < vAB.
Intuitively, it would not seem that LB ºlr LA would imply an optimal policy of se-
quencing A followed by B. We show that this implication does not hold, concluding that
the likelihood ratio ordering does not imply a priori knowledge of the optimal sequencing of
therapies. Let LA ∼ Unif [0, a] and LB ∼ Unif [0, b], where b > a. Then clearly, LB ºlr LA
since
fB(t)/fA(t) =
 a/b : 0 ≤ t < a,∞ : a ≤ t < b.
However, as presented previously with therapies having uniform lifetime distributions, it is
optimal to sequence B followed by A and hence vBA ≥ vAB.
We now consider the more general question of establishing sufficient conditions for a
priori sequencing of two therapies A and B based solely on distribution information. One
set of sufficient conditions could require that φBA(t) ≥ φAB(t) for all t, from which it would
immediately follow that φBA(tB) ≥ φAB(tA), implying that it is optimal to start with therapy
B before switching to A at some point. However, if φBA(t) ≥ φAB(t) for all t then φBA(0) =
µA ≥ φAB(0) = µB and φBA(∞) = µB ≥ φAB(∞) = µA. These conditions imply that µA
must equal µB. In general, we will be scheduling therapies which could have different lifetime
means.
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In continuing to explore sufficient conditions for determining the optimal sequencing,
let us suppose that µB ≥ µA, and consider the two functions φAB(t) and φBA(t). If we
switch from A to B immediately, then we have φAB(0) = µB. Conversely, if we start with
B and never switch to A, we have φBA(∞) = µB. Therefore, a sufficient condition for
φBA(tB) ≥ φAB(tA) is that µB ≥ φAB(t) for all t. In other words, the condition states that it
is better to start with therapy B and stay on it indefinitely than to start with therapy A and
switch to B at some time. This condition appears to be too strong because it implies that
therapy A induces such poor survival that using it for any amount of time is too risky. The
existence of other conditions that guarantee a priori knowledge of the optimal sequencing of
therapies remains an open question.
The Value of Information
We consider the following situation: Suppose an optimal policy has a patient initiate
therapy A and switch to therapy B at time tA. Does knowing that the patient is alive at
some time 0 < t′ < tA change the optimal time to switch to therapy B? We show that this
information has no effect on the optimal policy, and thus the patient waits another tA − t′
time units before switching therapies.
Theorem 6.1. Suppose the solution to vAB is obtained at time tA. Also, suppose that the
patient is alive on therapy A at time t′ < tA. Then it is still optimal to switch therapy at
time tA.
Proof. If tA yields the value vAB, then by (6.4) and (6.5), tA maximizes the following:
φAB(t) =
∫ t
0
τfA(τ) dτ + F¯A(t)(t+ µB)
=
∫ t
0
F¯A(τ) dτ + F¯A(t)µB.
By assumption, we observe that the patient is alive on therapy A at time t′ < tA. In reeval-
uating the optimal time to switch therapies, we search for the value of t which maximizes
the following:
φAB(t|t ≥ t′) =
∫ t
t′
τ
fA(τ)
F¯A(t′)
dτ +
F¯A(t)
F¯A(t′)
(t+ µB)
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which can be rewritten as:
φAB(t|t ≥ t′) = 1
F¯A(t′)
[∫ t
t′
τfA(τ) dτ + F¯A(t)(t+ µB)
]
After one more step, we have the equivalent expression:
φAB(t|t ≥ t′) = 1
F¯A(t′)
[∫ t
0
τfA(τ) dτ + F¯A(t)(t+ µB)−
∫ t′
0
τfA(τ) dτ
]
. (6.7)
The last integral in (6.7) is just a constant whose derivative is 0. Furthermore, the outside
multiplier of 1
F¯A(t′)
has no effect on finding where the derivative of φAB(t|t ≥ t′) is equal to
0. In other words, the roots of φ′AB(t|t ≥ t′) are the same as those for φ′AB(t). Moreover,
because the outside multiplier is positive, the sign of φ′′AB(t|t ≥ t′) matches the sign of φ′′AB(t)
at every t. Therefore, the value of t that maximizes φAB(t) also maximizes φAB(t|t ≥ t′).
Although knowing the patient is alive does not change the optimal policy, the optimal
value function increases.
Theorem 6.2. φAB(tA|t ≥ t′) > φAB(tA).
Proof. We have:
φAB(tA|t ≥ t′) > φAB(tA) iff
1
F¯A(t′)
[
φAB(tA)−
∫ t′
0
τfA(τ) dτ
]
> φAB(tA) iff (6.8)
φAB(tA)−
∫ t′
0
τfA(τ) dx > φAB(tA)F¯A(t
′) iff (6.9)
φAB(tA) >
∫ t′
0
τfA(τ) dτ
1− F¯A(t′) iff (6.10)
φAB(tA) >
∫ t′
0
τfA(τ) dτ
FA(t′)
. (6.11)
where (6.8) follows by definitions, (6.9) follows by the positivity of F¯A(t
′), (6.10) follows by a
rearrangement of terms and the positivity of 1− F¯A(t′), and (6.11) follows by the definition
of F in terms of F¯ . Therefore, if we show that (6.11) holds, then we are done. The right
hand side of (6.11) is the expectation of X ∼ fA(x), conditional on X ≤ t′. This is less
than the unconditional expectation of X ∼ fA(x), which is the expected value of starting on
96
therapy A at time 0 and never switching to therapy B. This is no greater than the best one
can do by having the option of switching to B at some point of time, which equals φAB(tA).
Therefore, (6.11) holds.
6.3.2 General Case: Multiple Therapies Remaining
Having seen the difficulty in establishing sufficient conditions for determining a priori the
optimal sequence of therapies, we return to the general problem described at the beginning
of Section 6.3 to see how we may solve it and what other structural properties may exist.
Recall the situation we described: a patient not currently on therapy has n therapies available
and wishes to determine the optimal sequencing of therapies and times to switch from one
therapy to the next one on the list. A naive way to do this is to evaluate all n! sequences
of the therapies and solve for the optimal switching times. We present a more efficient
dynamic programming approach. Recall that for each therapy i, µi is the mean of its
lifetime distribution. We let v∗S represent the optimal value associated with initiating therapy
immediately when the set S of therapies are available. Then v∗{i} = µi. Next, we consider
all
(
n
2
)
pairs of therapies and use the methods of Section 6.3.1 to determine the optimal
schedule of each pair. For example, for therapies i and j, we determine vij and vji. Then
v∗{ij} = max(vij, vji). In the next step of the algorithm, we consider all
(
n
3
)
triplets of
therapies and perform three evaluations necessary to determine the best optimal scheduling
of the three available therapies. For example, consider three available therapies: i, j, and
k. We first evaluate the optimal time to switch from therapy i to the best schedule of the
remaining therapies j and k. To do so, we consider an evaluation analogous to that given in
(6.5). In other words, we determine the best time to stop taking therapy i and follow it up
with the best schedule of j and k and its corresponding value v∗{j,k}. Then we do the same
evaluation when starting with j and following up with the best schedule of i and k, and
finally we consider switching from k to the best schedule of i and j. Taking the max of these
yields v∗{i,j,k}. We proceed along these lines until obtaining v
∗
{1,2,...,n} which gives the optimal
expected remaining lifetime upon initiating therapy. For our final evaluation, we consider
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the possibility of the patient waiting some time before initiating therapy and evaluate (6.5)
using F¯0 (the lifetime survival function for a patient never initiating therapy) and v
∗
{1,2,...,n}.
Solving this yields the value of t0, the time to wait before initiating therapy.
We now provide some results under this extended framework. Theorem 6.3 states that
expanding upon a set of available therapies cannot make a patient worse off.
Theorem 6.3. Let S1 and S2 be two sets of therapies such that S2 ⊃ S1. Then v∗S2 ≥ v∗S1.
Proof. Consider any sequencing of therapies which lists the therapies in S2\S1 before using
the optimal sequencing of therapies that yields v∗S1 . Then by scheduling the switching times
of the therapies in S2\S1 to occur at t = 0, we obtain a schedule whose value is v∗S1 . Therefore,
the optimal schedule of the therapies in S2 yields a value at least as great as v
∗
S1
.
We now consider a similar condition to the assumption that F is not NWUE made by
Derman et al. For every pair of therapies i and j, we assume the following:∫ T
t
F¯i(τ) dτ
F¯i(t)
< µj for some 0 ≤ t < T, (6.12)
which is equivalent to
µi <
∫ t
0
F¯i(τ) dτ + F¯i(t)µj for some 0 ≤ t < T. (6.13)
In the context of our problem, (6.13) says that if the patient starts on therapy i, there
is a time for which it is optimal to switch from i to j. The basis of this assumption is that
most therapies lose effectiveness over time, after which a patient can benefit from using an
unused therapy.
Note that although φij(t) is maximized at a finite value of time that satisfies (6.12), it is
not necessarily true that a time satisfying (6.12) also maximizes φij(t). Indeed, by continuity,
if ti is a maximizer of φij(t), then there exists a neighborhood N(ti) of ti which contains
some t ∈ N(ti) such that φij(t) < φij(ti) and such that∫ T
t
F¯i(τ) dτ
F¯i(t)
< µj. (6.14)
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Consequently, although we may be observing a patient on therapy i and come to a value
of t such that (6.14) holds, it may be optimal to wait some more time before switching to
therapy j. For example, consider two therapies both having a Unif [0, 10] distribution. After
two units of time, the conditional expected remaining mean of the first distribution is equal
to 4, which is less than 5 (the mean of the Unif [0, 10] distribution). However, it is optimal
to wait until time 5 and then switch to the second therapy.
With the assumption given in (6.12), there is a strict increase in value with an increase
in therapies.
Theorem 6.4. Under the condition of (6.12), if S2 ⊃ S1, then v∗S2 > v∗S1.
Proof. Consider a sequencing of therapies which lists the therapies in S1 in the order that
yields v∗S1 followed by an optimal sequencing of the therapies in S2\S1. Without loss of
generality, let i be the final therapy in the first sequence used prior to using the first therapy
in the optimal sequencing of S2\S1. The assumption in (6.12) implies that there is a time for
which it is optimal to switch from i to the optimal sequencing of S2\S1 (for the assumption
directly implies that it is better to switch from i to any single therapy k in S2\S1 at some
time, and v∗S2\S1 ≥ v∗k by Theorem 6.3). Therefore, the value associated with the optimal
scheduling of S1 (v
∗
S1
) increases when we allow the possibility of switching from i at some
point of time to the optimal sequencing of S2\S1. As this sequencing of the therapies in S2
was just one consideration, it must follow that v∗S2 > v
∗
S1
.
The above discussion has taken the perspective of comparing a given set of therapies with
a set that includes those same therapies with the addition of more options. Now we take a
slightly different perspective. We let Si be the set of all subsets of S with cardinality equal
to i, and we define y(i) to be the maximum of all the values associated with the optimal
scheduling of each of the
(
n
i
)
elements in Si. Formally, we have the following definitions:
Si ≡ {S ′ : S ′ ⊆ S and |S ′| = i},
y(i) ≡ max
S′∈Si
{v∗S′},
S∗(i) ∈ argmaxS′∈Si{v∗S′}.
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We now prove the following:
Theorem 6.5. If i < j, then y(i) < y(j).
Proof. Let i < j. Consider the set S∗(i) and any superset S ′ of S∗(i) with cardinality j.
By Theorem 6.4 we know that v∗S′ > v
∗
S∗(i) = y(i). Because S
′ is in Sj, it follows that
y(j) ≥ v∗S′ > v∗S∗(i) = y(i).
One of the interesting results in Derman et al. was that if it is optimal to wait tx units
of time to switch from the current component to a spare component, then the optimal time
to replace the new spare component with another spare component is some time ty > tx
[58]. In other words, fewer spares means longer times to use the currently functioning
component. We explore this idea in the current framework. Consider four therapies, A,B,C
and D, with lifetime distributions given as LA ∼ Triang [0, 5, 10], LB ∼ Triang [0, 6, 12],
LC ∼ Triang [0, 2, 17], and LD ∼ Triang [0, 2, 18]. Table 13 contains the different contenders
for the optimal sequencing of one, two, three, and four therapies from the possible set of four.
It also contains the approximate value associated with the sequence and the approximate
time to switch from the first therapy in the sequence to the second one. For example, if the
patient can only use one of the therapies, then it is best to use therapy D and expect to live
6.67 more units of time. If the patient can only use two of the four therapies, it is best to
use B followed by D, with an expected lifetime of 8.89. Also, the table indicates it is best
to switch from B to D after 4.12 units of time. If three therapies may be used, it is best
to take B, followed by A, and finish with D. The expected lifetime under this scenario is
10.18 and the patient should stay on therapy B for 3.57 units of time before switching to
therapy A. Finally, with all four therapies the optimal sequencing is BACD. The expected
remaining lifetime under this sequence is 11.03, and the patient should switch from B to A
after 3.29 units of time. After switching to A, we can use the table to see that the best time
to switch from A to C is after 2.71 units of time, and the best time to switch from C to D
is after 3.67 units of time. We see, therefore, that within an optimal schedule of M out of
N available therapies, the optimal times to use each subsequent therapy in the list may not
be monotonically increasing. One can check that this is also demonstrated when considering
the optimal schedule of three out of the four therapies.
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6.3.3 Dependence Considerations
Because of the independence assumption, until now we have not needed to concern ourselves
with the history of therapies taken when considering the lifetime distribution of a newly
administered therapy. In thinking of a general framework for considering dependencies, it
is conceivable that we may want to know the following information: the sequence of drugs
taken so far, how long ago each one was started, and how long the patient was on each
therapy. The reason for wanting such information is that the time spent on a therapy
gives information about the likelihood of development of resistance against that therapy and
others, and the time that has elapsed since that therapy was taken gives information about
the current strength of resistance that may have developed. Now, when considering a lifetime
distribution of a therapy j, instead of dealing with Fj(t) as before, we should think of the
form as: Fj(t|{a1, t1, a2, t2..., aj−1, tj−1}), where the patient was on therapy a1 for time t1,
then switched to therapy a2 and stayed on that for time t2, until being on therapy aj−1 for
time tj−1 before starting the current therapy.
Solving this kind of problem is extremely difficult. First, the data requirements to support
such considerations greatly exceed the data availability in the near term. Second, even with
the conditional distribution information immediately available, there is a large computational
burden of solving such a problem (this problem may be thought of as a generalization of
stochastic machine scheduling [136]). However, there may be considerable simplifications we
can make to the general dependency framework we just described. For example, perhaps
only the history of therapies until tx time units ago or the last k therapies need to be kept.
We leave for future work these and other simplifications that may render the dependency
considerations both clinically plausible and computationally tractable.
6.4 CONCLUSIONS
This chapter has considered switching and sequencing available therapies so as to maximize
a patient’s expected total lifetime. Our research was motivated by a paper in the machine
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Table 13: Sequencing data for four therapies with LA ∼ Triang [0, 5, 10], LB ∼
Triang [0, 6, 12], LC ∼ Triang [0, 2, 17], and LD ∼ Triang [0, 2, 18]
# of Therapies Available Sequence Optimal Value First Therapy Usage Time
A 5 -
B 6 -
1
C 6.333 -
D 6.667 -
AB 7.754 3.274
BA 7.688 4.849
AC 8.018 3.159
CA 6.987 7
AD 8.287 3.052
DA 7.245 8
2
BC 8.639 4.255
CB 7.463 5
BD 8.891 4.124
DB 7 .667 6
CD 7.883 3.667
DC 7.843 5.333
ABC 9.955 2.525
ABD 10.176 2.469
ACD 9.302 2.707
BAC 9.959 3.656
BAD 10.180 3.574
BCD 9.849 3.699
3
CAB 8.764 1.948
CAD 9.241 1.846
CBD 9.788 1.741
DAB 8.825 2.493
DAC 9.053 1.996
DBC 9.609 1.879
ABCD 11.026 2.275
BACD 11.029 3.289
4
CBAD 10.974 1.552
DBAC 10.815 1.668
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maintenance literature that sought to maximize the expected lifetime of a system with one
vital component and n spare parts [58]. In that paper, it was assumed that the lifetime
distributions of the parts were independent and identically distributed. We spent most of
the chapter exploring the implications of relaxing the assumption of replacements having
identical distributions, because different therapies will typically induce different lifetime dis-
tributions. In particular, we considered conditions on the distributions that would ensure
that we could know the optimal sequencing of therapies in advance of determining the opti-
mal timing of the switches. However, even very strong stochastic ordering conditions fail to
give sufficient conditions for a priori optimal sequencing. We considered the more general
situation where multiple therapies are available, proved some structural properties regarding
the optimal value function, and provided a dynamic programming algorithm based on earlier
ideas.
There are some limitations of the model we presented. One is that we did not consider
patient aging. We assumed that the lifetime distributions associated with being on a therapy
remain the same regardless of when the therapy is taken; in reality, a 60 year old patient
initiating a therapy will have a smaller expected remaining lifetime compared to a 20 year
old patient initiating the same therapy. One way to handle this may be to include a discount
factor in the rewards. We discuss this more in the next chapter. Also, we did not consider
the goal of maximizing the total expected quality-adjusted life years of a patient. We could
consider utility weights associated with being on each therapy without adding any difficulty
to the solution methodology. However, implementing utility weights is better suited for a
model that considers more patient states besides “alive” and “dead”. For example, a model
that considers varying degrees of health could better discriminate quality of life valuations.
We consider this as well in the next chapter.
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7.0 MDP APPROACH TO THE OPTIMAL SEQUENCING AND
SWITCHING OF THERAPIES
7.1 INTRODUCTION
Chapter 6 described a methodological approach for the optimal scheduling of HIV therapies
when the only information available is the lifetime distribution associated with being on
each therapy. The only observations considered were whether the patient was alive or dead.
We described a schedule of therapies as a sequence of the therapies {a1, a2, . . . , an} and an
associated sequence of durations {t0, t1, t2, . . . , tn−1}, where the patient starts taking therapy
a1 after t0 units of time pass, remains on therapy a1 for t1 units of time, and so on, until the
patient is on the final therapy, an, and remains on that therapy until death. Furthermore, we
showed in Theorem 6.1 that knowing a patient has survived until some time t does nothing
to change the optimal time to switch to the next therapy.
This chapter considers a framework in which physicians make periodic patient observa-
tions, which allow them to update their prior beliefs of the patient’s survival and prognosis
and thus make more informed treatment decisions. Rather than an a priori sequence of ther-
apies and usage times, this state-based approach indicates the optimal action to take at each
patient visit as a function of the patient’s state. This leads to a dynamic solution in which
certain states may indicate to continue taking the current therapy, others may indicate to
switch to therapy A, others to switch to therapy B, and so on.
As discussed in Chapter 1, MDPs are useful modeling techniques for solving sequential
stochastic decision problems. This is the situation with the management of therapies just
as it is for the question of when to initiate therapy. Whereas a stationary MDP framework
(one in which the components do not change over time) was justifiable for the latter (see
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comments in Section 4.6), there are some issues we need to address in the current context
to consider a feasible stationary MDP model. Stationary MDPs have significant conceptual,
computational, and data-requirement advantages over non-stationary MDPs.
As with the previous chapter, there are connections between this problem and machine
maintenance problems, where a machine is periodically inspected and based on its state,
a decision is made whether to continue using it or replace it with a new one. Many ma-
chine maintenance models assume that a replacement takes the system back to a new state
from which the same stochastic deterioration as the previous machine proceeds. There are
some exceptions, such as Klein [100], which considers maintenance actions that may take
the system to one of various states with certainty, or Hopp and Wu [83], which considers
probabilistic movement to various states after a maintenance action. A review by Pham and
Wang [130] provides an overview of other machine maintenance literature that address the
possibility of imperfect repair.
The previous research, however, has not addressed a situation analogous to that found
in HIV therapy planning: after the administration of a new therapy, patients typically
see a general stochastic improvement in their health for some time, followed by a general
stochastic deterioration after the virus builds resistance to the therapy (if we think about
this in terms of survival analysis [99, 104], the hazard rate function for a patient’s lifetime
on therapy should exhibit a sort of “bathtub” shape). An analogous machine maintenance
problem would be if a machine had an initial warmup period prior to peak performance,
followed by a general stochastic deterioration. Recall from Section 2.3.2, that Klein used
the exponential lifetime distributions observed in machines as justification for considering an
MDP approach to optimal machine maintenance problems [100]. However, an exponential
distribution implies a constant hazard function. Note that in the models of Chapters 4 and 5,
patients are in a general stochastically deteriorating state of health until they begin therapy,
at which time they receive the expected remaining lifetime reward associated with being on
therapy. Therefore, it was not necessary to explicitly consider the two-phase aspect of the
transitions as we do now. An even more sophisticated approach would involve breaking the
progression into multiple phases according to degrees of resistance accumulation. For this
chapter, we shall focus on a two-phase perspective.
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Another obstacle to modeling the problem as a stationary MDP is the notion of aging.
Patients, as well as machines, age over time, which should have a dynamic effect on the
probability of death beyond the state-based probability of death. With the optimal stopping
structure of Chapters 4 and 5, the time horizon before initiating therapy was not significantly
long, and we captured aging effects through our estimates of expected lifetime after initiating
therapy. In the present case, in which we explicitly model the switching of therapies over
time, we need to reconsider how to capture the aging effect.
Kao recommends a semi-Markov process model as a way to overcome the no-aging as-
sumption implied by standard Markov models for machine maintenance [92]. As with most
Markov models of machine maintenance, his model considers a system that may occupy a
number of states between new and failed; however, the difference is that he allows the system
to occupy these states for a random amount of time instead of for a fixed interval. Costs
are based on the time spent in a state as well as the cost of replacing a machine from a
state, and the objective is to minimize the long-run average cost per unit time. He considers
three types of policies: state-dependent, state-age-dependent, and age-dependent. As noted
in [19], however, Kao’s model only considers aging between state transitions and does not
consider a cumulative aging of the system that has a deleterious effect.
Benyamini and Yechiali explicitly address the aging problem in the machine maintenance
context by including both state and cumulative age in the MDP framework (we introduced
their work in Section 5.3) [19]. However, they make no mention of perhaps the biggest
obstacle to implementing their model: constructing data-based estimates of the reward and
transition probabilities for every state and age combination. Including the system age in the
model may render data too sparse to derive reliable age-based estimates of these components.
The large state space may present computational difficulties as well.
Yet another issue arises that we did not face in the MDP models of earlier chapters: the
fact that patients have a finite number of therapies (or analogously, that systems have a
finite number of replacements). The previous chapter discussed the paper by Derman et al.
[58], which is the only machine maintenance paper we are aware of that explicitly considers
106
a finite supply of replacements. Again, Chapters 4 and 5 did not consider this issue because
we did not model the physiological progression of HIV after a patient initiated therapy; the
patients received a terminal reward and the problem stopped.
7.2 MODELING FRAMEWORK
We address the above issues in a manner that allows us to utilize a stationary MDP model.
With respect to aging the patient, we will approximate the aging effect with a discount
factor instead of modeling age explicitly. For example, suppose we want to maximize the
expected remaining lifetime of a patient who enters the model at age 20. First, we shall
compute a monthly discount factor for an “average” person who is 20 years old as follows:
from a standard life table, suppose we find that the expected remaining lifetime for a 20 year
old is 60 years. Then, we compute the monthly discount factor as α = 1 − 1/(60 · 12). In
other words, α is the discount factor such that the net present value of an infinite stream of
discounted one-month rewards equals the expected remaining months of life (60 · 12 = 720).
Therefore, alpha solves
∑∞
i=0 α
i = 720. We let this represent an HIV-independent increased
mortality that the general population faces as they age.
As for the two-phase nature of the disease progression after switching to a new therapy,
we do the following. In addition to the usual state variable indicating the patient’s current
health, we include a state variable that indicates if the patient’s health is stochastically
improving, or stochastically deteriorating. The former will hold if the patient is on an
effective therapy, and the latter will hold if the patient is on an ineffective therapy. For now,
we assume therapies are identical and consider therapies with different levels of effectiveness
in Section 7.4. Upon switching to a new therapy, we assume it is effective and the patient
progresses according to a transition probability matrix representing stochastic improvement.
However, at each period, there is some state-dependent probability that the patient’s therapy
becomes ineffective (e.g., due to resistance buildup) and moves into a state of stochastically
deteriorating health. We assume that the only way to get back to a state of stochastically
improving health is to initiate a new therapy.
107
Finally, with respect to the issue of a finite number of therapies available to a patient, we
further expand the state space to include a parameter indicating the number of effective ther-
apies remaining. Upon switching to a new therapy, this parameter decreases by one. When
this value reaches zero, i.e., there are no more therapies from which to choose, we assume the
patient progresses according to that last therapy’s two-phase transition probabilities until
death.
We summarize the MDP model as follows. We consider monthly decision epochs, where
a patient may continue to wait (a = W ) or decide to switch to a new therapy (a = S) (if
there are any remaining). We describe the state by (h, d, n), where h represents the health
category (between 0 and H, with 0 representing death), d represents the direction status (1
or 0 according to whether the patient is in a state of stochastically improving or deteriorating
health, respectively) and n represents the number of therapies remaining (between 0 and N).
For now we assume therapies have independent and identical effects on HIV progression. In
Section 7.4, we relax this assumption. We will adopt the goal of maximizing total expected
lifetime and assign the reward for each action and state (with h > 0) to equal 1 month. The
resulting Bellman’s equations are:
v(h, d, n) = max
 1 +
∑d′=1
d′=0
∑h′=H
h′=0 p[(h
′, d′, n)|(h, d, n),W ]v(h′, d′, n),
1 +
∑d′=1
d′=0
∑h′=H
h′=0 p[(h
′, d′, n− 1)|(h, d, n), S]v(h′, d′, n− 1),
(7.1)
where p(·|·, a) represents the transition probabilities according to whether the patient waits
(top line) or switches to a new therapy (bottom line).
7.3 STRUCTURAL PROPERTIES
We begin with some assumptions. Figure 14 represents some of these assumptions through a
partial view of the transition probability matrix for a model with H = 5. It shows the parts
of the matrix relevant to the case of one and zero therapies remaining. PII represents the
submatrix of probabilities that patients waiting in a state of improving health transition to
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Figure 14: Partial view of the transition probability matrix
the various health states and remain in a state of improving health. For example, PII repre-
sents probabilities such as p[(h′, 1, n)|(h, 1, n),W ]. Similarly, PID represents the submatrix
of probabilities that patients waiting in a state of improving health transition to the various
health states and move to a state of deteriorating health. For example, PID represents prob-
abilities such as p[(h′, 0, n)|(h, 1, n),W ]. PDD represents the submatrix of probabilities that
patients waiting in a state of deteriorating health transition to the various health states and
remain in a state of deteriorating health. For example, PDD represents probabilities such as
p[(h′, 0, n)|(h, 0, n),W ].
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(As7.1) p[(h′, 1, n)|(h, 0, n),W ] = 0 for all h, h′, n.
In words, As7.1 says that a patient in a state of deteriorating health cannot move to a
state of improving health while waiting.
(As7.2) p[(h′, d′, i)|(h, d, i),W ] = p[(h′, d′, j)|(h, d, j),W ] and p[(h′, d′, i−1)|(h, d, i), S] =
p[(h′, d′, j − 1)|(h, d, j), S] for all i, j, h, d, h′, d′.
As7.2 says that regardless of the number of therapies remaining, each action induces the
same transition probabilities. Essentially, this is the assumption that the effects of therapies
are iid. This assumption is represented in the figure by rows R1 and R2 matching rows R5
and R6, with respect to feasible moves. For example, a patient can only move to a state
of fewer therapies remaining by switching to a new therapy; the action of waiting does not
consider the possibility of a loss of available therapies, hence the submatrix of zeroes to
the right of
(
PII
O
PID
PDD
)
in rows R1 and R2. Similarly, waiting cannot lead to an increase in
available therapies, leading to the submatrix of zeroes to the left of
(
PII
O
PID
PDD
)
in rows R5
and R6. The second statement in As7.2 would be seen by rows R3 and R4 matching other
rows representing switching to a new therapy when more than one therapy remains (not
shown in the figure).
(As7.3) p[(h′, d′, n − 1)|(h, 0, n), S] = p[(h′, d′, n − 1)|(h, 1, n), S] = p[(h′, d′, n −
1)|(h, 1, n− 1),W ] for all h, n, h′, d′.
The first equality of As7.3 says that switching to a new therapy has the same effect
regardless if it is initiated from a state of improving or deteriorating health. This is repre-
sented in the figure by rows R3 and R4 matching each other. The second equality says that
the effect of switching to a new therapy when n therapies remain is the same as for a patient
waiting in a state of improving health when n− 1 therapies remain. This is represented by
rows R3 and R4 matching row R5 (again, with respect to feasible moves).
Before proceeding with further assumptions, let p1(i) represent the probability that a
patient waiting in health category i with improving health remains in a state of improving
health, i.e., p1(i) =
∑j=H
j=0 p[(j, 1, n)|(i, 1, n),W ]. Similarly, let p0(i) represent the proba-
bility that a patient in health category i with improving health transitions to a state of
deteriorating health. We shall assume that the probability of dying from a state (h, d, n)
is represented by the transition to (0, 0, n) (if waiting) or to (0, 0, n − 1) (if switching to
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a new therapy). In other words, death occurs in the deteriorating health region only.
Then p0(i) = 1 − p1(i). We let P¯II represent the transition probabilities among health
categories, conditional on a patient in a state of improving health remaining in a state
of improving health, and we let P¯ID represent the transition probabilities among health
categories, conditional on a patient in a state of improving health moving to a state of
deteriorating health. In other words, P¯II is composed of individual probabilities such as
q[(j, 1, n)|(i, 1, n),W ] ≡ p[(j, 1, n)|(i, 1, n),W ]/p1(i), and P¯ID is composed of individual prob-
abilities such as q[(j, 0, n)|(i, 1, n),W ] ≡ p[(j, 0, n)|(i, 1, n),W ]/p0(i). Continuing with our
assumptions, we have:
(As7.4) PDD is IFR.
(As7.5) P¯ID = PDD.
(As7.6) P¯II is IFR.
(As7.7) P¯II ºst PDD.
(As7.8) p1(i) is nondecreasing in i.
As7.4 implies that patients waiting in a state of deteriorating health are still better off
being in a higher health category than a lower one. As7.5 says that given a patient in a state
of improving health transitions to a state of deteriorating health, the probabilistic transition
among health categories is identical to a patient who waits from a state of deteriorating
health. As7.6 can be interpreted similarly to As7.4, for patients remaining in a state of
improving health. As7.7 says that for patients remaining in a state of improving health,
the transitions among health categories is stochastically larger than the transitions among
the health categories for a patient waiting in a state of deteriorating health. The stochastic
ordering in this assumption is what conveys our notion of stochastically improving versus
deteriorating health. Therefore, our use of the phrase “stochastically improving” need not
imply a notion of drift towards higher health categories. Finally, As7.8 says that improving
patients waiting in higher health categories have a greater chance of remaining in a state of
improving health compared to patients waiting in lower health categories. As7.8 is equivalent
to p0(i) is nonincreasing in i.
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Table 14: Assumptions required by each result
Result Assumptions used
Theorem 7.1 As7.1 - As7.8
Theorem 7.2 As7.2, As7.3
Theorem 7.3 As7.2, As7.3
Theorem 7.4 As7.1 - As7.7, As7.9 - As7.11
Theorem 7.5 As7.1, As7.3 - As7.8
Lemma 7.1 As7.2 - As7.7, As7.9
Lemma 7.2 As7.1 - As7.7, As7.9 - As7.11
For the remainder of this section we assume we are modeling a system for which As7.1-
As7.8 all hold. For this reason, and for the sake of clarity, we assume they hold for each
result. The interested reader can refer to Table 14 to see the minimal set of assumptions
required by each result.
We begin with the following intuitive result.
Theorem 7.1. v∗(h, d, n) is nondecreasing in h, nondecreasing in d, and nondecreasing in
n.
Proof. For some i, let vi(h, d, n) be nondecreasing in h, nondecreasing in d, and nondecreasing
in n. Note that v0(h, d, n) = 0 for all h, d, n satisfies this condition. We fix n′ arbitrarily and
consider how vi+1(h, 1, n′) varies with h (note that we have fixed d = 1; we will discuss the
case of d = 0 below). Let h1 < h2. For ease of notation and space considerations, we define
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the following functions:
f(h, d, n,W ) ≡
M∑
j=0
q[(j, 1, n)|(h, d, n),W ]vi(j, 1, n), (7.2)
f(h, d, n, S) ≡
M∑
j=0
q[(j, 1, n− 1)|(h, d, n), S]vi(j, 1, n− 1), (7.3)
g(h, d, n,W ) ≡
M∑
j=0
q[(j, 0, n)|(h, d, n),W ]vi(j, 0, n), (7.4)
g(h, d, n, S) ≡
M∑
j=0
q[(j, 0, n− 1)|(h, d, n), S]vi(j, 0, n− 1). (7.5)
f(h, d, n,W ) represents the expected “cost-to-go” from the next time period on, condi-
tional on the patient moving to a state of stochastically improving health, when the pa-
tient is currently in state (h, d, n) and takes the action “wait”. g(h, d, n,W ) is interpreted
similarly, but conditional on the patient moving to a state of stochastically deteriorating
health. f(h, d, n, S) and g(h, d, n, S) are also interpreted similarly, but with the action being
“switch”.
Then vi+1(h2, 1, n
′) is the maximum of the following two expressions:
1 + p1(h2)f(h2, 1, n
′,W ) + p0(h2)g(h2, 1, n′,W ), (7.6)
and
1 + p1(h2)f(h2, 1, n
′, S) + p0(h2)g(h2, 1, n′, S), (7.7)
where expression (7.6) represents the value update associated with waiting on the current
therapy, and (7.7) represents the value update associated with initiating a new therapy
(without loss of generality, we assume n′ ≥ 1). Note that (7.7) makes use of assumption
As7.3 (that patients initiating a new therapy observe the same stochastic transitions over
health categories as patients waiting on a therapy and in a state of improving health).
In similar fashion, we can write vi+1(h1, 1, n
′) as the maximum of the following two
expressions:
1 + p1(h1)f(h1, 1, n
′,W ) + p0(h1)g(h1, 1, n′,W ), (7.8)
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and
1 + p1(h1)f(h1, 1, n
′, S) + p0(h1)g(h1, 1, n′, S). (7.9)
We compare expressions (7.6) and (7.8). By As7.6 (P¯II is IFR) and the assumption that
vi(h, d, n) is nondecreasing in h,
f(h2, 1, n
′,W ) ≥ f(h1, 1, n,W ). (7.10)
By As7.4, As7.5 (which establish that P¯ID is IFR), and the assumption that v
i(h, d, n) is
nondecreasing in h,
g(h2, 1, n
′,W ) ≥ g(h1, 1, n,W ). (7.11)
Also, by As7.7 and As7.5 (showing that P¯II ºst P¯ID) and the assumption that vi(h, d, n)
is nondecreasing in h and d,
f(h2, 1, n
′,W ) ≥ g(h2, 1, n′,W ), (7.12)
f(h1, 1, n,W ) ≥ g(h1, 1, n,W ). (7.13)
Finally, combining (7.10)-(7.13) with As7.8 establishes that:
1 + p1(h2)f(h2, 1, n
′,W ) + p0(h2)g(h2, 1, n′,W )
≥ 1 + p1(h1)f(h1, 1, n′,W ) + p0(h1)g(h1, 1, n′,W ). (7.14)
A similar exercise shows
1 + p1(h2)f(h2, 1, n
′, S) + p0(h2)g(h2, 1, n′, S)
≥ 1 + p1(h1)f(h1, 1, n′, S) + p0(h1)g(h1, 1, n′, S). (7.15)
Relating these results back to the expressions given in (7.6)- (7.9), shows that vi+1(h2, 1, n
′) ≥
vi+1(h1, 1, n
′). Therefore, vi+1(h, 1, n′) is nondecreasing in h. We also need to show that
vi+1(h, 0, n′) is also nondecreasing in h. If a patient in a state of deteriorating health decides
to wait, then it is better to do so from a health category h2 > h1 by As7.1, As7.4, and the
inductive assumption that vi(h, 0, n′) is nondecreasing in h. If the patient chooses to switch
114
to a new therapy, then it is still better to be in health category h2 by the same reasoning
that established (7.15). It follows, then, that vi+1(h, 0, n′) is nondecreasing in h.
We have shown that vi+1(h, d, n) is nondecreasing in h. Next we show that it is also non-
decreasing in d. In other words, we show that for fixed h and n, vi+1(h, 1, n) ≥ vi+1(h, 0, n).
We arbitrarily fix h′ and n′ (again, without loss of generality we assume n′ ≥ 1). vi+1(h′, 1, n′)
is the maximum of the following two expressions:
1 + p1(h
′)f(h′, 1, n′,W ) + p0(h′)g(h′, 1, n′,W ), (7.16)
and
1 + p1(h
′)f(h′, 1, n′, S) + p0(h′)g(h′, 1, n′, S). (7.17)
Also, vi+1(h′, 0, n′) is the maximum of these two expressions:
1 +
M∑
j=0
p[(j, 0, n′)|(h′, 0, n′),W ]vi(j, 0, n′), (7.18)
and
1 + p1(h
′)f(h′, 0, n′, S) + p0(h′)g(h′, 0, n′, S). (7.19)
Note that in (7.18), there is no consideration of movement to a state of improving health (as
assumed in As7.1). By As7.3 (patients switching to a new therapy have the same stochastic
transitions regardless of whether they switch from a state of improving or deteriorating
health),
1 + p1(h
′)f(h′, 1, n′, S) + p0(h′)g(h′, 1, n′, S)
= 1 + p1(h
′)f(h′, 0, n′, S) + p0(h′)g(h′, 0, n′, S). (7.20)
By As7.7 (that P¯II ºst PDD) and the assumption that vi(h, d, n) is nondecreasing in both h
and d,
f(h′, 1, n′,W ) ≥
M∑
j=0
p[(j, 0, n′)|(h′, 0, n′),W ]vi(j, 0, n′).
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By As7.5 (that P¯ID = PDD),
g(h′, 1, n′,W ) =
M∑
j=0
p[(j, 0, n′)|(h′, 0, n′),W ]vi(j, 0, n′).
Therefore, it follows that
1 + p1(h
′)f(h′, 1, n′,W ) + p0(h′)g(h′, 1, n′,W )
≥ 1 +
M∑
j=0
p[(j, 0, n′)|(h′, 0, n′),W ]vi(j, 0, n′). (7.21)
By the expressions in (7.16) - (7.19) and the relationships expressed in (7.20) and (7.21),
it follows that vi+1(h, d, n) is nondecreasing in d.
It remains to be shown that vi+1(h, d, n) is nondecreasing in n. We begin by fixing h′,
setting d′ = 1 (we consider d′ = 0 later) and consider 1 ≤ n1 < n2 ≤ n (we compare the case
of one and zero therapies remaining later). vi+1(h′, 1, n2) is the maximum of the following
two expressions
1 + p1(h
′)f(h′, 1, n2,W ) + p0(h′)g(h′, 1, n2,W ), (7.22)
and
1 + p1(h
′)f(h′, 1, n2, S) + p0(h′)g(h′, 1, n2, S). (7.23)
Similarly, vi+1(h′, 1, n1) is the maximum of the following two expressions:
1 + p1(h
′)f(h′, 1, n1,W ) + p0(h′)g(h′, 1, n1,W ), (7.24)
and
1 + p1(h
′)f(h′, 1, n1, S) + p0(h′)g(h′, 1, n1, S). (7.25)
By As7.2 (transitions probabilities among health categories while waiting are iid and simi-
larly for transition probabilities when switching to a new therapy), and the assumption that
vi(h, d, n) is nondecreasing in n, we get that
1 + p1(h
′)f(h′, 1, n2,W ) + p0(h′)g(h′, 1, n2,W )
≥ 1 + p1(h′)f(h′, 1, n1,W ) + p0(h′)g(h′, 1, n1,W ). (7.26)
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For the same reasons, we also get that
1 + p1(h
′)f(h′, 1, n2, S) + p0(h′)g(h′, 1, n2, S)
≥ 1 + p1(h′)f(h′, 1, n1, S) + p0(h′)g(h′, 1, n1, S).
By these results and expressions (7.22)-(7.25), it follows that vi+1(h, 1, n) is nondecreasing
in n for n ≥ 1. Returning to the comparison of one and zero therapies remaining, for the
reasons we established (7.26), we know that the value update associated with waiting in a
state with more therapies remaining is no less than the value of waiting in a state with zero
therapies remaining. Clearly, having a choice to wait or switch to a new therapy can be no
worse than choosing to wait, and therefore, vi+1(h, 1, 1) ≥ vi+1(h, 1, 0). We have now proven
that vi+1(h, 1, n) is nondecreasing in n for all n. Similar exercises show that vi+1(h, 0, n) is
also nondecreasing in n for all n.
In summary, we have shown that vi+1(h, d, n) is nondecreasing in h, nondecreasing in d,
and nondecreasing in n. Taking the limit as the value iterates approach infinity, we obtain the
desired result that v∗(h, d, n) is nondecreasing in h, nondecreasing in d, and nondecreasing
in n.
The following shows that it is optimal to wait when in a state of improving health.
Theorem 7.2. For all (h, 1, n), a∗(h, 1, n) = W.
Proof. We assume n ≥ 1 since there is no option other than to wait when n = 0. Then
v∗(h, 1, n) is the maximum of the following two expressions:
1 + p1(h)f(h, 1, n,W ) + p0(h)g(h, 1, n,W ), (7.27)
and
1 + p1(h)f(h, 1, n, S) + p0(h)g(h, 1, n, S). (7.28)
By As7.3, the probability components in (7.27) and (7.28) (including the conditional prob-
abilities in the f and g functions) are identical. By the previous result that v∗(j, 1, n) ≥
v∗(j, 1, n− 1) and v∗(j, 0, n) ≥ v∗(j, 0, n− 1), the result follows.
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In the following, we show that the value of being in a state of deteriorating health with
n therapies remaining is at least as good as being in a state of improving health with n− 1
therapies remaining.
Theorem 7.3. For all (h, 0, n), v∗(h, 0, n) ≥ v∗(h, 1, n− 1)
Proof. Let n ≥ 1. We have:
v∗(h, 0, n)
≥ 1 + p1(h)f(h, 0, n, S) + p0(h)g(h, 0, n, S) (7.29)
= 1 + p1(h)f(h, 0, n− 1,W ) + p0(h)g(h, 0, n− 1,W ) (7.30)
= v∗(h, 1, n− 1), (7.31)
where (7.29) follows by the definition of v∗(h, 0, n), (7.30) follows from As7.3, and (7.31)
follows by the result of Theorem 7.2.
We now develop conditions to guarantee that when there is at least one therapy remaining
and the patient is in a state of deteriorating health, there is at least one state for which it
is optimal to switch to one of the remaining therapies. In other words, there is a benefit
to having the therapies that remain available. We begin with some supporting assumptions
and results. As7.1-As7.8 continue to hold and each additional assumption that follows will
hold for the remainder of the section.
The following assumption says that the probability of dying while waiting in a state of
improving health is strictly decreasing in the health state.
(As7.9) p[(0, 0, n)|(h, d, n),W ] is strictly decreasing in h for each d.
Now we can prove that for a patient in a state of stochastically improving health, the
optimal value function is strictly increasing in the health category.
Lemma 7.1. v∗(h, 1, n) is strictly increasing in h.
Proof. Note that by Theorem 7.2, for each h, v∗(h, 1, n) is obtained by the action of waiting.
Let us consider v∗(1, 1, n). Because the immediate reward equals 1 in each state for which
h > 0, it follows that v∗(1, 1, n) > 0 = v∗(0, 1, n) (note that by our construction, there really
is no chance of a patient even getting to a state (0, 1, n) since death is represented only by
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state (0, 0, n) for each level of n. Therefore we just define the value of that state to be 0.)
Now let 1 ≤ h′ < H, arbitrarily, and let us compare v∗(h′, 1, n) with v∗(h′+1, 1, n). Referring
back to (7.2)-(7.5) (with v∗ in place of vi), we have:
v∗(h′ + 1, 1, n) = 1 + p1(h′ + 1)f(h′ + 1, 1, n,W ) + p0(h′ + 1)g(h′ + 1, 1, n,W ),
and
v∗(h′, 1, n) = 1 + p1(h′)f(h′, 1, n,W ) + p0(h′)g(h′, 1, n,W ).
Let us focus on g(h′ + 1, 1, n,W ) and g(h′, 1, n,W ). Referring back to lines (4.6) and
(4.7) of Lemma 4.1 from Chapter 4 and noting that v∗(0, 0, n) = 0, we have
g(h′ + 1, 1, n,W ) =
H∑
i=1
[v∗(i, 0, n)− v∗(i− 1, 0, n)]
H∑
j=i
q[(j, 0, n)|(h′ + 1, 1, n),W ], (7.32)
and
g(h′, 1, n,W ) =
H∑
i=1
[v∗(i, 0, n)− v∗(i− 1, 0, n)]
H∑
j=i
q[(j, 0, n)|(h′, 1, n),W ]. (7.33)
By the first part of the proof, we know that v∗(1, 0, n)−v∗(0, 0, n) > 0. Also, by As7.4, As7.5,
and As7.9, we know that
∑H
j=1 q[(j, 0, n)|(h′ + 1, 1, n),W ] >
∑H
j=1 q[(j, 0, n)|(h′, 1, n),W ].
Therefore, g(h′+1, d, n,W ) > g(h′, d, n,W ), which along with the steps leading up to (7.14)
as well as As7.9 (which establishes that p1(h) < 1 for all 1 ≤ h < H), implies:
1 + p1(h
′ + 1)f(h′ + 1, 1, n,W ) + p0(h′ + 1)g(h′ + 1, 1, n,W )
> 1 + p1(h
′)f(h′, 1, n,W ) + p0(h′)g(h′, 1, n,W ),
and hence v∗(h′ + 1, 1, n) > v∗(h′, 1, n).
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We next provide conditions that allow us to prove that when no therapies remain, the
value of being in a state of improving health is strictly greater than being in a state of
deteriorating health for each health category greater than 0.
(As7.10) p1(h) > 0 for all h > 0.
As7.10 says that for every state in which a patient’s health is stochastically improving,
there is a positive probability that it will remain improving at the next time period.
(As7.11) For each h > 0, there exists k such that
H∑
h′=k
q[(h′, 1, 0)|(h, 1, 0),W ] >
H∑
h′=k
q[(h′, 1, 0)|(h, 0, 0),W ].
As7.11 says that at least one of the inequalities that go into the condition of As7.7 for
each h > 0 is strict.
We can now prove the following.
Lemma 7.2. v∗(h, 1, 0) > v∗(h, 0, 0) for all h > 0.
Proof. Let h > 0, arbitrarily. When zero therapies remain, the only action is to wait, and
hence we have:
v∗(h, 1, 0) = 1 + p1(h)f(h, 1, 0,W ) + p0(h)f(h, 0, 0,W ), (7.34)
v∗(h, 0, 0) = 1 + f(h, 0, 0,W ). (7.35)
Similar to (7.32), we can write
f(h, 1, 0,W ) =
H∑
i=1
[v∗(i, 1, 0)− v∗(i− 1, 0, 0)]
H∑
j=i
q[(j, 1, 0)|(h, 1, 0),W ].
By the result of Lemma 7.1 and As7.11, it follows that
H∑
h′=0
q[(h′, 1, 0)|(h, 1, 0),W ]v∗(h, 1, 0) (7.36)
>
H∑
h′=0
q[(h′, 0, 0)|(h, 1, 0),W ]v∗(h, 1, 0). (7.37)
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Also, by Theorem 7.1,
H∑
h′=0
q[(h′, 0, 0)|(h, 1, 0),W ]v∗(h, 1, 0) (7.38)
≥
H∑
h′=0
q[(h′, 0, 0)|(h, 1, 0),W ]v∗(h, 0, 0). (7.39)
Finally, combining (7.36)-(7.39) with As7.10 establishes that the right-hand side of (7.34) is
greater than the right-hand side of (7.35) and hence v∗(h, 1, 0) > v∗(h, 0, 0).
We are now ready to prove the result that there is a benefit of having the therapies that
remain available.
Theorem 7.4. For each n ≥ 1, there exists h ≥ 1 such that a∗(h, 0, n) = S, uniquely.
Proof. Suppose, towards a contradiction, that there exists n ≥ 1, such that a∗(h, 0, n) = W
for all h ≥ 1. Then by As7.2, v∗(h, 0, n) = v∗(h, 0, 0) for all h. But Lemma 7.2 states
that v∗(h, 1, 0) > v∗(h, 0, 0), and by Theorems 7.1 and 7.3, it follows that v∗(h, 0, n) >
v∗(h, 0, 0).
In the following, we suppose that upon switching to a new therapy, the system transitions
to one of the various health categories and health directions independently of the state from
which the system moves. This generalizes a common assumption in machine replacement
problems, where upon replacement, the system moves to the best state with probability 1,
regardless of the state from which the replacement is made [22]. While the generalization
below is not clinically realistic in the HIV setting, we include it for additional structural
analysis.
Theorem 7.5. Suppose that instead of As7.3, we assume that upon switching to a new
therapy from a state (h1, d1, n1), patients transition to various states of the form (h2, d2, n1−
1) with probabilities independent of (h1, d1, n1). Then for each level of n ≥ 1, an optimal
control-limit policy exists.
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Proof. Let n ≥ 1 and suppose that there exists h, such that a∗(h, 0, n) = W , uniquely, and
a∗(h + 1, 0, n) = S. By the assumption of the current theorem, the value associated with
switching to a new therapy from state (h, 0, n) equals the value associated with switching
from state (h + 1, 0, n). This, along with our assumption that a∗(h, 0, n) = W , uniquely,
implies that v∗(h, 0, n) > v∗(h+1, 0, n), contradicting the result of Theorem 7.1. Therefore,
a∗(h, 0, n) = W , uniquely, implies a∗(h+ 1, 0, n) = W , and the result follows.
7.4 EXTENDING THE FRAMEWORK
Just as we did in Chapter 6, we want to consider the more clinically realistic setting of
therapies that are not identical and independent of each other’s use. We begin by relaxing
the assumption of identically distributed therapies and consider therapies that may have
different levels of effectiveness. We develop an algorithm that embeds MDPs within an outer
dynamic program, analogous to the algorithm developed in Section 6.3.2. For example, for
each therapy, we consider a patient who is on that therapy with no more therapies remaining,
and we obtain the value associated with each state (the only action is to continue waiting
on that therapy). Next, we consider all
(
n
2
)
pairs of therapies and for each state, evaluate
the optimal value associated with being on one therapy of the pair and having the other
therapy available. For example, for therapies i and j, we first consider that the patient is on
therapy i with j remaining, and for each state we determine whether it is optimal for the
patient to remain on i or switch to j. We then do the same thing, assuming the patient is
on j with i remaining. For ease of exposition, suppose a patient has never initiated therapy
and only has therapies i and j available. Then for each state, the patient may continue
waiting, initiate therapy i, or initiate therapy j. From the previous step of the algorithm,
we obtained the values of being in each state, on therapy i with j remaining, or on therapy
j with i remaining, so we do not need to repeat that work at this level of the algorithm.
Recall that in Chapters 4 and 5 we assumed that once patients initiate therapy, they
receive the expected remaining lifetime associated with the sequencing and switching of
therapies as done in current practice. In Section 4.6, we mentioned that after the presentation
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of the current and previous chapters, we may reconsider the problem of the optimal time to
initiate therapy under a framework that optimizes the entire therapy planning process. The
algorithm we described does just that: the final step of the algorithm considers a patient
never before on therapy and for each state, determines whether the patient should initiate
therapy and if so, which one.
Finally, we note that the same reasons we gave for the difficulty of relaxing the in-
dependence assumption in Section 6.3.3 apply to this context as well. However, similar
simplifications may make the problem feasible to solve. We leave that for future work.
7.5 CONCLUSIONS
There are various phenomena in HIV therapy planning (and therapeutic optimization prob-
lems in general) that challenge the often used framework of a stationary MDP. One is the
fact that patient aging must be considered when modeling a long time horizon. Another
is the reality that therapies are often effective for some period of time but then lose their
effectiveness. Finally, patients face a finite number of therapy replacements.
We addressed each of these issues in developing a stationary MDP for the problem of
switching and sequencing HIV therapies. Additionally, we demonstrated structural proper-
ties of this framework under an assumption of equally effective therapies. We also described
an MDP algorithm for the setting of therapies with possibly different levels of effectiveness.
The data requirements for a clinically based implementation of this model are immense
and we leave that for future work. Also, some of our modeling assumptions may be recon-
sidered in future work. For example, we assumed that therapies cannot be reused; however,
it may be useful to think about the possibility of reusing therapies at a reduced level of
effectiveness. Similarly, we assumed that waiting cannot cause the loss of available thera-
pies. In HIV care, it is possible that the development of resistance to an active drug confers
resistance to a drug never before taken, so we may consider the possibility of a stock of
unused therapies losing effectiveness over time (this has connections to the review of inven-
tory depletion management problems in Section 2.3.3). Finally, we also assumed that new
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therapies are not introduced over time; in reality, new drugs are often under research and
development. Therefore, we may want to consider this source of uncertainty as well.
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8.0 CONCLUSIONS
This dissertation has focused on applying mathematical techniques to address fundamental
and unresolved questions in HIV therapy planning: when to initiate, when to switch, and
how to sequence therapies. In Chapter 2, we reviewed the literature addressing these topics,
which includes various clinical as well as mathematical studies. For a process as complex
as treatment planning, mathematical studies have practical advantages over clinical studies,
though the latter are necessary to perform before making significant changes to treatment
guidelines. Two types of mathematical approaches have been prominent in HIV therapy
planning: Monte Carlo simulation models and control-theoretic models. As discussed, sim-
ulation models are excellent tools for testing “what if” scenarios but are not efficient means
for seeking optimal policies. On the other hand, while control-theoretic models optimize
some objective, they fail to consider essential issues in HIV care: risk of death and qual-
ity of life. Because HIV therapy planning is a sequential stochastic decision process which
should consider long-term survival and quality of life, we modeled the above questions with a
Markov decision process (MDP). MDPs are designed precisely to optimize periodic decisions
under an uncertain environment, and they are well suited for handling objectives such as
maximizing expected lifetime or quality-adjusted lifetime.
Chapters 4 and 5 examined the question of the optimal time to initiate HIV therapy,
with the former considering a single prognostic variable (CD4 count) and the latter consider
two variables (CD4 count and viral load). After developing the modeling frameworks for
both, we examined structural properties such as increasing value functions, optimal policies
of initiating therapy from all states, and optimal control-limit policies. We also considered
how to adapt the single-variable model to include patient-specific factors such as quality of
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life and adherence. In Chapter 3, we used clinical data to build the key components of the
MDP we solved in Chapter 4: a natural history transition probability matrix along with
estimates of patient survival after initiating therapy.
The results of the data-driven MDP demonstrated strong support for a strategy of ini-
tiating therapy immediately. Under a variety of sensitivity analyses with respect to both
objectives of maximizing lifetime and quality-adjusted lifetime, the solutions pointed to a
policy of initiating therapy from each CD4 strata. Moreover, we found other examples in
the literature to suggest that treatment guidelines reexamine recent trends toward treating
HIV later in its course.
Chapters 6 and 7 developed models for addressing the questions of when to switch thera-
pies and how to sequence them. In Chapter 6, we considered a continuous-time approach to
switching and sequencing therapies, given that one has information only about the lifetime
distributions associated with the therapies. Chapter 7 considered periodic observations and
state variables that indicate a patient’s state of health, whether or not the patient is on an
effective therapy, and the number of effective therapies remaining.
Limitations of the work lie both with the data as well as some of our modeling assump-
tions. For instance, we built our models based on male patients in the VA. Therefore, our
results may not extend readily to women or HIV patients in other settings. A primary data
challenge was how to handle the significant number of censored observations attributable
to initiating therapy in the natural history model. Future work may consider a more rig-
orous approach to dealing with this issue. Also, although we shall soon build and solve a
data-driven model of the optimal time to initiate therapy as a function of both CD4 count
and viral load, building a clinically valid, data-driven model of the switching and sequencing
questions will not appear soon due to great data requirements. One modeling assumption
we made was of perfect observations of a patient’s state. Depending on the amount of un-
certainty in the CD4 and viral load measurements, we may want to model the problem as
a partially-observable MDP that considers this uncertainty. Moreover, measurements of pa-
tient adherence are notoriously inaccurate and hence we should take this into account when
explicitly considering patient adherence. Furthermore, we would like to combine an explicit
consideration of patient adherence with utilities in a quality-of-life framework. Finally, we
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assumed periodic inspections of patient health (e.g., every month) and leave for future re-
search a cost-effectiveness analysis examining the question of how often a patient should visit
a physician for laboratory measurements.
Although there have been great strides in HIV therapies over the past 20 years, there
is still considerable debate over the best way to use them. Questions regarding the optimal
time to initiate therapy, the time to switch therapies, and the sequencing of therapies are
central to effective HIV care today. The solutions to our model of when to initiate therapy
support former strategies of administering HAART earlier in the course of HIV as opposed
to recent trends of delaying therapy. While data are not mature enough to solve our models
of the switching and sequencing of therapies, the models provide methodological frameworks
for thinking about these difficult questions.
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